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In the United Kingdom, the number of patients with liver failure awaiting
transplantation now exceeds the capacity of the nation's donor pool, with the
result that 20% of patients now die on the waiting list. The future for the
treatment of liver failure lies in part with cell-based therapies, in which liver
support may be provided on a short-term basis by biological liver-assist devices,
or in which sufficient mass of liver tissue may be transplanted into patients to
reverse liver failure as a graft. However, cell therapies are at a preliminary stage,
due to a lack of basic understanding as to how human liver cells can be made to
divide and to undergo functional maturation in vitro.
In order to understand how human liver cells can proliferate and differentiate in
vitro, a culture system was developed to support second trimester fetal liver
cells. Having characterised the culture system, and demonstrated viable
hepatocytes after seven days in vitro, experiments were carried out to determine
which circulating endocrine stimuli might initiate morphologic and functional
maturation in the developing hepatocytes. Cells were then incubated with
growth factors and cytokines and subject to two-colour flow cytometry to assess
which cell fraction might proliferate in vitro. Finally, urea metabolism and
protein secretion were assessed in the presence and absence of glucocorticoid
and different growth factors, to assess the interactions of these various stimuli at
a functional level.
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The results showed that glucocorticoid alone brought about functional
maturation in terms of increased protein secretion, with significant increases
observed in a-fetoprotein, fibrinogen and a-i-antichymotrypsin secretion. This
represented increased secretion per cell, as there was no effect of glucocorticoid
on cell number. However, incubation with growth factors and cytokines showed
that EGF stimulated cellular proliferation. This proliferation occurred within a
primitive epithelial fraction, positive for cytokeratin 18, but negative for
fibrinogen. Final experiments showed that EGF and HGF had modest
stimulatory effects on urea synthesis. By contrast, KGF reduced urea synthesis
by channelling ammonia into anabolic pathways. With regard to protein
secretion, EGF inhibited fibrinogen and oc-i-antichymotrypsin secretion,
whereas, tumour necrosis factor inhibited fibrinogen alone. All of these
observations were made only in the presence of dexamethasone.
These data show that a satisfactory method for fetal liver cell culture was
developed. This model demonstrated that proliferation of liver epithelial cells
was stimulated by EGF, whereas functional maturation of fetal liver cells could
be brought about by exposure to glucocorticoid. Various growth factors and
cytokines had modest effects on urea and protein secretion, but only in the
presence of glucocorticoid. These experiments have provided new insights into
the maturational and proliferative signals in developing human liver. These data
Contents xvii
provide a frame of reference from which to develop cell-based therapies for the
treatment of liver failure in clinical practice.
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Chapter 1.
Review of the literature.
Section 1. Overview
1.1 Introduction
The presence of a functioning liver is central to homeostasis, and liver failure is
ultimately incompatible with long term survival. Liver transplantation is
presently the definitive treatment for acute and chronic liver failure in humans.
However, the current supply of donor livers is insufficient to meet demand and
the mortality rate whilst awaiting transplantation is presently 20% in the United
Kingdom. In order to address this deficiency, it is necessary to develop new
strategies to treat liver disease.
As a basis for therapy, the developing liver may exhibit properties which provide
advantages and challenges compared to mature liver tissue (Mahli et al.,2002;
Minguet et al., 2003). An understanding of the acquisition of liver mass and
function during development is critically important to future cell-based
therapies. To illustrate the functional capacities of the developing liver, a brief
overview of fetal liver function is presented in this section.
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1.2 The roles of the developing liver
Liver development provides the fetus with the necessary biochemical machinery
to ensure homeostasis at the start of independent life. As the site for synthesis
and storage of glycogen, the liver ensures that the fetus does not succumb to
irretrievable hypoglycaemic injury during birth. Immediately after birth, hepatic
gluconeogenesis provides the metabolic substrate to maintain viability until
feeding is established. Bile secreted by the liver enables fat to be absorbed from
milk taken into the gut, and the re-packaging and distribution of fats around the
body is managed by the liver (Davenport, 1982).
Protein catabolism, particularly in the context of gluconeogenesis, results in the
production of ammonia, a highly toxic by-product. The liver renders this
potentially lethal agent harmless by incorporation into urea (Rodwell, 2000).
Foreign substances, toxins and drugs, are rendered hydrophilic by liver
oxidation and conjugation, and are harmlessly eliminated in bile and by the
kidneys. Many such toxins, and numerous physiological molecules, are
transported in blood bound to albumin, the major plasma protein, which is
synthesised by the liver. A great many plasma proteins present at lesser
concentrations subserve similarly important functions, as evidenced by
uncommon but devastating deficiency diseases.
During development, and at parturition, the fetal liver ensures haemostasis by
providing many of the coagulation factors in the blood, and many of the counter-
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regulatory anti-coagulation factors. The synthesis of a large subset of these
molecules requires vitamin K, a fat-soluble vitamin, the absorption of which is
which is mediated by bile salts secreted by the liver (Davenport, 1982).
1.3 Rationale for studies of fetal liver.
Having reviewed the functionality of the fetal liver, it is necessary to justify
whether studies of liver may be better addressed using fetal or adult liver cells.
The developing liver may possess properties quite different to the adult organ.
Proliferation of progenitor hepatocytes provides adequate functional liver mass
at term, a process which may be reproducible in vitro, so providing the cellular
basis for a liver support device, or the material for cell transplantation.
Similarly, an understanding of the mechanisms which lead to hepatocyte
proliferation and differentiation could lead to new treatments to prevent
progression of liver disease, so avoiding or delaying liver transplantation.
Furthermore, an understanding of biliary development may assist in therapies of
transplant cholangiopathy, in which 'vanishing bile ducts' leads to intractable
cholestasis and the need for re-transplantation.
Fetal tissues in general are recognised to show viability and proliferation in
vitro, and function may be retained or improved with time in culture (Currie et
al., 1994; Mahli et al., 2002), which contrasts with strictly short-term
experiments in adult liver cells (Wigmore et ah, 1997). However, there are no
data which describe the behaviour of fetal liver cells in vitro. The introduction of
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cell-based therapies in liver disease presently lacks any supportive data as to the
functional attributes of developing liver cells. Knowledge of the mechanisms
subserving proliferation and differentiation will be key to successful cell therapy.
1.4 Summary
The developing liver may possess many different competencies, the
understanding ofwhich renders this organ of central importance to cell-based
therapies for liver disease. Whilst studies of adult human liver are not
promising as material for cell therapy, insight into the developing capabilities of
this organ may provide the required scientific background to develop life-saving
novel treatments.
In order to understand how developing liver cells proliferate, and how they
acquire their metabolic and synthetic competencies, this thesis set out to
investigate novel properties of human fetal hepatocytes. The literature review
describes salient evidence from published work, and the subsequent chapters
describe the experiments which address the key issues of developing liver
function in fetal human liver.
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Section 2.
Introduction to liver development.
2.1 Embryogenesis.
Gastrulation, which results in the formation of the three embryonic layers of
ectoderm, mesoderm and endoderm from the inner cell mass of the blastocyst,
occurs between days 16 and 22 after fertilisation in the human. This establishes
the overall body plan and irrevocably determines which cells in general will give
rise to different tissues of the adult. Whilst cells of the blastocyst inner cell mass
are totipotent (embryonic stem cells), those of the trilaminar embryo display
lineage restriction, though a considerable degree of plasticity remains in many
lineages until later in development.
2.2 Organogenesis of the liver.
The primordial liver can be defined anatomically during the third week of
gestation, where it appears as an outgrowth of the ventral aspect of the distal
foregut epithelium (Severn, 1971). The embryonic endodermal layer forms the
hepatic diverticulum which penetrates the septum transversum as a series of
proliferating fronds. The septum transversum is the mesenchymal layer lying
between the vitelline duct (in free communication with the lining of the gut), and
the cardiac mesoderm and is shown in stylised form in Figure 1.1.








Figure 1.1. Outgrowth of foregut endoderm to form the presumptive
liver. The human emhryo is shown in sagittal section, corresponding to week 4 of development. The hepatic
diverticulum is an out pouching of the endoderm growing into the septum transversum, directed hy inductive signalling
from this structure and from the immediately adjacent cardiac mesoderm. The hepatic diverticulum gives rise to the
liver and to the extrahepatic biliary tree, including the common bile duct and gallbladder.
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The interactions between the cardiac mesoderm, the septum transversum and
the foregut endoderm provide an induction signal, triggering differentiation
along the liver pathway, rather than pancreatic differentiation which is the
endodermal default pathway.
Initially, proliferation of hepatoblasts, which are by definition the epithelial cells
present prior to differentiation of the intrahepatic biliary tree, is accompanied by
progressive enlargement of the presumptive liver, but with little anatomical
sophistication until the biliary tree begins to develop at week 11. The steps
which mediate liver cell proliferation and differentiation of the biliary tree are
poorly understood, particularly so in the human.
2.3 Development of the biliary tree
In human fetuses of 5mm crown-rump length, corresponding approximately to
the end of the 4th week of development, liver tissue in the hepatic diverticulum is
homogeneous, without evidence of either primitive intrahepatic bile ducts or
hepatic arterial inflow. The caudal and cephalic regions of the hepatic
diverticulum are embryologically distinct, and whilst the cephalic region
interacts with the septum transversum mesenchyme to give rise to liver
parenchyma, the caudal region gives rise to gall bladder, cystic duct and
extrahepatic bile duct. Between the 4th week and 6th weeks of gestation, the
extrahepatic bile duct develops from a primitive hollow tube a few cells thick
into the definitive extrahepatic bile duct (Tan and Vijayan, 2001). By contrast,
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the ductal plate only begins to differentiate at the porta hepatis around 6-7
weeks developmental age (Figure 1.2) and extends throughout the liver
subsequently (Ruebner et al., 1990). Remodelling of the ductal plate first occurs
at the porta hepatis around week 11, such that the sleeve-like single cell layer
which surrounds the portal tracts is reduplicated. This is followed by the
formation of primitive tubules which will become the definitive intra-hepatic bile
ducts (Crawford, 2002). These develop progressively throughout the liver
between weeks 11 - 16, and are connected to the extrahepatic biliary tree at the
hilum from the very earliest developmental stage. Thus, the liver is competent
to secrete bile from weeks 11-12 onwards. As development proceeds, the ductal
plate degenerates, leaving successively fewer biliary tubules in each portal tract,
until at birth one or perhaps two are left in each tract alongside the portal vein at
birth.
2.4 Vasculature of the developing liver
Vascular channels arise in the 3rd week of embryonic development, where
precursor haemangioblasts give rise to endothelium and primitive blood cells
(oligopotent haematopoietic stem cells). These lacunae of developing blood cells
and endothelial cells are initially scattered and isolated, and have been described
as 'blood islands'. They are found throughout the developing embryonic and
extra-embryonic tissues. Extension of these islands, and fusion of their
endothelial linings, gives rise to the primitive vasculature of the embryo. The















C. Primitive tubules arise within the ductal plate and invade portal tract









E. The ductal plate and excess tubules degenerate completely to leave one ductule
per tract at birth.
Figure 1.2. The developmental anatomy of the biliary tract.
Prior to week 6 in development, the parenchymal cells are homogeneous hepatoblasts. Cytokeratin 19 expression
becomes increasingly localised around the portal tract, indicating the morphogenesis of the ductal plate. The ductal plate
reduplicatates, and from this double layered concentric structure arise multiple ductules. These are deleted during
subsequent development to leave one ductule per tract at the time of birth.
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subsequent ontogeny of the blood vessels related to the liver is complex,
involving the vitelline veins, the umbilical veins and the hepatic veins.
2.4.1 The liver sinusoids
The vitelline veins drain blood from the yolk sac to the sinus venosus, the
common venous channel of the primitive heart tube. Prior to entering the sinus,
the vitelline veins pass through the septum transversum. The liver cords
growing within the septum induce the formation of a dense plexus of veins,
arising from the vitelline veins, which will ultimately form the hepatic sinusoids
(Figure 1.3). This plexus is formed by vitelline vein-derived angioblasts
proliferating within the septum transversum, probably in response to the
immediate proximity of the presumptive liver cells. This observation invokes the
presence of potential angioproliferative signals from hepatoblasts, and
hepatoproliferative signals from angioblasts, which are as yet unidentified.
Ultimately, the close approximation of these endothelial cells with hepatoblasts
will result in the liver sinusoids, lined by endothelium, containing proliferating
haematopoietic cells, and in immediate contact with hepatocytes. Although the
accepted wisdom is that haematopoiesis proper begins in the paraaortic clusters
in the splanchnopleuric mesoderm at week 6 which then seed the liver, it
remains entirely possible that haematopoiesis is established during the
formation of the vitelline capillaries and subsequent sinusoid proliferation.
Similarly, it is possible that hepatic haematopoiesis occurring in adults as a
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Angioblast proliferation and
Hepatoblast proliferation in stm
Vitelline veins give rise to
intrahepatic portal veins and
sinusoidal endothelium
in the hepatic parenchyma
Portal vein
Sinusoid
Figure 1.3. The development of sinusoidal endothelium
from vitelline veins. Stm; septum transversum mesenchyme. Angioblasts are shown in blue,
hepatoblasts in red. As the hepatoblasts proliferate within the septum transversum, angioblast proliferation occurs
in parallel. Evidence suggests a bidirectional proliferative signalling mechanism. Cords of hepatoblasts intertwine
with plates of endothelial cells, giving rise to the mature structure in which all hepatocytes have one face immediately
adjacent to sinusoidal endothelium.
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result of a marrow disorder may reflect a re-awakening of long-dormant
haematopoietic stem cells resident in the liver since the early embryonic stage.
2.4.2 Portal venous system.
The developmental anatomy of the portal venous system is complex. In the early
embryo, the right and left vitelline veins initially pass within the wall of the yolk
sac, then within the mesenchyme of the embryo, through the septum
transversum, and on to the sinus venosus. As the proximal components of these
structures become involved in the development of the hepatic sinusoids, the
main venous channels are forming a coarse anastomotic network around the
duodenum. This undergoes further development, along with the rightward
rotation of the duodenum, such that selected branches become dominant and
others are lost. The result of these developmental events is the formation of the
portal and superior mesenteric veins from the right vitelline vein and the splenic
and inferior mesenteric veins from the left vitelline vein.
2.4.3 Umbilical veins
The right and left umbilical veins drain initially into the sinus venosus after
passing through the septum transversum. In the early embryo, they are entirely
separate from the developing liver sinusoids. With time, branches develop
which join the hepatic sinusoids, contributing ever greater inflow to the
developing liver. Subsequently, the original channels draining to the sinus
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venosus become less and less significant until they are lost, and both the right
and left umbilical veins drain only to the hepatic sinusoids.
The extrahepatic right umbilical vein degenerates completely, and the left
establishes drainage through the liver, via the ductus venosus, which is initially
formed by a confluence of vitelline vein capillaries. The ductus venosus enters
the primitive left hepatic vein to drain to the inferior vena cava
In the adult, the left umbilical vein is observed as an obliterated remnant, the
ligamentum teres, in the free edge of the falciform ligament which joins the left
branch of the portal vein. The ductus venosus remnant forms the ligamentum
venosum, passing between the left branch of portal vein and the inferior vena
cava, lying in the groove between the caudate lobe and the left lobe of the liver.
2.4.4 Hepatic veins and inferior vena cava.
The drainage channels for the sinusoids in the early liver are the right and left
hepato-cardiac channels. These are derived from the original drainage of the
right and left vitelline veins into the sinus venosus. As the sinus venosus
undergoes anatomical maturation, there is a generalised shift of venous drainage
from a bilateral primitive pattern, to a right sided, mature pattern. In fact, the
extrahepatic component of the left hepato-cardiac channel undergoes complete
involution, and all the sinusoidal blood, plus that from the ductus venosus,
drains through the right hepato-cardiac channel. This structure ultimately
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forms the hepatic inferior vena cava, receiving blood from the hepatic veins,
which are derived from the right and left vitelline systems.
2.4.5 Hepatic artery
The early fetal liver contains no branches of hepatic arterywithin the portal
tracts. Within the portal tract mesenchyme, in parallel with the developing
biliary system, capillary loops begin to develop from progenitor cells,
reminiscent of the original development of the primitive embryonic circulatory
system from haemangioblasts. These nascent capillary loops extend and fuse
with their neighbours, around the time that the ductal plate arises between
weeks 6-11 of development. These demonstrate the same pattern of anatomical
maturation as the biliary tract, in that vessels are first seen at the hilum and then
appear in a wave spreading from hilum to periphery as development progresses.
The development of the hepatic arterial inflow is coupled to the maturation of
bile ducts, such that the mature hepatic artery complement in each portal tract is
observed just around the time that the intrahepatic biliary radical has formed
from the degenerating ductal plate. Abnormalities of ductal plate maturation,
such as in the various congenital ductal plate malformations, are invariably
associated with abnormal hepatic arterial complement in the portal tracts.
The developing hepatic arterial branches drain to the hepatic sinusoids, such
that mixing of arterial and portal venous blood occurs here. In post-natal stages,
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this results in blood of higher oxygen tension present in the region closest to the
portal tract (zone l), and blood of lowest oxygen tension closest to the central
veins (zone 3). Of course, in the fetus, sinusoidal blood contains inflow from the
umbilical vein, which has the highest possible oxygen tension in the fetus.
Admixture with hepatic arterial blood paradoxically lowers oxygen tension,
however, it is still the case that blood closest to the portal tract contains the
highest oxygen tension.
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Section 3.
Cell biology of liver organogenesis.
3.1 Introduction
The following section is focused on the development of hepatic parenchymal
cells, namely hepatocytes and cholangiocytes, how they are induced to
proliferate, and the signals inducing their maturation.
Prior to the morphological development of the primitive liver, the foregut
endoderm lies in close contact with the mesenchyme of the septum transversum,
and immediately caudal to the developing heart (Figure 1.1). Inductive signals
pass between the septum transversum mesenchyme, the cardiac mesoderm, and
the gut endoderm. These interactions, which involve soluble molecules diffusing
along gradients to act on target tissues, result in a change of gene expression in
the target. In this way, the endoderm begins to express albumin and AFP, the
earliest indication that an inductive signal has been received, which confers a
liver phenotype on this part of the foregut endoderm (liver specification).
Subsequently, the endoderm preferentially invades the septum transversum and
proliferates within this structure. Again, this is a response to inductive signals
passing between the various structures. It is clear that this simple
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morphological event is exceptionally complex in terms of the signalling required
to produce this sequence of proliferation, differentiation and morphogenesis.
The default pathway for this part of the foregut is to develop along a pancreatic
lineage, and so failure of this signalling interplaywill prevent the development of
the liver, which is not compatible with survival. These signalling networks are
complex; however, an understanding of these pathways is important when
contemplating the mechanisms which control proliferation and differentiation in
the developing liver. This section describes in detail the various signalling
pathways which are active in the earliest stages of liver development.
3.2 Specification of the liver and restriction to an hepatic fate
During the 3rd week of human development, or at the 6 somite stage in mice
(-8.5 days gestation; term 20 days), the ventral endoderm undergoes a
specification event which irrevocably commits a sub-region to an hepatic fate.
Data in the human are absent from the literature, however, classical
transplantation studies with chick and mouse embryos have shown that the
initial stimulus to cause hepatic gene activation and proliferation of the hepatic
diverticulum originates in the immediately adjacent cardiac mesoderm (Le
Douarin, 1975, Gualdi etal., 1996).
3.2.1 Fibroblast Growth Factors and the cardiac mesoderm
Fibroblast Growth Factors (FGFs) are critical mediators signalling hepatic
specification in gut endoderm. Jung et al. (1999) reported in mouse that cardiac
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mesoderm is immunopositive for FGFs l, 2 and 8 in early development. At the
7-8 somite stage, when liver specification occurs, all three are present. Notably,
there was intense staining for FGF8 at the boundary of cardiac mesoderm and
ventral endoderm, whereas FGFi had just appeared at this stage. FGF receptors
1 and 4, which mediate the activities of FGF2 and FGF8b respectively, were
expressed in the endoderm at the same time.
Incubation of endoderm isolated before hepatic specification with cardiac
mesoderm or FGFi at song/ml, or FGF2 at sng/ml, but not FGF8b at either
concentration, strongly induced expression of albumin in ventral endoderm.
Confirmation of a physiological role for FGFs was obtained by adding soluble
fusion proteins capable ofbinding FGFs to mesoderm-endoderm co-cultures;
these experiments showed grossly attenuated albumin expression, in particular
when FGF2 signalling was blocked.
Taken together, these data underscore a significant role for FGF2 in liver
specification. Most likely, FGF2 released from cardiac mesoderm acts on FGF
receptor 1 expressed by the ventral endoderm, a process which results in the
stable expression of albumin by foregut endoderm and commits a specific area
to an hepatic fate.
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3.2.2 Fate determination and lineage restriction in the foregut endoderm
Elegant experiments have shown that the default pathway of differentiation in
the endoderm destined to become liver is in fact pancreatic differentiation
(Deutsch et al, 2001). Presumptive hepatic endoderm isolated from mouse
embryos at the 4-6 somite stage and cultured in vitro for 2 days was
demonstrated to express pdxi, a homeobox protein and one of the earliest
known pancreas markers, but not albumin (Offield et al., 1996). By contrast, the
same tissue isolated at the 7-8 somite stage stably expressed albumin in vitro,
and not pdxi, confirming commitment to an hepatic lineage. The addition of
fibroblast growth factor 2 or 8b, or cardiac mesoderm, to cultures of ventral
foregut endoderm isolated at the 4-6 somite stage restricted the expression of
pdxi, and promoted albumin expression, indicating the hepatic lineage
specification induced by FGF release from cardiac mesoderm.
These observations corroborate other studies, showing that FGF signalling from
cardiac mesoderm is necessary and sufficient to induce liver formation in the
ventral endoderm (Gualdi et al, 1996; Jung et al., 1999). Interestingly, exposure
of the presumptive pancreatic endoderm to FGFs caused stable liver
specification. This suggests a degree of plasticity of the early endoderm in terms
of lineage restriction and tissue specification. Immunostaining co-cultures of
cardiac mesoderm and ventral endoderm for pdxi or albumin consistently
demonstrated that physical proximity to the cardiac mesoderm resulted in
absent pdxi expression and abundant albumin expression (Deutsch et al., 2001).
Chapter 1 Literature Review 20
Tissues distal to cardiac mesoderm however, expressed pdxi and not albumin,
demonstrating the physiological pattern of endoderm development into a ventral
pancreatic bud.
3.2.3 Sonic Hedgehog
Sonic Hedgehog (Shh) has a well described role as a signalling molecule in
endoderm differentiation. Shh is expressed by dorsal gut endoderm, where it
prevents expression of pancreatic lineage. Signalling by the overlying notochord
locally inhibits Shh expression, relieving Shh inhibition, and permitting
expression of the dorsal pancreatic bud (Kim and Melton, 1998). The role of Shh
in the expression of the ventral pancreatic bud has recently been clarified, and it
relates closely to the lineage restriction events of the developing liver (Deutsch et
al., 2001). In foregut endoderm explants, isolated before liver specification, Shh
peptide is absent, which permits development towards a pancreatic fate. By
contrast, incubation with cardiac mesoderm, or FGF2, results in widespread
immunostaining for Shh, suggesting that the mesodermal FGF signalling
inhibits the pancreatic lineage by inducing Shh expression. Addition of
recombinant Shh peptide to endoderm explants prevented the expression of
pdxi. However, it did not induce albumin expression. This component of liver
specification invariably required FGF.
Taken together, these data show that signalling from cardiac mesoderm to
foregut endoderm is central to correct tissue patterning during development.
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FGFs, originating in the cardiac mesoderm, signal the gut endoderm to express
Shh, which inhibits the endodermal pancreatic lineage. FGFs also instruct the
endoderm to activate the liver sequence, such that albumin and AFP
immunopositivity are the first detectable signs of liver specification. Foregut
endoderm, which is not immediately adjacent to the cardiac mesoderm, does not
express Shh and is therefore permitted to develop towards a pancreatic lineage.
Furthermore, this foregut endoderm receives insufficient FGF signalling. Thus,
the liver pathway is not pursued, and the pancreatic lineage, which is the default
pathway, is activated.
3.2.4 Bone Morphogenetic Proteins
Recent work has raised the question that septum transversum mesenchyme may
also play a significant role in the earliest stages of liver development. Previous
studies had not specifically excluded the possibility that septum transversum
mesenchyme had accidentally been included with cardiac mesoderm or
endoderm cultures. To investigate this potentially confounding issue, Rossi et
al. (2001) used a co-culture technique to investigate the role of the septum
transversum and Bone Morphogenetic Proteins (BMPs) in the earliest stages of
liver development Immunostaining showed that the cardiac mesoderm and the
septum transversum were positive for BMP4 at the at the 8 somite stage of liver
specification in mice (Rossi et al., 2001). A lacZ reporter construct at the BMP4
locus confirmed that BMP4 was expressed in the cardiac mesoderm and the
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septum transversum mesenchyme, but not in endodermal tissues destined to
become liver.
In order to determine the physiological role for BMPs, BMP4 null homozygotes
were followed through the somite stages during which the presumptive liver
tissues invades the septum transversum mesenchyme to establish the liver bud.
The BMP4 null homozygotes showed a marked delay in the normal endodermal
thickening which precedes invasion of the septum transversum by the hepatic
diverticulum, and gross impairment of the proliferation and invasion steps
which occur subsequently. Despite this, differentiation of the presumptive liver
cells occurred, as albumin mRNA expression was detected within the endoderm.
However, the level of expression was much lower than normal, possibly due to
the smaller number of presumptive hepatoblasts observed in this study.
To examine the relevance of BMPs in the context of FGF-mediated liver
specification by the cardiac mesoderm, co-cultures (mesoderm, septum
transversum and ventral endoderm) were incubated with FGF2 to induce liver
development. Co-cultures incubated with Noggin protein, a non-selective BMP
antagonist which binds BMPs, in addition to FGF2 did not demonstrate albumin
expression in 7 out of 9 experiments, strongly implicating BMPs in the earliest
stages of liver specification. To address this key issue, further experiments
showed that BMP2, 4, 7 or 9 at 200ng/ml, or BMP 2 at 50ng/ml, could
overcome the noggin-mediated inhibition of albumin expression.
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The mechanism by which BMPs might influence specification of hepatocytes has
not been clarified, however, the presence of Noggin protein vastly reduced the
expression of GATA4, a transcription factor essential for albumin synthesis.
This suggests that BMPs provide a critical permissive input to the expression of
GATA4, so enhancing the differentiation of the hepatocellular phenotype.
Interestingly, these cells expressed pdxi, the early pancreatic marker, suggesting
that the presumptive liver tissue had not received the appropriate induction
signal and was demonstrating the default lineage pathway. All of these
observations are depicted in Figure 1.4, overleaf.
The data presented in this section demonstrate the levels of complexity in the
specification and lineage restriction of the early liver. Whilst FGF2 from the
cardiac mesoderm is critically important to induce liver specification in the
endoderm, and rescue this tissue from a pancreatic fate, BMP2 is also required
to permit the normal development of the liver. Noggin protein, the BMP-
binding antagonist, was able to prevent the earliest liver marker expression,
even in the presence of FGFs. Subsequently, BMP4 null homozygotes showed
that BMPs were critically important to the endodermal thickening and migration
into septum transversum mesenchyme which occurs as a normal part of liver
development after specification.









Figure 1.4. Liver specification in development, fgf induces shh
expression in the presumptive hepatic endoderm, which prevents expression of the pancreatic lineage. The
presumptive pancreas is too distant to receive the FGF signal, and so develops along the default, pancreatic,
lineage. In the developing liver, Shh by itself does not initiate hepatic gene expression. FGF from cardiac
mesoderm, acting in concert with BMP4 as a permissive factor from septum transversum, activates the
hepatic expression pattern.
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Section 4.
Cell biology of liver development
4.1 Introduction
After liver specification has occurred, liver development is primarily directed
towards cellular proliferation until morphogenesis of the biliary tree occurs at
week 11. Prior to this point, the proliferating hepatoblasts, which are by
definition the parenchymal cells present until differentiation into cholangiocytes
and hepatocytes occurs, show evidence of bi-potentiality in terms of their
cytokeratin complement. In this regard, there is considerable overlap between
the phenotype of these developing liver cells, and liver progenitor cells detected
in adult rat liver, so-called 'oval cells', which originate from the biliary tree and
proliferate in response to injury, giving rise to ductules and hepatocytes (Alison
et al., 1996; Petersen et ah, 1998; Thiese et al., 1999).
As development progresses, biliary cytokeratins, which are initially detected in
most hepatoblasts, become concentrated around the portal tract, and the
morphology of the cells in this area changes from hepatocyte-like to
cholangiocyte-like. Whilst this is only minimally discernable with simple stains
such as Haematoxylin and Eosin, immunostaining provides clear evidence for
this phenotypic change which heralds the formation of the ductal plate. At the
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same time, the hepatic arterial inflow is established to the portal tract. This step
relates closely to the development of the ductal plate and the biliary ductules.
This section describes the nature of the early hepatoblasts, the potential
signalling pathways active on these developing liver cells which allows
proliferation and differentiation, and the early development of the biliary tree.
4.2 Hepatoblast Phenotype; IntracellularMarkers
In order to study developing liver, it is critically important to be able to define
the phenotype of the developing cells, so that differentiation can be followed in
response to developmental cues and experimental treatments. The phenotype,
which could be defined at the level of secreted proteins, cytoskeletal proteins, or
tissue-specific transcription factors, might be expected to be fluid during
development. This relates to the differing requirement for cells to undergo
proliferation earlier in development, and to acquire mature biosynthetic
capabilities later in development. The various phenotypic markers which might
be used to detect liver cells during development, and to follow patterns of
maturation in vivo and in vitro, are discussed below.
4.2.1 Intermediate Filaments
Intermediate filaments are primary structural proteins of cells, named for their
size, which is intermediate between actin and myosin. In epithelia,
heterodimers, but not homodimers, of cytokeratins form these intermediate
filaments. Each pair is comprised of one member from type I (acidic) and one
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from type II (neutral/basic) cytokeratins, each with a molecular weight of 40-
70kD. Simple epithelia tend to express one pair alone, and mature hepatocytes
express cytokeratins 8/18. By contrast, bile duct expresses 8/18 and 7/19, so
containing two different intermediate filaments. In development, tissues can
express different cytokeratin profiles, which may reflect potential for
differentiation, or suggest a previous less differentiated state.
Mesenchymally-derived tissues, such as endothelium and fibroblasts, also
contain intermediate filaments, however, in these tissues vimentin and related
proteins comprise the building blocks. By contrast with cytokeratins, vimentin
alone is sufficient to form filaments. Desmin is a related protein which is most
often associated with muscle cells. Desmin and vimentin readily co-polymerise
and so may be detected in the same cell type in the same filament. During
development, vimentin may be expressed in epithelia along with cytokeratins.
Should this occur, cytokeratins and vimentins do not form filaments together;
rather, they each form their own intermediate filaments which can be detected
separately in cells.
Cytokeratins
At the 0.5cm stage in the human fetus, which is approximately 4 weeks of age,
nascent liver epithelial cells are immmunopositive for Cytokeratin 19 (Stosiek et
al., 1990; Haruna et al.,1996). This observation indicates that cytokeratin 19
labelling is a marker for bi-potential hepatoblasts prior to ductal plate
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differentiation, as cytokeratin 19 does not occur in maturing hepatocytes later in
gestation. In addition, developing hepatoblasts, cholangiocytes and hepatocytes
are all reported to be positive for cytokeratin 14 early in development, becoming
negative by week 14 of gestation and remaining so (Haruna et al., 1996).
Cytokeratin 18, which also labels adult hepatocytes, is present in developing
hepatoblasts, hepatocytes and biliary cells at all gestational ages examined
(Shimonishi et al., 2000; Aswathi et al., 2004).
Although the studies described above identify the fetal liver type II cytokeratins,
data are scant with regard to the appropriate type I cytokeratin required to form
the intermediate filament heterodimer. Human fetal liver cells are reported to
be cytokeratin 8 positive, however, this was established only by western blot
analysis ofwhole 2nd trimester liver, and did not address which cells might be
positive (Mahli et al., 2002). A more detalailed study by Aswathi et al. (2004)
demonstrated cytokeratin 8 immunoreactivity in hepatoblasts as early as week
10. Surprisingly, bile ducts are reported to become positive for cytokeratin 7
only after 20 weeks gestation, although these authors did not examine liver prior
to 15 weeks gestational age (Sergi et al., 2000). These data were corroborated by
Blakolmer et al. (1995), who noted cytokeratin 7 immunoreactivity developing
from week 22 onwards. Cytokeratins 7 and 8 are detected in bile ducts in adult
tissues, whereas hepatocytes are labeled by cytokeratin 8 antibody alone
(Shimonishi et al., 2000).
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The above observations allow a developmental cytokeratin phenotype to be
surmised for developing human liver. In early liver, hepatoblasts are cytokeratin
8/14/18/19 positive. At this stage, no ductal plate is evident. As the ductal plate
differentiates around week 10, ductal plate cells must also be cytokeratin
8/14/18/19 positive, however, they show an intense cytokeratin 19 reaction
product (Haruna et al., 1996), whilst the remaining hepatocytes lose cytokeratin
19 immunopositivity (8/14/18/19+ve fading to 8/14/18+ve). When the biliary
tract becomes morphologically distinct in mid-gestation, the neo-ductules are
cytokeratin 8/18/19 positive, whilst hepatocytes are cytokeratin 8/18 positive.
Latterly, bile ducts show the mature pattern of cytokeratin 7/8/18/19 staining,
whereas hepatocytes still show cytokeratin 8/18 alone. These last two
phenotypes are precisely the same as observed in mature adult liver tissue
(Shimonishi et al., 2000).
Vimentin and desmin
Vimentin is considered to be a marker for mesenchymally-derived tissues such
as fibroblasts and endothelium. However, in developing human liver, vimentin
is detected within the portal tract mesenchyme generally, and in developing bile
ducts specifically, between 9 and 36 weeks gestation, but not in hepatoblasts or
hepatocytes (Haruna et al, 1996). These observations, in which a mesodermal
marker appears in liver epithelium, have been corroborated in an adult rat
model. Rats subject to partial hepatectomy and acetylaminofluorene treatment
demonstrate an intense biliary proliferative response (Alison et al., 1996), which
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provides a bipotential progenitor compartment to restore the hepatocyte and
cholangiocyte complement. Proliferating ductules show a marked
immmunopositive reaction for vimentin during the proliferative, migratory
phase of this response, which subsequently disappears when tissue repair is
complete (Alison et ah, 1996). By contrast, desmin has been demonstrated in
developing hepatic stellate cells, but not in hepatocytes, hepatoblasts or
cholangiocytes, indicating a more restricted role for desmin during development
(Nitou et al., 2000).
4.2.2 Secreted proteins and functional markers
A key feature of liver function is the secretion of a broad spectrum of plasma
proteins. Albumin and AFP are well recognised as proteins indicative of liver
differentiation and function. At the 0.5cm stage in the human fetus, which is
approximately 4 weeks of age, liver cells are positive for albumin and AFP (Rossi
et al. 2001; Haruna et al. 1996; Jones et al., 2001). In fact, these studies showed
that albumin and AFP are detected in the very earliest hepatoblasts. A
functional correlation of these data has previously been obtained by Gitlin and
co-workers. AFP was detected in supernatant from cultured fetal liver cells
collected in week 6 of gestation (Gitlin and Boesman, 1967), fibrinogen from
livers cultured at 5.5 weeks, and albumin from liver cultures at 32 days (Gitlin
and Biasucci, 1969).
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The identification of a secreted protein, along with an intermediate filament,
allows the identification of epithelial subtype, namely hepatocellular,
cholangiocyte or bi-potential progenitor. Such data permit the phenotyping of
cells in vitro, so that differentiation may be pursued during development.
4.3 Hepatoblast Phenotype; Cell Surface Markers
4.3.1 Thy-i
Thy-i (CD 90) is a transmembrane protein of molecular weight 95kD, the
various motifs of which suggest a binding site on the extracellular moiety for
which the ligand is unknown. Thy-i surface antigen has been well described as a
marker for adult liver progenitor cells ('oval cells') in mature rat liver (Petersen
et al., 1998), and is also a marker used to purify primitive haematopoietic stem
cells in clinical bone marrow transplantation (Shimazaki et al., 2004).
No data regarding purification are yet available in the fetal human liver,
however, fetal rat studies report the use ofThy-i to purify putative liver stem
cells (Fiegel et al., 2003). Cells purified using magnetic beads coated with anti-
Thy-i monoclonal antibody were positive for cytokeratin 18, albumin, AFP and
Thy-i mRNA by RT-PCR. Immunostaining these cells showed positive reaction
product using anti-albumin, anti-AFP and anti-cytokeratin 18 antibodies, which
strongly supports the hypothesis that Thy-i positive cells are closely related to
epithelial hepatocytes or hepatoblasts. Sadly, no data were presented to
illustrate which compartment in the developing liver the Thy-i positive cells
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originated from. Interestingly, Thy-i positive cells from fetal mouse liver did not
express markers of epithelial differentiation, rather, mesenchymal markers such
as vimentin and a-smooth muscle actin were noted (Hoppo et ah, 2004). These
authors were satisfied that liver progenitor cells in fetal mouse did not express
Thy-i, and that the Thy-i+ve fraction in fetal mouse liver was in fact a
mesenchymal stem cell which supported the hepatic stem cell compartment.
In adult rat liver, oval cells are capable of proliferation and differentiation so as
to regenerate hepatocytes and biliary structures (Alison et ah, 1996). These cells
are thought to derive from the smallest biliary radicles, the Canals of Hering
(Thiese et al., 1999). Responding to signals which are not yet defined, the stem
cells proliferate as an expanding oval cell fraction, in particular when liver injury
is massive or when mature hepatocytes have been prevented from proliferation,
for example using 2 acetylaminofluorene. Most data are available from the adult
rat, where Petersen has shown that these oval cells express the surface marker
Thy-i (Petersen et ah, 1998). Thus, Thy-i+ve oval cells can be selected by flow
cytometry or magnetic separation techniques, and subsequent immunostaining
reveals cytokeratin 18, AFP and albumin, confirming a primitive liver epithelial
phenotype in the injured adult rat liver. These cells undergo initial
morphological differentiation which renders them hepatocyte-like, before
expressing markers of hepatocyte maturity, such as P450 enzymes (Alison et al.,
1996).
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Thy-i was not identified as a liver stem cell marker by Petersen's group in the
adult mouse (Petersen et al., 2003). Rather, a complex phenotype, Sea
1/CD34/CD45/A6 +ve, was likely to be the stem cell fraction, as most were AFP
+ve. These observations were corroborated in fetal mouse liver when Thy-i
antibody was used to purify fetal mouse Thy-i+ cells. Whilst CD49f+ cells
(alpha-6 integrin) were positive by RT-PCR for AFP, albumin and cytokeratin 19
mRNA species, Thy-i positive cells were found to express mesenchymal
markers, such as vimentin, desmin and alpha-smooth muscle actin (Hoppo et
al., 2004). The presence of the Thy-i+ mesenchymal cells greatly enhanced the
hepatocellular differentiation of the CD49f+ liver epithelial progenitor fraction.
In parallel studies of 1st trimester human liver, bone marrow and blood, a
mesenchymal progenitor was identified which was immmunopositive for similar
markers to the above mouse Thy-1+ cell; this cell type was an effective support
for haematopoietic stem cell proliferation and was thought to be the fetal
equivalent of the adult human mesenchymal stem cell isolated from bone
marrow (Campagnoli et al., 2001). These authors did not, however, determine
whether their stem cells were Thy-i positive. From the present literature, it is
not clear whether a proportion of fetal Thy-1+ cells in the human liver are of
mesenchymal origin.
With regards to the role of Thy-i+ cell in the epithelial lineage in humans, Thy-i
positive cells have been detected in long term culture of fetal human liver, where
mixed cell cultures were characterised by flow cytometry (Lazaro et al., 2003).
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This must be regarded with some suspicion as no further characterisation was
carried out in the Thy-1 +ve fraction.
As a parallel to the data available, Fiegel et al. (2004) have studied
hepatoblastoma tumour cell types from human paediatric liver resection
specimens. Interestingly, they found cells expressing Thy-1 and either
hepatocyte or biliary lineage markers within abnormal ducts of the primitive
tumours. These data support a relationship between Thy-1 and primitive liver
progenitors, and further suggest a link between liver stem cells and cancer.
It would seem that the biology of Thy-i + cells in the mouse, rat and human is
not identical, and that whilst generalisations can be made about the roles of Thy-
1+ cells across the species, the precise biology may be quite different in each. At
present, it seems likely that Thy-i may represent a surface marker for
hepatoblasts or liver stem cells in the rat. In the mouse, data indicate that Thy-i
is not a hepatoblast marker, nor an epithelial stem cell marker. In the human,
data are too scarce to provide a useful guide. However, Thy-1 co-localisation
with cytokeratins in hepatoblastoma provides some evidence that Thy-i is at
least relevant to liver progenitor biology in humans.
4.3.2 Dlk
Delta-like leucine zipper kinase (Dlk; preadipocyte factor 1, the full length form
of fetal antigen 1 (FAi)), is a transmembrane protein which contains 6 EGF-like
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sequences in the extracellular domain, a transmembrane region and a small
intracellular component (Laborda, 2000). It is a member of the EGF homeotic
protein family, which includes the Notch receptor, and the Notch ligands such as
Delta, Serrate, and their mammalian counterparts Jagged 1 and Jagged 2. It has
been implicated in haematopoiesis and the development ofmyelodysplasia
(Miyazato et al., 2001), which extends observations that Notch is expressed by
human CD34+ haematopoietic progenitors (Milner et al., 1994). Dlk is
expressed in the human central nervous system, in particular in the
monoaminergic nuclei (Jensen et al., 2001). It is associated with inhibition of
maturation of bone marrow osteoblasts and adipocytes (Abdallah et al., 2004),
and is found in high levels in amniotic fluid, where it represents a significant
fraction of non-maternal proteins (Drohse et al., 1998).
In developmental studies, FAi, which is the truncated from of Dlk corresponding
to the extracellular component alone, was detected by immunostaining in
human fetal liver. At week 5 of gestation, immunostaining was confined to
hepatoblasts, whereas haematopoietic cells were negative (Floridon et al.,
2000). As gestation progressed, staining intensity fell until by week 15, little
immunoreaction was observed. FAi staining was observed in the fetal pancreas
in this study, with all glandular cells strongly labelled. In both human and rat,
immunoreactive FAi/dlk was found latterly in gestation to be associated with
insulin-secreting pancreatic beta cells alone (Tornehave et al., 1996: Carlsson et
Chapter 1 Literature Review 36
al., 1997), prompting suggestions that this pathway was important in beta cell
differentiation.
In rat liver, Dlk is expressed on the surface of hepatoblasts and antibodies
directed against the extracellular moiety have been used to purify hepatoblasts
from day 21 of gestation fetal rats (Jensen et al., 2004) and from E14.5 fetal
mouse liver (Tanimizu et al., 2003; 2004). No such attempts have been
described using human tissues. In rat and mouse, hepatoblasts purified using
anti-Dlk antibodies and magnetic separation express alpha-fetoprotein and
albumin mRNA and/or protein. Interestingly, very few cells were
immmunopositive for both albumin and cytokeratin 19, the biliary marker, in
the mouse cells, and intra-splenic transplantation of these cells in a mouse
model resulted in donor hepatocytes alone (Tanimizu et al., 2003). These data
suggest that the dlk+ cells may be at a more differentiated stage than those cells
isolated using more traditional stem cell markers (see Suzuki et al., 2000, 2002).
However, further studies by the same group refuted this observation. Using
magnetic separation to purify dlk+ cells, these authors isolated pure cultures
from E14.5 day mouse livers. Cells were cultured on laminin and incubated with
oncostatin M and Matrigel. A second group of cells were grown in a collagen gel
(Type I) and treated with HGF. A third group of cells were cultured on plastic in
the absence of dexamethasone, but in the presence of HGF and retinoic acid.
These different culture conditions gave rise to hepatocyte, cholangiocyte and
pancreatic (3-cell differentiation, underscoring the developmental relationships
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between all three cell types, which are of course all derived from gut endoderm.
With regard to the phenotype of the cultured liver progenitors, all expressed
albumin and cytokeratin 19 when cultured at confluence in non-differentiating
conditions, however, the expression of dlk rapidly fell to undetectable levels
within days (Tanimizu et ah; 2004). It is worthy of note that the original
purified dlk+ cells were stated to be negative for cytokeratin 19. This in some
way contrasts with the human data, where very early liver cells are noted to be
albumin+ and cytokeratin 19+ (Stosiek et ah; 1990: Rossi et al.; 2001).
Taking all of the data together, Dlk is a surface marker of hepatoblasts in rats
and mice, and the developmental data although scant in human fetal liver,
supports the hypothesis that Dlk is a hepatoblast marker in the fetal human
liver.
4.3.3 E-Cadherin
E-Cadherin is a cell surface calcium-dependent binding molecule which
mediates intercellular adhesion in epithelia, and is expressed in human
hepatocytes (Ogou et al., 1983). In the developing mouse liver, it is present on
the hepatocellular membrane (Nitou et al., 2000). This property has been used
to purify presumptive hepatoblasts from the fetal mouse liver at E12.5 by
magnetic bead separation. E-cadherin positive cells were found to express
cytokeratins, albumin, AFP and E-Cadherin, but were negative for Desmin, by
immunofluorescence (Nitou et al., 2002). Isolated culture of hepatoblasts
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rapidly lead to loss of albumin, AFP and E-cadherin staining, an effect which was
reversed by co-culture with the E-cadherin negative fraction (non-parenchymal
cells), strongly suggesting a mutually supportive role for parenchymal and non-
parenchymal cells. This was previously alluded to by Hoppo et al. (2004).
Studies in the human fetal liver have been carried out to examine the
developmental profile of E-cadherin and the intracellular species which mediate
the linkage between E-cadherin and actin filaments, a and (3-catenins (Terada et
al., 1998). E-cadherin was immunostained in livers as early as 8 weeks, but the
authors only describe findings from 10 weeks onward. E-cadherin was
expressed in the ductal plate cells, and not in hepatocytes or hepatoblasts, and
the staining suggested a cytoplasmic localisation, rather than the membranous
location as demonstrated for adult human hepatocytes in the same study.
However, the livers studied were at a more advanced stage in development
compared to the mouse studies of Nitou et al (2002) where E-cadherin was a
hepatoblast surface marker. There is, as yet, no good evidence in the human
that early hepatoblasts express E-cadherin. Nonetheless, E-cadherin is a
component of intercellular junctions, particularly tight junctions mediated by
cellular desmosomes, and would be expected to be expressed in liver epithelium.
Further studies are required to establish definitivelywhether E-cadherin plays a
role in human liver hepatoblast development. Nonetheless, the expression of E-
cadherin by maturing biliary tract, which finally becomes membranous at the
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immature bile duct stage (Terada et al; 1998), suggests a method to identify
purified populations of this cell type.
4.3.4 Integrins
Integrins are widely implicated in the structural integrity of epithelia. The
integrin complex (3ioc6 (CD29CD49f) is expressed by proliferating mouse liver
progenitors in vitro (Tanimizu et al., 2004). This complex binds laminin, a
substrate demonstrated to enhance survival ofmouse liver progenitors
(Tanimizu et al., 2004). Mouse chimaeras created with (h-integrin null ES cells
resulted in progeny which demonstrated [ii-integrin null cells present in
mesodermal structures, but a striking absence of null cells in any endodermally-
derived epithelia, for example liver (Berger et al., 2003). [3-1 integrin is critically
involved in maintenance of human hepatocyte viability, and activation of (3-1
integrins using the activating antibody TS2/16 reduces apoptosis caused by loss
of the integrin in adult human hepatocytes (Newsome et al., 2004), possibly via
a MAP kinase dependent pathway (Zhang et al., 2002). No data exist describing
the presence or role of (3-1 integrins in the early human liver, however, it is likely
that the absence of beta-i integrin cells in endodermally derived epithelia relates
to apoptotic deletion, underscoring the importance of intercellular integrity in
liver development (Couvelard et al., 1998).
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4.4 The proliferation of liver progenitors
Early hepatoblasts undergo proliferation without appreciable differentiation
until the appearance of the ductal plate as detected initially by immunostaining
around week 6 of gestation. Even at this point, most hepatoblasts remain
undifferentiated until much later, when the primitive cytokeratin profile changes
to that of hepatocytes. This proliferative phase is likely dependent, in part, on
the absence of mediators of differentiation and the presence of specific growth
factors which support proliferation without differentiation.
In order to understand the biology of developing liver cells, and to harness their
potential for clinical treatment, it is necessary to determine which factors might
be responsible for initiating proliferation without differentiation in the
progenitor pool. This section seeks to examine several factors previously
identified as promoting liver cell proliferation which may be active in fetal life.
4.4.1 Epidermal Growth Factor (EGF)
Of various growth factors reputed to cause hepatocyte proliferation, significant
data have accumulated to support a role for EGF. Epidermal growth factor is a
53 amino acid cytokine of 6.2kDa, which binds with highest affinity to EGF-Ri,
also known as erbi (c.f. erb 2-4). In human hepatocytes, data suggest that EGF
is a potent mitogen (Engl et al., 2004), and is important for histogenesis of liver
tissue (Michalopoulos et al., 2003). In normal human liver, hepatocytes
strongly express EGF receptor mRNA, in contrast to the biliary system, which is
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negative (Milani et al., 1991, Komuves et al., 2000). TGF-a, which is a potent
physiological agonist at the EGF receptor, is present in fetal human hepatocytes
(Yasui et al., 1992) and may act in an autocrine manner (Harada et al., 1996). In
the proliferating liver cells found in cirrhotic nodules, hepatocytes are strongly
positive for EGF pre-pro-peptide, the EGF precursor, whereas accompanying
bile ducts are only very faintly labelled, despite the high levels of EGF mRNA in
the biliary system (Komuves at al., 2000). In further support of a role for EGF
in physiological liver cell proliferation, data show that EGF expression is
upregulated within 30 minutes of partial hepatectomy (Mullhaupt et al., 1994).
EGF also induces proliferation in hepatoma cells, acting via a genistein-sensitive
pathway (Wu et al., 2003).
In developing human liver, the EGF receptor gene is substantially
hypomethylated compared to adult tissue, implying increased gene expression
(Kaneko et al., 1985). To complement this observation, Terada et al. (1994)
documented the ontogeny of Transforming Growth Factor-a (TGF-a) and its
receptor (the EGF receptor) in human fetal liver. During fetal life, bile ducts
contained the strongest staining for both TGF-a and receptor, whereas
hepatocytes were moderately immunopositive for TGF-a and only mildly
positive for receptor. By contrast, adult liver showed strong staining in
hepatocytes and bile ducts for receptor, with only bile ducts staining for TGF-a.
Disappointingly, these authors did not study this pathway prior to the ,
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emergence of bile ducts in development. It therefore remains unclear as to
whether the EGF pathway is present earlier in development, and if so, what its
role might be with regard to developing hepatoblasts.
In studies of cultured human fetal liver cells, EGF has been shown to induce
proliferation of cells in vitro (Mahli et al, 2002), which is associated with
increased yGlutamyl transferase (y-GT) and tyrosine aminotransferase
activities (Rehman et al., 2004). However, these studies did not identity the
specific cell types involved, and so the conclusion that hepatocyte proliferation
per se was induced by EGF cannot be supported by this work.
With regard the tissue responses to EGF, and the developmental time frame for
EGF activity, EGF receptor immunoreactivity was first detected on day 17 of
fetal development in the rat, with intrinsic kinase activity appearing by day 18
(De et al., 1991). These data were complemented by the high levels ofTGF-a, an
EGF receptor ligand, found in fetal rat liver at day 20 of gestation (Brown et al.,
1990). Such data argue against a role for EGF in early liver development, as this
time period occurs considerably after the time of liver specification and initial
hepatoblast proliferation. Rather, such EGF activity may be involved in
hepatocyte proliferation occurring as a liver growth phenomenon immediately
prior to birth. On the other hand, these observations reveal the possibility of a
further level of control in the EGF pathway during development.
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In summary, the evidence implicating EGF in the developing human liver is
circumstantial. In the rat, data support a role late in development. The time
frames for human and rat liver development are very different in the two
species, and it is probably unwise to over-extend observations from one to the
other. A putative role for EGF in developing human liver awaits dynamic studies
in vitro to determine which cell types might respond to EGF.
4.4.2 Hepatocyte Growth Factor
Hepatocyte Growth Factor (HGF) is a glycosylated protein heterodimer
comprised of alpha and beta chains bound by a disulphide bond. This growth
factor is secreted as an inactive precursor (pro-HGF) then cleaved by a
urokinase-like activity to yield an alpha-beta HGF structure capable of binding
and activating the HGF receptor tyrosine kinase (Vigna et al., 1994). HGF is well
recognised as the 'scatter factor', and is now thought to mediate significant
aspects of the switch from non-invasive to invasive phenotypes of certain
cancers (De Luca et al., 1999: Medico et al., 2001). The role of HGF to induce a
morphological and phenotypic change in liver cells from a stable epithelial
pattern to a mobile mesenchymal immature cell type during development has
been well established (Pagan et al., 1999).
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In early human liver development, HGF is expressed by the septum transversum
mesenchyme, and c-Met, the HGF receptor, is located on hepatoblasts (Schmidt
et al., 1995; Bladt et al., 1995). HGF is also found in the haematopoietic cells of
the liver (Defrances et al., 1992). Inactivation of either of these molecules causes
liver hypoplasia as a result of significantly increased apoptosis The mechanism
which subserves this cell death has not been described, but it is tempting to
invoke failure of HGF-dependent synthesis of Bcl-2 or Bcl-xl as the cause of
apoptotic cell death. Interestingly, HGF knockout is lethal in utero, and fetuses
show grossly hypoplastic livers with parenchymal cell depletion and, in addition,
severely malformed placentas leading to intrauterine death (Schmidt et al.,
1995)- To complement these data, c-met positive cells, but not CD45, the
leukocyte common antigen, positive cells, from fetal liver were able to
repopulate the injured liver with hepatocytes in a retrorsine/two-thirds
hepatectomy rat model (Suzuki et al., 2004). These observations establish that,
the HGF/c-met pathway is central to normal liver development. In support of a
role in the acquisition of liver mass, adult mouse studies show that c-met/HGF
is critical to liver regeneration after liver resection or liver injury (Huh et al.,
2004).
In the developing human, c-met and HGF have been detected in fetal liver
between 6 and 13 weeks of gestation, suggesting a role continuing beyond the
earliest specification and invasion phases of liver development (Kolatsi-Joannou
et al., 1997). Later, c-met is expressed in the ductal plate and in the developing
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bile ducts, as well as in hepatocytes, but only at low level; subsequently c-met
protein is not detectable after 30 weeks gestation nor in normal adult liver
(Terada et al., 1998). These findings go along with the general hypothesis that
the HGF/c-met pathway may be required as an anti-apoptosis mechanism in
development. This may act in concert with the NF-kB pathwaywhich also
prevents apoptosis in development (see below).
A simple role for HGF/c-met in development, as previously discussed, may be
complemented by a role in hepatocellular maturation (Spijkers etal., 2001). In
the rat, c-met was shown to be weakly positive throughout the liver early in
development, however, at day 13 of gestation, expression rose sharply, whilst the
localisation moved rapidly to the hepatic periphery. At the same time, the urea
cycle enzyme carbamoylphosphate synthase appeared at the porta hepatis. The
authors concluded that the change in localisation of the c-met protein heralded
the end of the embryonic phase and the beginning of the fetal, maturational
phase. There may be some relationship in this between the expression of c-met
protein and the appearance of the Notch/Jagged pathway which is thought to
mediate ductal plate differentiation (see section 4.5.2, below).
Taken together, the data presented show that the c-met/HGF pathway is
critically important in the normal development of the liver. Parenchymal cell
complement is very much dependent on HGF/c-met, as demonstrated in the
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knockout studies. Conversely, later development appears not to require HGF in
quite the same way. However, there are species differences, and the data in
humans in particular are scant. An understanding of the role of HGF in the
developing human liver awaits further studies.
4.4.3 Tumour Necrosis Factor
In adult liver, proliferation ofmature hepatocytes readily occurs in response to
liver injury, as clearly documented in historical (Higgins and Anderson, 1931;
Lawrence et al., 1959) and contemporary studies (Boulton et al., 1998). Mature
hepatocytes enter S phase within 16-17 hours of two-thirds hepatectomy, with a
proliferative response approximately 15-fold that of control levels (Gerlach et al.,
1997).
In mature animals, Tumour Necrosis Factor a (TNFa) priming leads to a 2 -4
fold greater hepatocyte proliferation in response to growth factors (Webber et
al., 1998). Antibodies to TNF inhibit the IL-6 rise and inhibit hepatocyte
proliferation after partial hepatectomy (Akerman et al,. 1992). TNFRi gene
knockout leads to severely impoverished hepatocyte proliferation as a response
to partial hepatectomy (Yamada et al., 1997). These data confirm that in mature
animals, in addition to a major role in the sepsis response, TNF is central to the
reparative proliferation seen in liver regeneration after injury.
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The developing mouse liver at day 10-13.5 of gestation expresses TNFa in a
majority of cells, although the immaturity of the liver makes morphological
identification of the specific cell types problematic (Doi et ah, 1999). Knockout
mice lacking the gene for TNFa show no ill effects in liver development and are
born with normal livers, demonstrating that TNFa is not required. Conversely,
knockout mice lacking the relA subunit ofNuclear Factor kappa B (NF kB), or
the I kappa B kinase gamma subunit, demonstrate embryonic lethality
accompanied by massive liver apoptosis (Doi et ah; 1999: Rudolph et al., 2000).
Mice with relA deficiency can be rescued from embryonic lethality by a further
knockout of the TNFa gene (Doi et al., 1999). These data demonstrate that
TNFa is responsible for cell death in the knockout fetal liver, and that NF kB
normally protects the developing liver from TNFa -induced apoptosis.
Although double knockout mice are born with no evidence of liver abnormality,
they later succumb to an episode of what appears to be sepsis around day 40 of
life, having been made profoundly susceptible to infection by the relA knockout.
In adult animals, the evidence supports a role for TNFa in triggering the wave of
cell proliferation that occurs in response to liver injury or liver resection.
However, the evidence cited from developmental studies suggests that TNFa is
not a major factor, and may be responsible for parenchymal cell apoptosis in
particular situations.
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4.4.4 Gpi30 receptor ligand family
This cytokine family includes oncostatin M (OSM), Interleukin 6 (IL-6), IL-ll,
Leukaemia inhibitory factor, ciliary neurotrophic factor and cardiotrophin-i. All
family members interact with a receptor, comprising a ligand-specific
component and gpi30, the common signalling component. This leads to
common effects observed in the presence of different ligands. Acting via Janus
Kinase activation, STAT3 is phosphorylated, and the resulting dimer then passes
to the nucleus to bring about various transcriptional effects. In parallel, SH2 is
bound and activated by the gpi30 subunit, which then recruits the Raf/MAPK
pathway as part of the pleiotropic effects of these ligands (Taga and Kishimoto,
1997).
The greatest evidence base which supports a role for gpi30 ligands during liver
development concerns Oncostatin M (OSM) and the effects on liver maturation,
rather than proliferation. In very early embryogenesis, OSM is responsible for
the induction of haematopoietic stem cells from the primitive haemangioblasts
of the aorta-gonad-mesonephros area in Eli mouse embryos (Mukouyama et al.,
1998), cells which then invade the liver to form the definitive haematopoietic
tissues of the fetus. OSM is then produced by the haematopoietic cells of the
fetal mouse liver, whereas the OSM receptors are predominantly expressed by
hepatocytes, strongly supporting a paracrine role for OSM during liver
development (Kamiya et al., 1999). Gpi30 null mice do not show the large
accumulation of glycogen in late fetal stages, again supporting a role for OSM in
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hepatic maturation (Kamiya et al., 1999). Despite the weighty assertions made
by Kamiya et al. (1999), careful examination of their data reveal that the
experiments were not specifically designed to answer the questions they posed.
For example, low glycogen levels in gpi.30 null liver are attested to by low
magnification and poor quality micrographs. The alternative hypothesis, that
hepatocyte apoptosis explains the lack of glycogen storage, is not rejected by the
data presented. Similarly, their data suggesting that OSM is expressed by
haematopoietic cells and OSM receptor by hepatocytes is based on mRNA data
alone, and on a method of cell purification for which no evidence of actual cell
purification is provided. This paper in particular must be regarded as
provisional until stronger data are reported.
By contrast to the OSM data, IL-6 added to cell cultures had little effect on
indices of liver maturation. However, addition of soluble IL-6 receptor to the
cultures allowed IL-6 to induce effects similar to OSM (Kamiya et al 1999).
These data suggest that IL-6, another gp-130 family member, could have
significant effects in developing liver, provided that soluble IL-6 receptor is
present.
Despite certain weaknesses in the literature, there seems little doubt that gpi30
ligands are significant in hepatocyte maturation. OSM at a level of 10 ng/ml was
required along with glucocorticoid (Dex; 10-7M) to induce the polygonal
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epithelial phenotype associated with developing hepatocytes (Kamiya et al.;
1999); neither alone was sufficient in this regard. OSM is implicated in the
development of E-cadherin-mediated adherens junctions between hepatocytes, a
mechanism which is critically dependent on the K-Ras, but not H-Ras nor N-
Ras, pathway (Matsui et al., 2002a). OSM down regulates Cyclin D in liver
development, supporting the idea that OSM favours maturation rather than
proliferation (Matsui et al., 2002b).
Despite the significant literature in fetal rat and mouse liver, little data are
available in humans. Attempts to develop artificial liver devices using
commercially available human fetal liver tissue have shown that OSM can induce
albumin production and P450 enzyme activity, whilst suppressing alpha
fetoprotein. However, the cell cultures expressed 10 fold less functionality than
Hep G2 tumour cells, strongly suggesting a profound difficulty with these
commercial preparations (Hanada et al., 2003).
4.5 The induction of the ductal plate and bile ductmaturation.
4.5.1 Introduction
The ductal plate first appears at the hilum of the liver in the 1.8 cm human
embryo (Ruebner et al., 1990), which corresponds approximately to 6 weeks
gestational age, the corresponding figure in the rat being day 15 of gestation
(Shiojiri et al., 1991). The ductal plate arises from the hepatoblasts which are in
contact with the mesenchyme surrounding the portal tract, which at this stage
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contains only portal vein. Initially, the ductal plate forms a sleeve-like interface
between portal tract and hepatocytes (See Figure 1.2). The hepatic artery
branches are absent when the ductal plate forms, but are fully developed before
the primitive tubules differentiate. Clearly, there are many potential
mesenchymal-epithelial interactions which may co-ordinate the induction and
differentiation of the biliary tree.
4.5.2 Induction of the ductal plate.
The induction event responsible for the appearance of biliary tract precursors
has only recently been investigated in animal models, and has not so far been
studied in detail in the human. In humans, available data strongly implicate the
Jagged/Notch pathway in the commitment of hepatoblasts to a biliary fate and
the morphogenesis of the biliary tree. Alagille syndrome, which is known to
result from an allelic null mutation of the Jaggedi gene (JAGi), the ligand for
the receptor protein Notch, is observed to cause developmental abnormalities in
the liver, a primary feature of which is impaired differentiation of the
intrahepatic bile ducts from ductal plate. Sequencing analysis of the genotype in
patients with Alagille syndrome indicates that various genetic lesions, all of
which are within the Jagged 1 gene, may result in the phenotypic expression of
the disease (Yuan et al., 1998). Mouse studies indicate, as one might expect, that
abnormalities in Notch may also result in the disease phenotype. Mice
heterozygous for the Jaggedi null allele and the Notch2 hypomorphic allele
demonstrate the characteristic developmental abnormalities ofAlagille
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syndrome, including those of the intrahepatic biliary tree (McCright et al.,
2002).
These data suggest a role in human liver development for the Jagged/Notch
pathway. This has been pursued at a preliminary level using histological studies
of developing human liver (Flynn et al., 2004). Notch 1-4 mRNA was present in
fetal liver during development. Notch 3 receptor protein was expressed in the
portal tract mesenchyme, whereas Jagged 1 was localised to the ductal plate. No
other developmental data were offered in this study, and so the dynamic
developmental interactions for this pathway in the human remains obscure.
In the fetal mouse at 15.5 days gestational age, Notch 2 mRNA was most
abundant, whereas mRNA species for Notch 1, 3 and 4 were, by comparison,
barely detectable (Tanimizu and Miyajima; 2004). Only Notch 2 protein was
visualised by immunocytochemistry. In early development, Notch 2 was
detected in a diffuse pattern which as development progressed, rapidly
concentrated in the ductal plate and in parenchymal cells close by. By contrast,
Jagged 1 was detected in abundance in the mesenchyme surrounding portal
vein. Immediately adjacent to this Jagged 1 positive layer lay the ductal plate.
Given that both Jagged and Notch are cell surface molecules it may be that direct
contact mediates this induction, so leading so a single layer of ductal plate cells
abutting the portal tract mesenchyme. Further experiments by the same group
showed that Notch inactivation, either by siRNA directed against Notch 2 or
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pharmacological inhibition with the y-secretase inhibitor L685,458, caused up-
regulation of liver specific genes such as tyrosine aminotransferase and
carbamoyl phosphate synthase.
By contrast, activation of this pathway by constitutive expression of the
intracellular signalling domain of the Notch molecule, lead to expression of
cholangiolar markers, such as CK19, CK7, HNF-i(3 and integrin B4. These data
are supported by observations that overexpression of Jagged 1 in mouse liver
drives expression of CK19 and gamma-glutamyl-transpeptidase via
transactivation of the Hes 1 promoter (Kodama et al., 2004).
Taken together, these findings strongly suggest in the mouse that the Jagged 1
ligand, found in cells of the portal vein mesenchyme, acts on immediately
neighbouring parenchymal cells to induce ductal plate phenotype. By contrast,
the situation in the human fetal liver seems less clear, as the Jagged 1 lay in the
ductal plate and Notch 3 in the portal tract mesenchyme. The inversion of the
ligand/receptor pair in the human suggests a more complex mechanism. It
remains possible that mesenchymal Notch activation causes a second signal to
pass to the nascent ductal plate from the portal tract mesenchyme to induce
ductal plate differentiation. Such mechanisms require dynamic studies in vitro
to determine the interactions of various pathways.
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4.5.3 Remodelling the ductal plate
The signalling mechanism which mediates formation of primitive biliary tubules
from the ductal plate is unknown. The addition of HGF to cultures of human
biliary cells induced invasion of a collagen gel in vitro to yield an anastomosing
network ofbiliary cords (Ishida et al., 2001), much like the migration of ductal
plate cells into the portal mesenchyme during remodelling. No data were
advanced by these authors beyond these observations, and no other groups have
studied this phenomenon. Other groups have made important observations
regarding the signalling required to initiate ductal plate differentiation. Fetal rat
liver cells collected at day 14 of development transplanted into syngeneic adult
rat spleen demonstrated orderly differentiation of ductal plate and biliary
ductules (Notenboom et al., 2003). The authors made the observation that this
may be an intrinsic property of hepatoblasts exposed to mesenchyme. This is a
very important observation, as it suggests that clues from placenta or gut venous
blood are unimportant, compared to the presence of mesenchymal tissue.
Clearly, further study is required in this area, in particular as these mechanisms
may underlie disorders of the biliary tree observed in infantile biliary dysgenesis
and in post-transplant cholangiopathy.
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4.6 Development of the vascular structures of the liver
4.6.1 Portal vein and sinusoids
At the very earliest stages of liver development, the endodermal bud grows into
the septum transversum, at which time there is no vascular supply. Within the
septum transversum, primitive angioblasts proliferate and coalesce to form a
capillary endothelial plexus which intermingles with the developing hepatic
epithelium to form the hepatic sinusoids. The importance of these endothelial
cells has been thrown into sharp relief by data from Matsumoto et al. (2001).
They prepared flk-i-/- mutant mice with absent endothelial cells and
demonstrated that the nascent endothelial cells are responsible for the
demarcation of the tissues into which the liver bud will grow, and that deletion
of endothelium causes failure of outgrowth of the liver bud. These data suggest
developmental signalling between the two compartments well before other
studies had previously implied.
4.6.2 Hepatic artery
Until week 10 of development in the human, no hepatic arterial representation
exists within portal tracts. Subsequently, portal tract capillaries form in situ by a
process of vasculogenesis from CD34+ve mesenchymal stem cells which are
detected in the portal tract around this time (Terada and Nakanuma, 1993;
Nakanuma et al., 1993: Gouysse et al., 2002). There is a topographic sequence
ofmaturation, exactly as for the ductal plate, with vessels first appearing in the
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hilar region around week to, with successively maturing vessels developing
towards the periphery of the liver up to week 15.
The relationship between hepatic artery and ductal plate is a complex one.
Observations indicate that the hepatic arterial inflow to a portal tract is always
completed before the biliary radical proper arises from the ductal plate
(Libbrecht et ah, 2002). In developmental disorders of the intrahepatic biliary
tree, anomalies of the hepatic arterial inflow within portal tracts are strongly
associated with abnormal differentiation of the bile ducts (Awasthi et al., 2004).
In fact, whilst no specific differences were observed in portal veins, hepatic
arteries were observed to be hypertrophied and hyperplastic in cases of
intrahepatic bile duct dysgenesis. Given that Jagged 1 is synthesised in portal
vein, hepatic artery and ductal plate (Tanimizu and Miyajima, 2004: Flynn et al.,
2004), and that Notch 3 receptor protein lies within the portal tract
mesenchyme (Flynn et al., 2004), there may be a reciprocal signalling
mechanism between mesenchyme, ductal plate and vessels. As yet, there are no
data in the literature to indicate any mechanistic interaction between bile duct
cells and hepatic artery branches. Nonetheless, an interdependence is strongly
suggested by available data.
4.7 Functional studies of liver progenitors
Hepatoblasts potentially could form the basis for cell therapy of liver disease.
Clearly, it is critical to identify which cell fraction in the developing liver might
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possess the requisite proliferative capabilities and biochemical maturity. The
developmental potential of hepatoblasts has been investigated mostly through
transplantation experiments, principally in the rat. Dabeva et al. (2000) utilised
a very rough preparation of day 14 fetal rat liver, with the dipeptidyl-peptidase
IV (DPPIV) positive F344 rat as a donor. At this developmental stage, liver
epithelial cells are hepatoblasts by definition, as the primitive biliary tract is yet
to develop (Van Eyken et al., 1988). In the study by Dabeva et al (2000), the
liver was subject to collagenase digestion and selective removal of red cells
alone, resulting in a purity ofAFP positive cells estimated at 15%. This mixed
preparation was then infused into portal vein of DPPIV negative F344 recipients
either immediately after two thirds partial hepatectomy or after no procedure.
The data clearly show that the liver cells differentiated into both hepatocytes and
biliary tract cells. Further work suggested that as much as 60-80% repopulation
may occur (Sandhu et al., 2001). Animals not subject to hepatectomy
demonstrated minimal engraftment of transplanted cells. In fact, a proliferative
signal to the native liver was shown to be critical to engraftment, proliferation
and differentiation, and that whilst hepatectomy provided the most potent
stimulus, tri-iodothyronine treatment could also stimulate these processes.
Interestingly, animals left for several months after cell transplantation
demonstrated continuing proliferation of the transplanted cells in contrast to
adult hepatocytes, confirming the long-term proliferative capacity of fetal liver
epithelial cells (Sandhu et al., 2001).
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Human fetal liver cells have recently been investigated in a similar manner.
Mahieu-Caputo et al. (2004) took liver from fetuses 11-13 weeks gestational age,
isolated the epithelial cells and, after cryopreservation, transplanted them into
athymic mice. Up to 10% engraftment was reported, and human liver serum
proteins were detected by immunostaining in the mouse liver. This is potentially
a very important study, however, the authors failed to take the opportunity to
determine the functional competence of the transplanted cells. For example,
70% hepatectomy after engraftment would potentially have lead to an expansion
of the human liver cell fraction, to the degree that the animal was arguably
dependent on the presence of the human liver cells, demonstrable by plasma
protein concentrations. This would have strengthened the importance of this
paper considerably. Therefore, reports of credible functional data concerning
human fetal liver cell transplantation remain absent from the literature.
In mouse studies, liver removed from day 11 post coitus embryos was subject to
Fluorescence Activated Cell Sorting (FACS) to provide a fraction characterised as
c-kitlow (CD45/TER119)-, which was demonstrated to repopulate all epithelial
lineages (cholangiocytes and hepatocytes) of depleted liver tissue in vitro
(Minguet et al., 2003). Although these authors made no attempt to specify
exactly which cells were responsible for repopulation, they made the point that
the specific cell type was contained in their FACS-isolated fraction. Of course,
this experiment did not assess functionality in vivo, nonetheless, these data
strongly suggest that this phenotype may be important in cell transplantation.
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These data were extended by further studies of a similar fraction from mouse
liver, c-kitlow (CD45/TER119) - a6-integrin+/|3i-integrin+. These authors
transplanted the cells into adult mouse spleen, whereupon cells migrated to liver
and differentiated into liver parenchymal cells (Suzuki et al, 2000).
In order to purify mouse hepatoblasts, E-cadherin antibodies coupled to
magnetic beads were used with liver cells from day 12.5 of gestation. (Nitou et
al., 2002). These cells were isolated and cultured, and found to express
albumin, AFP and carbamoylphosphate synthetase. Expression was supported
only when non-parenchymal cells were allowed to interact with the purified
hepatoblasts, an effect which was mimicked by conditioned medium from the
non-parenchymal cells.
Taken together, these data show that hepatoblasts are competent to provide
functional hepatocytes and biliary epithelial cells in vivo, at least in the rat.
Surprisingly, a method as coarse as portal venous infusion appears sufficient to
deliver cells which can occupy any liver epithelial compartment. Whilst
published data concerning hepatoblasts seems relatively unrefined at present, a
separate population of cells, hepatic stem cells, is presently being pursued as a
potential source of liver cells. Of note, highly purified CD34+ve human
haematopoietic stem cells isolated from umbilical cord blood or from adult
human bone marrow have been transplanted into mice. Liver histochemistry
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one month post transplant demonstrated the incorporation of hepatocytes
immunopositive for human albumin, and the presence of detectable quantities,
albeit very small, of circulating human albumin in these animals (Wang et ah,
2003). Such data imply that engraftment of human stem cells in the liver has
occurred, and that differentiation to form hepatocytes has also been confirmed.
These studies are dissimilar to the work described above, in that these authors
sought to identity precursors to hepatoblasts, rather then hepatoblasts per se.
Essentially, two approaches are slowly arising in the attempt to understand
developing liver biology; the first is utilising hepatoblasts and the second
hepatoblast stem cells. Clearly, these fields are highly complementary, and
knowledge of both disciplines will be required to develop cell therapies into the
clinical domain.
Whilst the observation that highly purified liver stem cells can be transplanted
into mice and engraft is very exciting, some very basic data are clearly lacking
from the literature. No critical studies of the functionality of developing human
liver cells in vitro or in vivo have been attempted, in particular, no studies have
described protein secretion or urea synthesis, or whether certain agents can
bring about maturation or proliferation of hepatoblasts, or even whether
functional status is altered by, for example, proliferation signals. Without
knowledge of these factors, the observation of engraftment becomes strictly
academic. In fact, in studies reported so far, no evidence has been provided that
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fetal human liver cells retain any competence after transplantation; for example,
no metabolic diseases have been corrected by human fetal liver cell transplant.
Without key understanding of the relevant maturation and proliferation signals
for human fetal liver cells, the tremendous promise of these cells as a therapeutic
tool remains to be realised.
Chapter I Literature Review 62
Section 5
Functional maturation of the liver
5.1 Introduction
During the embryonic period, which is up to the end of the second month in
humans, the development of the liver is primarily directed towards tissue
morphogenesis and lineage development, so as to deliver the cell complement
appropriate to the functional maturation of the liver. Development during the
embryonic stage is strictly limited to an increasing complement of genes
expressed and cytoplasmic proteins relevant to this proliferative stage.
The anatomical maturation of the liver, which predominantly relates to
development of bile ducts and hepatic arterial inflow, clearly has implications for
developing function. All of these developmental steps have at least delivered an
organ capable of secreting bile into the duodenum by week 11-12. Further
development in utero features this anatomical maturation moving out
progressively from hilum to periphery, a phase which lasts some way into the
third trimester.
At birth, the liver must be capable of gluconeogenesis, ammonia detoxification,
plasma and coagulation protein synthesis and metabolite conjugation. Whilst
the neonatal liver is not fully mature, it must have a level of function consistent
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with survival whilst further maturation occurs. This section reviews the rather
scant but important literature describing functional development of the liver.
5.2 Plasma Proteins
Albumin mRNA and protein are detected within the cytoplasm of presumptive
hepatoblasts during the 4th week. Albumin synthesis and secretion is a unique
biological function of this organ in the adult. At the same stage of development,
alpha-fetoprotein expression is recognized in hepatoblasts (Jones et al., 2001).
Whilst albumin is regarded as the major component contributing to plasma
oncotic pressure in adults, as well as a transport medium for various
physiological and xenobiotic species, AFP is thought to be the corresponding
plasma protein during fetal development. AFP is secreted by liver cell cultures
as early as 4-5 weeks of gestation, as well as by cultures of yolk sac and
gastrointestinal tract cell preparations (Gitlin et al., 1972).
Parallel studies have described albumin, AFP, alpha-i-antitrypsin, transferrin,
and alpha-2 macroglobulin production by the yolk sac in first trimester fetuses
(Gulbis et al., 1998). These authors considered that the yolk sac was the primary
site of protein synthesis until the liver had sufficiently matured. Of course,
evidence from Gitlin et al. (1972) demonstrates that the liver is already
competent to secrete AFP at least, although other viscera may contribute to the
developing plasma protein complement.
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In support of the hypothesis that the early liver is competent to secrete many
proteins, a pioneering study by Gitlin and Biasucci (1969) combined tissue
culture with radioimmunoelectrophoresis to demonstrate the breadth of plasma
proteins which were synthesised in the human embryo as early as day 29 of
gestation. These authors documented secretion of transferrin, albumin,
prealbumin, ai-antitrypsin, C'l esterase inhibitor, hemopexin, ^-lipoprotein and
a2-macroglobulin from embryo cultures at day 29, and caeruloplasmin and
orosomucoid by day 32. Later, fibrinogen secretion was documented, but not
until 5.5 weeks. All of these proteins were synthesised by the liver. IgG and IgM
synthesis was also detected at 10.5 and 12 weeks respectively. However, these
proteins were synthesised by the developing spleen. Although protein synthesis
in general increased remarkably during gestation, most remained well short of
maternal levels by parturition. These observations suggest that synthetic
capacity of the liver matures considerably during gestation; however, the liver in
the newborn is still immature.
In second trimester fetuses, albumin levels increase from approximately 4 g/1 to
over 10 g/1 by week 23 (Christiansen et al., 2000). By the third trimester, levels
of albumin are virtually identical to adult levels, approximately 35-45 g/1 (Nayak
and Mital, 1977). By contrast to the upward trends in fetal albumin, AFP at term
has fallen to approximately 10% of the level observed 7 weeks previously (Bader
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et al., 2004). AFP continues to fall post partum, consistent with further
maturation of the fetal liver.
Albumin and AFP synthesis and secretion are clearly differently regulated.
Immunocytochemistry reveals that these proteins may be found separately in
different hepatocytes, but may also be detected simultaneously in the same cell.
The plasma concentrations of each appear to be related to the total number of
cells synthesising the particular protein. In each case, cells distributed around
central veins appear to be the preferred location for synthesis (Bader et al.,
2004).
5.3 Coagulation Factors and Fibrinogen
The coagulation pathway in neonates has long been recognized as immature,
and bleeding diatheses in newborns have prompted the introduction of routine
vitamin K injections within the first few days of life for all British children.
Although there are no published data for the first trimester, vitamin In¬
dependent coagulation factor activities in the second trimester are just 9-28% of
adult levels (Forestier et al., 1985). More detailed study of healthy fetuses in
which cord blood samples were collected under ultrasound guidance from the
second trimester until the neonatal stage showed progressive gestational
changes. The vitamin K-dependent factors, II, VII, IX and X, generally trend
upwards during fetal life (Reverdiau-Moalic et al., 1996). Interestingly, the
prothrombin time and the activated partial thromboplastin time fell from 32 to
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17 seconds and 169 to 44 seconds respectively over the period from 19 weeks to
newborn; at the same time, fibrinogen levels rose from 0.85 to 1.7 g/1. These
data are consistent with developmental maturation which provides a functional
coagulation system at birth. By way of physiological compensation, coagulation
inhibitor concentrations were also very low during development, providing a
balance for the low levels of coagulation factors.
During development, adequate fetal haemostasis is essential to prevent fetal loss
or neonatal death (Sun et al., 1998). The majority of coagulation factors are
synthesized in the liver, and so liver maturation has a further role to protect the
fetus against spontaneous, catastrophic, haemorrhage. Fibrinogen null/null
mice demonstrate normal survival during gestation, but only half survive 2
weeks post-natally, with the remainder dying as a result of intraperitoneal
bleeding (Camerer et al., 2004). This is contrasted with pro-thrombin deficiency
which leads to mid-gestation loss or death by haemorrhage in the immediate
neonatal period (Sun et al., 1998). In humans, the recessive genetic condition
afibrinogenaemia resulls in an absence of detectable fibrinogen and affected
children may demonstrate spontaneous haemorrhage (intracranial bleeding,
gastrointestinal bleeding, haemarthrosis, splenic rupture) at any time in
gestation or post-natal life (Neerman-Arbez et al., 2003).
These data indicate how important a functioning coagulation cascade is for fetal
and neonatal survival. During fetal life, there is a progressive increase in
fibrinogen levels, although there is a marked discrepancy between functional
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and total fibrinogen and the levels at birth are still low compared to adult
(Reverdiau-Moalic et al., 1996). The maturational signal which mediates this
important gestational change is unknown.
5.4 Maturation ofbile synthesis in fetal life.
The anatomical development of the biliary tree is clearly a pre-requisite to bile
secretion in fetal life. At week 11 in the human fetus, the hollow extrahepatic bile
duct connects with the sleeve-like ductal plate which surrounds the portal tracts
at the hilum. The ductal plate then begins to remodel in a centripetal manner,
such that intrahepatic bile ducts form first at the porta hepatis. Having
established a communication between parenchymal hepatocytes and the lumen
of the gut, the way is paved for bile secretion into the gut to commence at week
12.
Cell cultures prepared from second trimester human livers excrete fluorescein,
permitting the authors to hypothesise that the liver at this stage was competent
to secrete bile (Bauer eL al., 1991). However, no evidence was provided to
demonstrate that bile secretion actually occurred in this model. Dumaswala et
al. (1989) had already shown that human fetal gallbladder bile contained a
broad spectrum of bile acids from weeks 16 to 19 of gestation. Later work
demonstrated bile acid secretion as early as week 12 (Itoh and Onishi, 2000).
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The question as to whether such bile acids might possibly have been ofmaternal
origin was refuted comprehensively in two studies which showed a very different
spectrum of bile acids in fetal bile as compared to the adult. These studies
identified novel pathways of bile acid synthesis in human fetal development; C-i
and C-6 hydroxylation was observed by Colombo et al. (1987) and C-4
hydroxylation by Dumaswala et al. (1989), indicating a relative immaturity of
the adult C-12 pathway. Interestingly, the C-4 hydroxylation pathway had not
previously been described in mammalian bile acid synthesis (Dumaswala et al.,
1989; Nakagawa and Setchell; 1990).
The predominant bile acid in the mid trimester liver is chenodeoxycholic acid,
with cholic acid second in abundance. However, concentrations are extremely
low prior to week 17 (less than o.osmM; Colombo et al., 1987). Thereafter,
concentrations began to rise sharply, possibly reflecting the anatomical
maturation of the intrahepatic bile ducts at that stage (Crawford, 2002). Whilst
chenodeoxycholic acid predominated over cholic acid in early development, full
term fetuses demonstrated an inversion of this finding, undoubtedly reflecting
the maturation of the C-12 pathway later in development (Nakagawa and
Setchell; 1990). At birth, bile secretion is critical to survival; fat absorption from
milk, and the avoidance of steatorrhoea, is critically dependent on a well-
functioning enterohepatic bile salt circulation.
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5.5 Glucose homeostasis.
Not until parturition is the fetus dependent on endogenous glucose. At this
time, the relative hypoxia of labour places significant pressure on anaerobic
metabolism and, therefore, on hepatic glucose production. This becomes critical
to survival during parturition.
5.4.1 Glycogen metabolism
The key enzymes involved in glycogen metabolism are glycogen synthase and
phosphorylase, responsible respectively for synthesis and breakdown of
glycogen. Glucose-6-phosphatase, the enzyme releasing glucose to blood,
catalyses the final step in glucose release from hepatic stores.
Glycogen is detectable in the fetal human liver at week 8 of gestation and builds
slowly thereafter, with levels of glycogen synthase increasing in parallel
(Schwartz et al., 1975). Glycogen synthase activity continues to rise as late as 36
weeks (Devi et al., 1992). Indirect measurements of human fetal liver glycogen,
using the ultrasound attenuation coefficient of fetal liver, have shown that
glycogen levels increase towards a maximal pre-parturient level, then fall
sharply during labour (Carson et al., 1990; 1991). These data suggest that
increasing glycogen stores relate to increasing activity in the synthetic pathway.
Animal studies confirm that glucocorticoids and insulin produce a synergistic
effect in stimulating glycogen synthesis in fetal hepatocytes, with no effect of
Chapter 1 Literature Review 70
insulin alone in rats (Plas and Nunez, 1976), although human fetal liver
responds by increasing glycogen content (Schwartz et ah, 1975).
Early experiments with fetal liver slices made the observation that glucagon,
acting via cAMP, caused glycogenolysis (Schwartz et ah, 1975). In a parallel
paper, these data were refined to show that the cAMP pathway could be
augmented by the glucocorticoid agonist triamcinolone (Schwartz and Rail,
!975)- Notably, agonists working through cAMP (glucagon, (3-agonists) or IP3
(ATP, vasopressin, angiotensin) are able to induce glycogenolysis in human liver,
with a slightly greater potency ascribed to the former group (Keppens et ah,
1993)- Physiological agonists acting via these pathways are present in elevated
concentrations in fetal plasma during labour (Pohjavouri et al., 1985),
supporting the hypothesis that fetal stress may provide the trigger for
glycogenolysis at term.
Glucose-6-phosphatase is the specific liver enzyme which permits glucose to be
released into blood. This enzyme has been documented as early as 7.5 weeks
gestation in human liver (Simpson et al., 1987). Interestingly, no change was
observed in activity between weeks 7.5 and 24, with levels approximately 30% of
postnatal controls throughout. These data imply that the change from fetal to
neonatal levels may occur late in development (Girard, 1986). The most detailed
studies have been carried out by Burchell and Hume (1995), whose data
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reinforce historical studies, and demonstrate a marked, developmental^
regulated, change in tissue distribution and levels.
5.4.2 Gluconeogenesis.
Gluconeogenesis is dependent on a supply of precursors, usually lactate and
glucogenic amino acids, ofwhich alanine is most important. These are funnelled
after transamination, for example by alanine aminotransferase, either through
pyruvate or via the citric acid cycle so as ultimately to provide oxaloacetate. This
is the common pathway feeding in to phosphoenolpyruvate carboxykinase
(PEPCK), which is the rate-limiting step in gluconeogenesis. Latterly, glucose-6-
phosphatase releases free glucose from hepatocytes into blood.
Neonatal hypoglycaemia is a significant issue in paediatric practice; published
studies reveal that 37-43% of neonates show hypoglycaemia within 2 hours of
birth (Cole and Peevy, 1994). The absolute requirement for hepatocellular
cytoplasmic PEPCK to protect against hypoglycaemia in neonatal life is well
shown in studies of human neonates lacking this enzyme; such newborns rapidly
succumb to hypoglycaemia within hours of birth (Vidnes and Sovik, 1976). Of
the four key enzymes of gluconeogenesis, only cytoplasmic PEPCK is absent
from fetal liver. This enzyme is repressed by the physiological levels of insulin in
the fetus, and it is the fall in insulin levels in the immediate postnatal period
which induces PEPCK expression rather than hypoglycaemia (Yeung and Oliver,
1968).
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Importantly, fetal Cortisol appears to protect against hypoglycaemia
(Economides et al., 1988), and Cortisol levels are higher and the incidence of
hypoglycaemia lower in those babies born by vaginal delivery (Economides et al.,
1988; Cole and Peevy, 1994). PEPCK activity rises dramatically in the 24 hours
after delivery which may relate to increased Cortisol levels post-partum, however
the role of glucagon (and of insulin) cannot be ignored (Girard, 1986).
Molecular studies of PEPCK show a cAMP response element, a Glucocorticoid
response element and a thyroid hormone response element in the promoter
region of PEPCK. In addition, C/EBPa has a critical role, as null homozygous
mice with a C/EBPa deletion die of hypoglycaemia within hours of birth
(Hanson and Reshef, 1997). It is clear from these data that despite the critical
importance of PEPCK in gluconeogenesis, the role for PEPCK in preventing
hypoglycaemia is strictly in the post-natal period. Similarly, it is clear that
hepatic gluconeogenesis cannot form the primary mechanism to support glucose
levels prior to birth. Therefore, fetal glycogen synthesis and glycogenolysis must
be the most important mechanism to maintain glucose levels before
gluconeogenesis is fully functional.
Taking these data together, the fetal liver is able to deliver glucose during birth
as a result of a progressive maturation of pathways subserving glycogen
synthesis and breakdown. Postnatally, gluconeogenesis is activated in the
immediate post-partum stage to maintain glucose levels at physiological levels.
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Clearly, maturation of these pathways during fetal life is central to survival in the
perinatal stage.
5.6 The urea cycle and organification of ammonia.
The incorporation of ammonia into urea converts a highly toxic species into a
non toxic, highly soluble by-product which may be easily excreted. This pathway
protects the fetus from irretrievable neurological injury which would supervene
should ammonia levels rise much above the physiological range. Maturation of
this pathway in development is necessary for fetal survival beyond the first few
days (Schofield et al., 1999).
During fetal development, urea cycle enzyme activity increases to approximately
90% of adult levels by week 36 (Mukarram Ali Baig et al., 1992). Some authors
have documented the full complement of urea cycle enzymes as early as week 9
(Karsai and Elodi, 1982). Carbamoyl phosphate synthase I is the rate limiting
enzyme for the urea cycle, and is present at the highest level compared to other
enzymes in 1st trimester liver (Karsai and Elodi, 1982). Immunostaining for CPSI
demonstrates reaction product in human liver by day 31, only 5 days after liver
specification (Van Beers et al., 1998). Detectable urea synthesis occurs in the
second half of gestation, doubtless related to increasing enzyme activity
(Mukarram Ali Baig et al., 1992; Karsai and Elodi, 1982).
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Urea cycle enzymes have been studied in greatest detail in animal models. Fetal
rat liver has very low synthetic capacity, which rapidly rises to V4 of adult levels
within 24 hours of birth (Kadowaki et al., 1983). Corticostreroids and glucagon
have central roles in this induction of urea cycle activity (Husson and Vaillant,
1982), which has a striking similarity to the induction of glycogenolysis in term
rat fetuses as described in previous sections. CPSI mRNA and protein are absent
at day 16 of development, and only appear in significant amount by day 20,1 day
before birth (Van Beers et al., 1998). The late appearance of this rate-limiting
enzyme in urea synthesis, coupled with the low fetal urea cycle activity and a
rapid neonatal increase in activity contrasts sharply with the situation in the
human. As alluded to above, urea cycle activity is at 90% of adult levels by week
36 of gestation. No detailed data are available which illuminate the mechanisms
whereby this gestational rise occurs. However, it may be that the human
neonate has a lesser tolerance for ammonia toxicity than the rat, hence the
differing perinatal urea cycle capacities.
This section sought to review the functional maturation of fetal liver in vivo, so
as to provide insight to the potential liver function at different gestational ages.
It is clear that the functionality of early liver, at the time when scientific studies
of liver tissue have been undertaken, is modest. Certainly, those studies which
have examined trends in liver function during gestation show very large changes
this time frame, however, the neonatal liver just barely has the requisite function
to ensure survival. Whilst there is credible data showing that differentiated fetal
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liver cells survive in culture, at least in the rat, there is no credible data to
describe specific mediators of maturation and proliferation, and no data to show
enhanced functional status as a response to intervention. Transplantation of
fetal liver cells, as presently understood, could not be a therapeutic intervention,
until more data are available to clarify how these cells can be made suitable for
such a purpose.
5.7 Maturation signals in the fetal liver.
5.7.1 Introduction.
During fetal life, organ growth and physiological maturation occur, in order to
equip the fetus with such physiological reserve as appropriate to the rigours of
parturition and the initial stages of independent life. Maturation of the fetal
liver is central to survival during this phase.
5.7.2 Glucocorticoids
In animal studies, glucocorticoids in the fetal circulation increase markedly
during late gestation (Norman et al., 1985), in parallel with glucocorticoid
receptor expression (Speirs et al., 2004) in fetal liver. Although glucocorticoid
receptors have been detected in human fetal liver (Ballard and Ballard, 1974),
the action of glucocorticoids has not been documented in developing humans.
Cell culture work using animal tissue reveals that glucocorticoids promote urea
synthesis from ammonia by enhancing activity of all five urea cycle enzymes
(Ulbright and Snodgrass, 1993) in fetal rat. Maturation of the urea cycle is an
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absolute requirement for perinatal survival (Schofield et al., 1999) and for
perinatal gluconeogenesis, which is also under direct stimulatory input from
glucocorticoids (Hanson and Reshef, 1997), as approximately 2 moles of
ammonia are generated for every mole of glucose synthesised from amino acids.
Glucagon is reported as being of increasing importance in the immediate
perinatal phase of gluconeogenesis (Hanson and Reshef, 1997), with some
evidence for glucagon resistance in fetal life (Devaskar et al., 1984; Vinicor et al.,
1976). Together, glucocorticoids and glucagon may have a potent role to bring
about the functional development of the liver.
5.7.3 Thyroid hormones
In parallel with glucocorticoids, thyroid hormone in fetal liver may exert
developmental effects. T3 causes a re-prioritisation of plasma protein synthesis
in fetal rat liver; albumin mRNA and protein synthesis is increased in a dose-
dependent manner by T3, whilst AFP mRNA and protein is co-ordinately
decreased (Anteby et al., 1993). In human HepG2 cells, AFP and alpha-i-
antitrypsin secretion is similarly decreased, whilst alpha-i-acid glycoprotein was
increased by T3 (Kobayashi and Horiuchi, 1995). T3 is also noted in animal
studies for a potent proliferative effect in hepatocytes (Cubero et al., (2005), and
a role to support glycogen synthesis (Betley et al., 1993), both of which are
features of the developing liver. These data suggest that T3 may be important in
human liver development, but do not clearly indicate whether proliferation or
function will be supported by this hormone.
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5.7.4 Sex steroids
Oestrogens and progesterone are present in umbilical vein blood where they are
conducted directly to the fetal liver. As gestation progresses, a complex interplay
between fetal liver and placenta develops which is responsible for the synthesis
of oestriol, the predominant oestrogen towards term in the human. Whether sex
steroids have a role in liver development is not known, as the data from the
literature regarding sex steroids and liver development are extremely scant.
Simpson and Carr (1984) demonstrated increased synthesis of cholesterol from
human fetal liver cells in response to high levels of oestradiol, which occurred in
a dose-responsive manner. In adult humans, exogenous sex steroids are
associated with the formation of liver adenomas, which are thought to have
malignant potential. The data suggest a proliferative response, or a change in
differentiation status, as a result of oestrogens or androgens (Belghiti and
Farges, 2001). Given the extremely high levels of sex stroids in the liver inflow,
it remains entirely possible that these hormones may have significant effects on
liver function, however, there are no published data.
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Section 6.
Summary and Objectives
The fetal liver provides significant potential for the treatment of liver failure.
During fetal life, the developing liver is required to attain sufficient mass and
biochemical competence to support neonatal survival at term. These various
competencies, which include plasma protein secretion, ureagenesis,
gluconeogenesis, bile secretion and conjugation, are precisely those required in
adults with liver failure. In contrast to the failing liver, the fetal liver
demonstrates increasing functional competence over time, presumably in
response to various signals provided by the fetal environment. It is this capacity
for proliferation and functional maturation which makes the developing liver so
important in the search for new modalities of treatment in liver disease.
It is clear from the review of the literature that there is considerable depth of
knowledge regarding the cell biology controlling the earliest stages of liver
development. Similarly, there is considerable knowledge which relates to the
developmental anatomy. Despite this, the functional status of the liver cells,
which cannot be determined by PCR or immunocytochemistry, has been
neglected, despite the critical observation that it is the functionality of the liver
rather than its fascinating organogenesis which sustains life. In particular, the
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environmental cues which trigger functional liver development in humans are
unknown.
In order to address these issues, an hypothesis was formed to focus specifically
on the acquisition of liver function in development. This hypothesis states that
'Soluble factors which mediate tissue development act on fetal liver to induce
proliferation and maturation of liver tissue'.
To address this hypothesis, the following aims were identified;
1. To develop a culture system which could support developing human liver
tissue in vitro, and to confirm that liver tissue retained measurable
functionality in vitro (Chapter 3).
2. To determine candidate maturation signals using functional assays of
liver cells in the presence and absence of putative signalling ligands
(Chapter 4).
3. To investigate proliferation signals in developing liver, and to assess the
cellular phenotype responding to the individual proliferation signals
(Chapter 5).
4. To assess the effects of maturation and proliferation signals on functional
aspects of developing liver (Chapter 6).
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The purpose of this thesis is to develop a suitable model of developing human
liver, and to examine progenitor hepatocyte proliferation and maturation.
Further, this thesis sought to determine how biological competence varied after
exposure to these various agents which are capable of inducing proliferation and
maturation.
A series of experimental chapters follows which describes these avenues of
investigation. A final chapter presents a unified view of the experimental
findings, and suggest areas for further study.




This chapter describes techniques common to a number of studies in this thesis.
Methods which relate to a specific chapter are elaborated upon in the relevant
chapters. The specific methods for fetal liver tissue culture are discussed in
chapter 3, where the various steps required to develop the technique are also
presented.
2.2 Urea assay.
The kit commercially available to measure urea from ammonia (Sigma) is based
on the Berthelot reaction. This reaction results in the formation of indophenol, a
highly coloured blue product, from ammonia, hypochlorite and phenol in the
presence of nitroprusside, which acts as a catalyst. This reaction is shown in full
below (Figure 2.1). In order to measure urea with this reaction, urease is added
initially, converting all urea to ammonia which then participates in the Berthelot
reaction. A problem arises in cell cultures to which free ammonia has been
added to provide a precursor for urea synthesis. In order to measure urea alone,
the samples are assayed twice, once with urease and once without. The
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Figure 2.1. The Berthelot reaction to detect urea by colorimetry
A; Urea is converted to ammonia by enzymatic hydrolysis (urease). B; Ammonia, hypochlorite and phenol are
mixed. C; In the presence of nitroprusside, indophenol blue is formed and detected at 630nm.
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difference between the two estimations reveals the amount of ammonia derived
from urea, whereas the estimation in the absence of urease shows the total
amount of free ammonia remaining in the sample.
The kit available from Sigma was designed to utilise a sample size of 10 pi, with a
final reaction volume of 7.5ml in a 10ml test tube. As every single experiment
would generate a minimum of 48 samples, which would be prohibitively time
consuming and inaccurate to manage in individual test tubes, it was decided to
re-develop the assay on a semi-micro basis which would allow handling of large
numbers of samples relatively easily.
The Sigma urea assay kit No. P 640 was used throughout as the basis for this
technique. Costar 96-well ELISA low protein binding plates (Corning Inc.) were
used throughout. Samples were kept frozen at -20°C prior to assay. On the day
of assay, samples were thawed, kept on wet ice, and divided into two aliquots
which were assayed separately in triplicate, with aliquot 1 assayed in the
presence of urease and aliquot 2 in its absence. So as to reduce the assay from
tube to microplate level, the assay volumes were divided by 40 and the assay
replicated directly, giving a final reaction volume of 1904!.
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2.2.1 Standards
Standards were made from analytical grade urea (Sigma) dissolved in
ureagenesis buffer (Table 2.1). Other constituents are shown in Table 2.2.
2.2.2 Method
To each well was added I2.5pl of urease in buffer or buffer alone and 2.spl of
sample, standard or blank in triplicate. The plate was briefly agitated on a plate
shaker, and then incubated for 30 minutes at 37°C in a humidified incubator.
The phenol/nitroprusside, alkaline hypochlorite and water were then added; the
plate was again agitated and incubated at room temperature for 30 minutes.
The absorbance of each well was then measured at 630nm on a Dynex MRXII
platereader (DYNEX Technologies, USA)., using the mean of triplicate readings
with blank subtraction.
It was not clear as to what the range of the assay would be in microplate format,
and so an experiment was designed to establish the concentrations of urea which
might be detected by the assay. A range of standards was made up using serial
dilutions. The absorbance readings relating to the various standards are shown
in Figure 2.2 below.
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Table 2.1 Ureagenesis Buffer.
10 ml of lox Earle's Balanced Salt Solution (Invitrogen) with calcium and
magnesium
0.5 ml of 20% human serum albumin
1 ml of Penicillin/Streptomycin
1 ml of sodium pyruvate stock (loomM)
1 ml of lM HEPES
1 ml of 2 M glucose stock
3ml of 7.5% NaHC03 stock
Ammonium chloride lM stock (sterile filtered) 1:1000 dilution as required.
Make up volume to 100ml with sterile culture-grade water.
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Figure 2.2. Titration of the range for the ureamicroplate assay.
In triplicate wells, urea standards were prepared in assay buffer from 1000 down to l micromol/l. The assay
protocol was carried out and the colour reaction product indophenol blue was measured by absorption at
630nm. Absorption minus reagent blank was plotted against urea standard concentration. From the curve
plotted above, the useful range of the assay appeared to be from too to iooomicromol/1, and further
modification was required to deliver a more sensitive assay technique.
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The limit of detection appeared to be between 50 and 100 pmol/1, which was felt
to be insensitive. As it was likely that the amounts of urea synthesis by the
cultures would be small, the sample volume was increased 10 times to 25pl and
the urease volume was increased to 50pl. Other volumes remained the same.
The duration of urease incubation at 37°C was set at 30 minutes or 60 minutes,
and the assay was then repeated. The results are shown below in Figure 2.3.
As can be readily seen, the assay appears more sensitive than previously.
Incubation for 60 minutes gives a curve which lay on the horizontal axis after
blank subtraction, and was felt to give better assay performance. These data
were re-plotted to demonstrate the linearity of the relationship, which was
entirely acceptable, as shown in Figure 2.4, below.
Ultimately, the decision was taken to utilise standards between o and 500pmol/l
in ioopmol/1 increments. As can be seen in the figures, this appears to be the
most linear part of the curve.






















Figure 2.3. Determination of the incubation period at 37°C.
In triplicate, urea standards were prepared in assay buffer from 2000 to 1 micromol/l by serial dilution. The
volume of standard in the assay was increased to 25 microlitres, and the volume of urease solution to 50
microlitres. The assay was carried out as previously except that the incubation at 37°C was extended to 30
minutes or 60 minutes. The reaction product indophenol blue was measured by absorption at 630nm and the
absorption minus reagent blank was plotted against urea standard concentration. From the curves above, the
assay appeared to be more sensitive than previously. A 60 minute incubation was preferred as it allowed an
asymptotic approach to the x-axis.
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Figure 2.4. Linearity of the urea microplate assay.
In triplicate, urea standards were prepared in assay buffer from 2000 to 1 micromol/l by serial dilution. With
25 microlitres of standard, and 50 microlitres of urease, the assay was carried out with the incubation at 37°C
of 30 or 60 minutes. The reaction product indophenol blue was measured by absorption at 63onm and the
absorption minus reagent blank was plotted against a linear scale of urea standard concentration. The 60
minute incubation was chosen as the assay reagent blanks approached the origin as shown above.
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2.3 General methods for tissue culture
Whilst different cell types and culture methods are used in this thesis, certain
techniques are common throughout and are described here.
2.3.1 Materials
All culture media and balanced salt solutions were obtained from Invitrogen, as
were fetal calf serum, Penicillin/Streptomycin mix (10,000 Units/ml + lomg/ml
respectively) and Insulin/Transferrin/Selenium supplement (ITS-X). L-
glutamine, lM HEPES, and human serum albumin were obtained from Sigma.
Type II collagenase was supplied by Worthington (Lome Laboratories, Reading)
and trypsin EDTA solution by Invitrogen. Type I Rat tail collagen solution was
obtained from Roche Diagnostics (East Sussex). All other biochemicals were
culture grade or better, and were obtained from Sigma. All plasticware was
sterile, disposable, and was supplied by Invitrogen.
2.3.2 Cell culture
Cells were cultured in Costar polystyrene flasks, or in 6,12, 24 and 96 well
plates. The culture medium depended on the cell type used, however, culture of
HepG2 cells (hepatoma cell line) required io%FCS in DMEM with antibiotics
(1:100 dilution of stock) and L-glutamine (2mmol/l final concentration).
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2.3.3 Trypsinisation
Cells were trypsinised by pouring off culture medium, washing twice in an
appropriate volume ofwarm Hank's Balanced Salt Solution without calcium or
magnesium, then adding an aliquot of 5ml trypsin/EDTA solution warmed to
37°C, and pouring off the excess. After this step was repeated, cultures were
incubated at 37°C until the cells were released from the substrate, as
demonstrated by loosening after a sharp tap. Ice cold culture medium
containing 10% fetal calf serum was added to the suspension to neutralise the
trypsin, and the cells were poured off into a 20 ml universal container and spun
down at 1500 rpm (320g) for 5 minutes (MSE Centaur I, Thermo Life Sciences).
The supernatant was poured off, and cells were then resuspended as appropriate
in a specific volume of medium or buffer. An aliquot was then removed for cell
counting using a trypan blue technique as described below.
2.3.4 Cell counting.
An aliquot of cell suspension with a known volume was removed and added to a
known volume of 4% trypan blue (Sigma) and mixed on a vortex mixer,
providing a dilution between 1:2 to 1:20 as desired. This suspension was added
to the counting chamber of a Neubauer haemocytometer and viewed at high
power under an Olympus CHA microscope (Olympus UK). Five small squares
from the field of 25 were counted, with those cells touching the upper or right
sided dividing lines being counted, and those crossing the lower or left sided
lines excluded. The total count and the number of blue (dead) cells were noted,
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and the various calculations were carried out as described below to provide an
indication ofviability and cell density.
Viability = total cells - dead cells/total cells x 100%
Mean live count per square = total live count/5 = A
Dilution factor = B
Number of cells/ml = A*B*104
Total number of cells = A*B*i04*volume of suspension
Cells were then replated as appropriate in warmed culture medium at a specific
density/cm2, or otherwise processed for experiments.
2.4. Characterisation of liver cells by flow cytometry
Flow cytometry utilises specific antibodies linked to fluorescent labels to identify
cell populations expressing the antigen of interest. In brief, a cell suspension
containing cells which have bound antibody is treated with a fluorescently
labelled second antibody. This cell suspension is fed through the cytometer, and
laser excitation at specific wavelengths induces fluorescence at different
wavelengths. This fluorescence is detected as the cell passes a photomultiplier,
and the cell is 'counted' as immmunopositive/negative for the antigen of
interest.
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Most commonly, cell surface antigens are first choice when developing a method
for flow cytometry. However, the cell surface antigens for human fetal
hepatocytes were not recorded in the literature, and so methods were developed
to detect the known intracellular antigens of developing hepatocytes and biliary
tract cells.
These techniques were not available in the laboratory, and so were developed as
part of the preliminary characterisation of the fetal cell cultures. All antibodies
were obtained from DakoCytomation. In the first instance, Hep G2 cells were
used to assess which fixation and permeabilisation protocol would be suitable.
Subsequent studies utilised either HepG2 or fetal liver cells to validate the
technique. Flow cytometry to assess cell surface antigens, as described in
chapter 3, was carried out in exactly the same manner, except that the
permeabilisation step was omitted.
2.4.1 Fixation and Permeabilisation for Flow Cytometry.
40g Paraformaldehyde (Sigma) was weighed out accurately and added to 850ml
deionised water. This was heated to 70°C for 30 minutes with stirring. A few
drops of lM NaOH were added to solubilise the paraformaldehyde, after which
100ml iox phosphate buffered saline was added (Table 2.3). The solution was
then allowed to cool, made up to 1000ml with deionised water, the pH adjusted
to 7.4 as required and stored for up to 3 weeks at 4°C. This stock solution of 4%
formaldehyde was used to prepare more dilute fixatives as required.
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To make 10X PBS, the salts were made up to 1 litre with deionised water, and the pH was
adjusted with concentrated HC1 or NaOH to PH7.4 (pH meter, model 410, Thermo Orion, UK).
This was diluted 10 fold with deionised water for use.
Chapter 2 General Methods 96
In order to fix cells for flow cytometry, cell cultures were trypsinised and washed
as described above. Cell suspension in cold culture medium was placed in 3ml
polypropylene tubes (100,000 cells per tube; Sarstedt, Cologne) and cells were
spun down at 200g for 5 minutes. Cells were resuspended in 0.5ml fixative and
incubated at 4°C for 15 minutes. To compare fixatives, this technique was
carried out in two concentrations of formaldehyde in PBS, 0.05% and 0.5%.
Fixatives for this experiment were prepared by diluting stock fixative (4%
paraformaldehyde in lomM PBS, pH 7.4), with iomM PBS.
2 ml i%BSA/o.i% sodium azide in PBS pH 7.4 (wash buffer) was subsequently
added to each tube to neutralise fixative and block non-specific binding sites.
Cells were then spun down at 320g for 5 minutes as before and the inactivated
fixative was poured off. Having fixed and washed the cells, cell membranes
were permeabilised with either 0.1% triton X (Sigma) in blocking solution (10%
normal swine serum (DakoCytomation), in wash buffer) or blocking solution
alone for 30 minutes. 2 ml wash buffer was subsequently added to each tube
which was spun down as previously.
2.4.2 Fibrinogen Flow Cytometry.
Cells were resuspended in 50 microlitres rabbit anti-Fibrinogen antibody
(DakoCytomation) at 1:50,1:100 or 1:200 dilution in blocking solution for 60
minutes at room temperature. 2 ml wash buffer was added to each tube which
was vortexed and centrifuged as before. 50 microlitres swine anti- rabbit-
Chapter 2 General Methods 97
fluorescein isothiocyanate conjugate (SWAR-FITC; DakoCytomation) were
added to each tube at 1:20 dilution in blocking agent and the tubes were
incubated for a further 30 minutes. 2 ml wash buffer was added, and the cells
spun down and resuspended in 200 microlitres of wash buffer ready for flow
cytometry. Control primary antibody was an affinity-purified normal rabbit IgG
fraction at the same dilutions as primary antibody (DakoCytomation).
The flow cytometer (Coulter EPICS XL-MCL; Coulter UK) was calibrated using
control tubes prepared at the same time as the experimental samples. Excitation
was by 488nm argon laser, and emission fluorescence was collected through a
525 (green), 575 (red) or 620 (deep red) nm narrow bandpass filter (+/- 5nm).
In the case of FITC conjugated antibodies, the 525 nm filter set was used.
Forward scatter and side scatter were set to exclude debris. Photomultiplier gain
was adjusted to ensure data collection from all cells. Data were collected
electronically. Tubes incubated with control rabbit antibody and secondary
antibody were included in these tubes so as to estimate true background
fluorescence. The gain on the flow cytometer was then finely adjusted, as were
various gates, to discriminate between the negative and positive controls and
collect specific data relating to different cell populations. Mixtures ofboth
positive and negative controls were prepared and run through the cytometer to
confirm that discrimination was satisfactory.
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2.4.3 Results
Figure 2.5 shows the results expressed as relative fluorescence compared to
control antibody, in cells with and without permeabilisation, at different levels of
fixation. As can be seen, 0.5% formaldehyde with 0.1% Triton X provided the
best permeabilisation and fluorescence signal, and the best signal to noise ratio
was obtained with an antibody dilution of 1:200.
Figure 2.6 shows the individual cytograms obtained during the dilution curve of
anti-fibrinogen antibody in permeabilised cells fixed with 0.5% formaldehyde.
Although individual antibody dilutions must be determined empirically, all
subsequent experiments with intracellular antigens utilised 0.5%
paraformaldehyde in iomM PBS as a fixative and 0.1% triton X as a
permeabilisation agent.
2.4.4 Two colour flow cytometry for fetal hepatocytes.
Cultured fetal liver contains many different cells by phase contrast microscopy,
and the histology of the liver at this developmental stage reveals that hepatocytes
represent less than 50% of all cells. It was therefore necessary to develop a
method to quantity hepatocytes unequivocally, so as to determine effects of
various proliferation and maturation signals.
































Figure 2.5. Fixation and permeabilisation for flow cytometry
Cell cultures were trypsinised, washed, and resuspended in 0.5ml fixative (0.05 or 0.5% formaldehyde) per tube and
incubated at 4°C for 15 minutes. 2 ml wash buffer was added to each tube to neutralise fixative. Cells were spun down
and permeabilised with either 0.1% triton X in blocking solution or blocking solution alone for 30 minutes. Cells were
resuspended in 50 microlitres rabbit anti-Fibrinogen antibody at 1:50,1:100 or 1:200 dilution in blocking solution for 60
minutes at room temperature. Cells were then washed with 2 ml wash buffer per tube, spun down and the supernatant
discarded. 50 microlitres swine anti- rabbit-fluorescein isothiocyanate conjugate were added to each tube at 1:20
dilution in blocking agent, and the tubes were incubated for a further 30 minutes. 2 ml wash buffer was added, and the
cells spun down and resuspended in 200 microlitres of wash buffer ready for flow cytometry. Control primary antibody
was an affinity-purified normal rabbit IgG fraction at the same dilutions as primary antibody. The results were expressed
as relative fluorescence compared to control antibody, in cells with and without permeabilisation, with the two fixatives.
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Normal Rabbit Serum control 1:50
Rabbit anti-Fibrinogen 1:50
Normal Rabbit Serum control 1:100
1 / Rabbit anti-Fibrinogen 1:100
Normal Rabbit Serum control 1:200
Rabbit anti-Fibrinogen 1:200
Figure 2.6. Cytograms for anti-fibrinogen flow cytometry in HepG2 cells.
Cells were fixed with 0.5% formaldehyde and permeabilised with 0.1% triton X. After washing, cells were incubated with rabbit
anti-Fibrinogen antibody or normal rabbit serum at 1:50 to 1:200 dilution. After a wash step, cells were incubated with swine anti-
rabbit F1TC antibody at 1:20 dilution. Immunopositive cells were detected by flow cytometrywith excitation at 488nm and
detection at 525nm.
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To quantify fetal hepatocytes, cytokeratin 18 monoclonal antibody was chosen in
addition to the previously developed anti-fibrinogen technique. Two-colour flow
cytometry would allow the identification and quantification of cytokeratin
18+ve/fibrinogen+ve hepatocytes, and would also allow the characterisation of
any cytokeratin 18+ve/fibrinogen-ve epithelial cells, such as cells committed to
biliary tract lineages, or primitive epithelial precursors.
Cytokeratin 18 flow cytometry.
Cells in culture were fixed and permeabilised with the protocol already
established above. The blocking serum used was 10% normal goat serum
(Scottish National Blood Transfusion Service, Edinburgh) in flow cytometry
buffer, and the primary antibody was mouse monoclonal anti-human
cytokeratin 18 (DakoCytomation). The second antibody was Goat anti-mouse
Phycoerythrin conjugate (DakoCytomation) at a dilution of 1:20 in cytometry
buffer. Otherwise all other conditions were the same as for the fibrinogen flow
cytometry. The flow cytometer was set to receive fluorescence via the 575nm
narrow band pass filter, with excitation at 488nmm.
Serial dilutions of the primary antibody (1:25 to 1:100) were used to identify the
dilution which gave the optimal specific signal with the lowest background.
Figure 2.7 shows the cytograms obtained with anti-cytokeratin 18 and control
antibody. The results showed that antibody at 1:100 dilution gave excellent
results and this dilution was subsequently used.
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Mouse Immunoglobulin control 1:25
Mouse anti-cytokeratin 18 1:25
Mouse Immunoglobulin control 1:50
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Mouse anti-cytokeratin 18 1:50
Mouse Immunoglobulin control 1:100
Mouse anti-cytokeratin 18 1:100
Figure 2.7. Cytograms for anti-cytokeratin 18 flow cytometry in HepG2 cells.
Cells were fixed with o.g?6 formaldehyde and permeabilisod with o.i?6 triton x. After washing, cells were incubated with mouse anti
cytokoratin lS antibody or mouse immunoglobulin at 1:25 to 1:100 dilution. After a wash step, cells were incubated with Coat anti
mouco Phycoorythrin conjugate antibody at 1:20 dilution. Immunopositivc cells were detected by flow cytometry with excitation at
488nm and detection at 575nm.
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Having developed the methods for fibrinogen and cytokeratin 18 flow cytometry
separately, the methods were then combined to deliver two-colour identification
of four possible populations; dual positive hepatocytes, cytokeratin 18+ve
epithelial cells (liver precursors), fibrinogen alone +ve cells (artefact) and dual
negative cells. The protocol for this technique is described below.
Two colour flow cytometry.
Cultured cells were trypsinised and washed as previously described. Cells were
then resuspended in 0.5% paraformaldehyde in iomM PBS on ice, and
incubated for 15 minutes at 4°C. 2 ml flow cytometry buffer was then added per
tube, and cells spun down again.
Cells were then resuspended in 5% normal swine serum/5% normal goat serum
in cytometry buffer (blocking buffer) containing 0.1% Triton X 100 and
incubated at room temperature for 30 minutes. 2ml buffer were added per tube,
and the cells were spun down as before. The supernatant was poured off, and
blocking solution, primary antibodies (anti—cytokeratin 18 at 1:100 and anti-
fibrinogen at 1:200) or control antibodies in blocking solution were added in a
total volume of sopl. Control antibodies were mouse immunoglobulin (MIG;
DakoCytomation) and normal rabbit purified immunoglobulin fraction (NRIG;
DakoCytomation). The control antibodies were made up so as to contain the
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same immunoglobulin concentration as the primary antibodies, therefore MIG
was used at a final dilution of 1:34, and the NRIG at 1:200.
The tubes were incubated at room temp for 60 minutes, and then 2 ml wash
buffer was added and the cells were spun down as before. The supernatant was
poured off, and the secondary antibodies, Goat anti-mouse phycoerythrin
conjugate 1:10 in block and Swine anti-rabbit FITC conjugate 1:10 in block were
mixed in equal volumes to give a solution with each antibody at 1:20. 50
microlitres were added to all tubes, and tubes were incubated at room
temperature for 30 minutes in the dark. 2 ml wash buffer were added per tube,
and cells were spun down as before. Cells were then resuspended in 250pl
buffer on ice and kept in the dark until processed through the flow cytometer.
Forward scatter and side scatter were used to adjust the photomultipliers to get
the cells to show 'on-screen'. Separate control tubes, made up in parallel to any
experimental tubes, were used to calibrate the flow cytometer, to set the
quadrant and linear gates to reject negative cells and count positive cells, and so
ensure that colour balancing was correct. This was carried out using a
preparation of cells, either unlabelled, single labelled or dual labelled, and by
preparing various mixed samples so that cells were identified regardless of the
background fluorescence on red or green channels (575 nm and 525 nm
respectively). This procedure was carried out each time the flow cytometer was
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used. On a daily basis, the flow cytometer was also calibrated and run through a
quality control procedure with calibration microbeads, so as to ensure a
satisfactory technical performance.
Having set the gates to count cells using the controls, the experimental samples
were run through the cytometer without any further adjustment, so as to
maintain the same exclusion and inclusion criteria to all cells in all tubes.
Figure 2.8 shows the cytograms for validation of the two-colour flow cytometry.
The data show an excellent separation between positive and negative controls,
and the double-labelled HepG2 cells are shown in the top right box, as would be
expected for a cell population expressing both antigens.
Chapter 2 General Methods 106
100 1HHH
Cytokeratin 18 Fibrinogen
Figure 2.8. Dual labelling ofHepG2 cells for Fibrinogen and
cytokeratin 18. Cells were fixed with 0.5% formaldehyde and permeabilised with 0.1% triton X.
After washing, cells were incubated with mouse anti-cytokeratin 18 antibody or mouse immunoglobulin at
1:100 dilution, in combination with rabbit anti-Fibrinogen antibody or normal rabbit immunoglobulin at
1:200 dilution. After a wash step, cells were incubated with Goat anti-mouse Phycoerythrin conjugate
antibody at 1:20 dilution and Swine anti-rabbit FITC conjugate at 1:20 dilution. Immunopositive cells were
detected by flow cytometrywith excitation at 488nm and detection at 525 and 575nm. The panels represent
cells labelled with anti-cytokeratin 18 and normal rabbit serum, anti-Fibrinogen and mouse
immunoglobulin, or anti-cytokeratin 18 and anti-fibrinogen. The 'mix' panel represents a mixture of cells
labelled with either cytokeratin 18, fibrinogen, or neither.
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2.5 Enzyme Linked ImmunosorbentAssays for liver proteins.
2.5.1 General Method.
All chemicals were analytical grade or better, and from Sigma, unless otherwise
indicated. The general method is as recommended by DakoCytomation,
suppliers of the various primary and secondary antibodies. For individual
assays, incubations and antibody dilutions were determined empirically in the
laboratory to give optimal sensitivity and reproducibility. Costar 96-well ELISA
low protein binding plates were used throughout. The constituents of the
various buffers and solutions required for the ELISA assays are depicted in Table
2.4.
Samples
Samples were stored frozen until the day of assay. Samples were then thawed
and kept on wet ice prior to assay. Samples were centrifuged at io,OOOg for 1
minute, diluted in wash/diluting buffer prior to use, from 1:10 to 1:50 as
appropriate.
Plate coating
toopl of primary antibody was added to each well in coating buffer, covered, and
incubated at 4°C overnight. The plate was then washed 4 times in wash buffer
using an automated plate washer (Skatron plate washer; Skatron, Denmark).
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Table 2.4 Solutions for ELISA Assays
Coating buffer




H2O to 1 litre
Washing/dilution buffer





H2O to 1 litre
Chromogenic substrate
Orthophenyline diamine tablet (2mg) x 4 (DakoCytomation)
H2O 12ml
Add 30% H2O2 after tablets dissolved 5pl
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Reaction stop: o.^M sulphuric acid
95-97% H2SO4 28ml
dH20 900ml
Adjust to llitre with dH20
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Standards and Samples
Standard or sample was diluted in wash buffer and loopl of each were added to
the microplate in triplicate. Each assay included blanks and a quality control in
triplicate. Plates were then covered, incubated at room temperature for 2 hours,
and washed again as described above.
toopl of peroxidase-conjugated antibody with the same specificity as the capture
antibody was added to each well diluted in wash buffer, covered, and incubated
at room temperature for l hour in the dark, before being washed again,
toopl of chromogen was subsequently added to each well, and the plate was
incubated for 15 minutes at room temperature in the dark. The reaction was
then stopped by adding loopl of stop solution to each well. The absorption of
each well at 49onm was then measured using an automated plate reader
(Dynex) set to 49onm with a 630nm reference wavelength.
The data were processed using the onboard plate reader software and plotted as
a sigmoid semi logarithmic plot of optical density against standard
concentration. Results were derived directly by the plate reader. Means of the
triplicate results were taken for individual data points.
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2.5.2 Individual Assay Methods.
For the fibrinogen assay, the primary coating antibody was polyclonal rabbit
anti-human antibody (DakoCytomation, Code A0080), diluted 1:10,000 in
coating buffer. Standards were made up using a human fibrinogen standard
(Sigma), which was made up to 8mg/ml in wash buffer and stored at -70°C in
aliquots, so as to provide sufficient standard pool for this large series of assays.
Doubling dilutions gave a standard curve from 800 to 3.12 ng/ml. A quality
control sample (QC) was made using standard fibrinogen to give approximately
I50ng/ml on the standard curve. This solution was stored similarly to the
standard solution. The peroxidase-conjugated antibody was provided by
DakoCytomation, and was identical to the primary antibody in all respects,
except that the antibody had been labelled with horse radish peroxidase (Code
P0445). It was used at 1:5,000 dilution. A sample standard curve for the
Fibrinogen ELISA is shown in Figure 2.9.
Equivalent information for other ELISAs is shown in Table 2.5. All antibodies
were obtained from DakoCytomation.
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Figure 2.9. Fibrinogen ELISA standard curve Standard fibrinogen was
made up in assay buffer at concentrations between 800 and 3.i2ng/ml in doubling dilutions. Assay plates
were coated with polyclonal rabbit anti-human Fibrinogen antibody, diluted 1:10,000 in coating buffer.
Standard or sample was added to coated wells in triplicate and incubated for 2 hours. Peroxidase-conjugated
rabbit anti-human fibrinogen antibody was added at 1:5,000 dilution and incubated from 1 hour in the dark.
Chromogen (orthophenylene diamine solution. o.67mg/ml/H202) was added and the reaction allowed to
develop over 15 minutes in the dark. Stop solution (100 microlitres H2SO4) was added, and the absorption
measured at 57onm.
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Table 2.~. ELISA antibodies and standards.
Analyte Capture Ab Standards QC Peroxidase
Alpha- Ra-H* Doubling AFP Ra-H AFP-
Fetoprotein polyclonal dilutions, (X0900) HRP
1:2,000 130- long/ml 1:2,500
(A0008) 0.5ing/ml (P0128)
AFP (X0900)
Prealbumin Ra-H Doubling Sigma Ra-H
polyclonal dilutions, prealbumin 1:2,500
1:2,000 250- 40ng/ml (PN22)
(A0002) i.95ng/ml
Sigma
Alpha-i- Ra-H Doubling protein Ra-H
antichymotrypsin polyclonal dilutions, calibration 1:2,000






Ra-H Doubling CRP Ra-H
polyclonal dilutions, calibration 1:4,000
1:1,000 200- solution (P0227)





*Ra-H; Rabbit anti human
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2.6 Thiazylol blue assay for cell proliferation.
To estimate the viability of cells in culture, the conventional approach is to count
the cells manually and determine viability in that way. However, where large
numbers of samples are present, or small numbers of cells, this technique
becomes too cumbersome and slow to provide accurate data. In these situations,
a biochemical technique based on the formazan reaction may be used (Patel et
al., 2004).
Various tetrazolium dyes may be converted by mitochondrial oxidases to
insoluble formazan crystals which can be solubilised and their absorbance
measured spectrophotometrically.
Cells are cultured in the conventional manner in 96 well plates in triplicate in a
volume of loopl medium. At the end of the experiment, topi of thiazylol blue
tetrazolium (MTT) solution (smg/ml made up in lomM PBS, pH 7.4, sterile
filtered with a 0.22pm filter) is added to each well, and the cells are incubated as
before for 4 hours, isopi SDS solution (10% Sodium dodecyl sulphate in 0.01M
HC1 pH 3.0) is added to each well, and the cultures are incubated overnight in
the incubator as previously to dissolve the formazan crystals. The plate is then
read on the Dynex plate reader at a wavelength of 570nM and a reference
wavelength of 630nM. Blank wells without cells are subtracted from all wells,
and the data expressed as a percentage of control. A calibration curve (Figure
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2.10) overleaf demonstrates excellent linearity of the technique across a wide
range of cell densities in culture.
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Cells per well x 10
Figure 2.10 Thiazylol blue and cell density.
Cells were cultured in96 well plates in triplicate in a volume of toopl medium, lopl of thiazylol blue
tetrazolium (MTT) solution (smg/ml made up in tomM PBS, pH 7.4) were added to each well, and the cells
were incubated at 37°C for 4 hours, tsopl SDS solution (10% Sodium dodecyl sulphate in 0.01M HC1 pH
3.0) were added to each well, and the cultures were incubated overnight to dissolve formazan crystals.
Absorption minus reagent blank was measured at 57onm with a reference wavelength of 630nM.
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Chapter 3.
Characterisation ofhuman fetal liver
in tissue culture.
3.1 Introduction.
The primary objective of this chapter was to develop a technique to culture
human fetal liver tissue in vitro. This chapter details the development of the
technique and characterisation required to permit subsequent detailed studies of
human liver cells.
The preparation of human fetal liver cultures has been reported in historical
studies (Gitlin and Biasucci, 1969). However, such studies did not attempt to
maintain tissue in culture over time. Such techniques are therefore not
applicable to the investigation of dynamic tissue processes, such as maturation
and proliferation, as proposed in this thesis. To address the experimental
questions posed in this work, it was necessary to develop such a technique
whereby human fetal liver could be maintained in vitro for many days, and could
be studied easily over this time period.
Cell culture is an extremely well established technique which offers advantages
in the experimental approach considered here. However, the loss of tissue
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architecture, and of three-dimensional interactions of different cell types in
dispersed cell culture, is a significant issue, particularly in a complex organ such
as developing liver. In order to investigate factors regulating proliferation and
maturation in fetal liver, it was necessary to develop a cell culture system
suitable for developing liver, and then to characterise the cell cultures
extensively, prior to embarking on the major experiments of the thesis.
3.2 Materials and Methods
3.2.1. Tissue assessment.
In order to begin cell culture experiments it was first necessary to assess the
quality of the tissues obtained. In order to make a simple histological
assessment, liver tissue was collected as previously described and placed directly
in fixative (4% formaldehyde in PBS) overnight, then transferred to absolute
ethanol and stored at 4°C, prior to paraffin embedding.
Tissues were dehydrated and embedded in paraffin wax using an automated
Shandon VIP vacuum embedding processor (Shandon UK). The embedded
tissue was then added to a sectioning grid, covered in hot wax, then allowed to
cool prior to sectioning. Sections were cut at 3 microns on a Shandon 325
microtome. Sections were placed on coated slides (Superfrost slides, VWR,
Glasgow, UK) prior to dewaxing.
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Slides were dewaxed in baths of 100% xylene x 2, ioo% ethanol, 90% ethanol,
80% ethanol, 70% ethanol and then water for 2 minutes each. Tissues were then
stained with haematoxylin briefly, washed in distilled water, differentiated in
acid alcohol (1% concentrated HC1 in 70% ethanol), and 'blued' in Scott's tap
water. After a wash in distilled water, sections were dipped in eosin and washed.
Xylene and ethanol were obtained from BDH. Counterstains were supplied by
Sigma.
After staining and washing, slides were assessed whilst wet under the
microscope (Olympus BH2, Olympus UK) to confirm that there was satisfactory
stain uptake. Slides were then dehydrated using a reversal of the dewaxing
protocol above, but with different solvent baths so as to eliminate
contamination. Slides were then mounted in Pertex (CellPath Powys, Wales),
coverslipped (Chance Propper, UK) and photomicrographs were taken using an
Olympus CK2 photomicroscope with Kodacolour ASA 200 film using a tungsten
correction filter. Negatives were digitally scanned by the commercial developer
(Pyramid Photography, Edinburgh).
3.2.2. Optimising tissue digestion.
The technique to prepare cell suspensions from tissue pieces was developed
from prior work by the author in which fetal neuronal tissue was digested to
yield single cell suspension (Currie et ah, 1994). Fetal liver has a strikingly
insubstantial nature, which suggested that a mild enzymatic digestion with
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gentle mechanical agitation might be adequate to prepare single cells.
Traditionally, collagenase has been used in the author's laboratory to
disaggregate adult liver tissue, and so use of this enzyme preparation was
retained.
Fetal liver tissue was collected with informed consent as part of ethically
approved studies (Lothian Regional Ethics Committee Reference Numbers
LREC 2001/6/13 and LREC2000/6/57) from therapeutic abortion of fetuses
ati3-i8 weeks of gestation. The livers were removed on ice using an aseptic
technique and placed in ice-cold sterile William's Medium on ice for transport to
the laboratory.
The liver was dissected free of the biliary tree and large vessels, and the
parenchymal tissue was then diced with a scalpel in a sterile glass Petri dish in a
class II cabinet (Medical Air Technology, Manchester, UK). The tissue pieces
were added to 20 ml ice cold Hank's Balanced Salt Solution without calcium or
magnesium (HBSS-ve; Invitrogen) which was gently turned end over end to
suspend the pieces and wash out blood cells. The pieces were allowed to settle
and the supernatant was removed with a pastette (Corning) and discarded. This
wash step was repeated 4 more times so that the supernatant became clear and
free of red blood cells. Tissue pieces were then added to 10ml 0.1% Type II
collagenase solution (Worthington), made up in warmed HBSS with calcium and
magnesium (HBSS+ve; Invitrogen) to which was added lomM HEPES, 0.1%
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Human albumin, Penicillin/Streptomycin (looU/ml and loomicrograms/ml
respectively) and incubated at 37°C for 15 minutes with gentle orbital shaking.
After tissue pieces were allowed to settle, the supernatant (Harvest 1) was added
to 10ml ice coldWME/10% FCS to neutralize the collagenase. The suspension
was then spun down for 6 minutes at 1200 rpm (320g) at 4°C (MSE Mistral
3000i, Thermo Scientific). Meanwhile, the tissue pieces were gently drawn up
and ejected through a 1 ml pastette to break up larger chunks, and a further 10
ml ofwarm enzyme solution was added. The pieces were then incubated for a
further 15 minutes exactly as before.
The second supernatant (Harvest 2) was taken off, and any remaining pieces
were broken up by the pastette method. The supernatant was briefly added back
to suspend cells freshly liberated from the tissue pieces. Large chunks were
allowed to settle, and the supernatant was carefully removed. This was added to
10ml ice coldWME/10% FCS as before, and centrifuged under the same
conditions.
After centrifugation, the supernatants from Harvests 1 and 2 were discarded,
and the cells were gently resuspended in culture medium (see below) on ice. An
aliquot of cell suspension was diluted in culture medium and added to an equal
volume of 0.5% trypan blue solution in PBS (Sigma). Cell counting and viability
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estimation was then carried out using a standard Neubauer haemocytometer as
described below.
Initial work showed that the cell preparation might have been inadequately
provided with glucose, and so the technique was modified by adding additional
glucose to all media to provide a final concentration of 2ommol/l, rather than
5mmol/l. Viabilities of the cell preparations obtained were then compared.
3.2.3 Flow cytometry for fetal hepatocytes.
To demonstrate the presence of hepatocytes before and after cell culture, cells
were subject to single label flow cytometry (Fibrinogen) as soon as the cell
preparation was completed, and a portion of cells was plated and subject to
further flow cytometry after culture (described below). To show conclusively
that the cells were indeed hepatocytes, one culture was subject to two-colour
flow cytometry, as described in chapter 2.
3.2.4 Phase contrast microscopy of cultured cells.
To provide morphological data in support of the results from flow cytometry, the
appearance of the cells immediately after plating, and at 7 days in vitro, was
recorded by phase contrast microscopy.
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3.2.5. Optimisation of culture substrate and cell adhesion.
In order to maintain cells in satisfactory condition in vitro, it is necessary to
provide an adhesive substrate to promote cell growth and function. To address
the role of cell adhesion in the success of the fetal liver cultures, cell suspension
was freshly prepared as previously described. Cells were then diluted to 2 x io?
cells/ml in warmed culture medium, comprisingWilliam's Medium Eagle, 10%
fetal calf serum, 2 mmol L-glutamine, Penicillin/Streptomycin (tooU/ml and
loomicrograms/ml respectively) and Insulin-Transferrrin-Selenium concentrate
(lml per 100ml; Invitrogen). Two types of collagen were compared, as were
different levels of fibronectin.
Collagen coating
Cells were plated out in 12 well plates which had previously been coated with
type I collagen (Roche) or type IV collagen (Sigma). Coating was carried out by
adding i8opl of collagen in 0.2% acetic acid at a concentration of o.img/ml.
This gave a coating of 5pg/cm2. Wells were allowed to dry in the Class II cabinet
so as to permit a thin film of collagen to form on the culture dishes. Collagen
stock solutions were prepared by dissolving collagen powder in 2% glacial acetic
acid and preparing soopl aliquots which were stored at -70°C. To dilute for use,
4.5ml sterile tissue culture grade water was added to a stock vial.
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Plating out in Fibronectin solution.
To each well at the time of plating was added 250 pi culture medium containing
o, 10, 20 or 40pg/ml of fibronectin (Sigma). 250 pi of cell suspension at a
density of 2x10? cells per ml were then added to give a final volume of 500pi, a
total cell count of 5 x 106, and fibronectin concentrations of o, 5,10 or 20pg/ml.
Each experimental condition was replicated in 6 identical wells, giving a total of
48 wells. Cells were maintained in 5%C02 at 37°C in a humidified atmosphere
over a 7 day period.
Assessment of culture conditions for hepatocytes.
The culture supernatant was changed for fresh medium on day 1, 3, 6 and 7, with
the culture supernatant being centrifuged at io,ooog for 1 minute, then frozen
and stored at -20°C for later fibrinogen ELISA. In a parallel experiment, in
which the same cell preparation and the same substrate modifications had been
made, and in which the medium was changed at the same time, cell content of
fibrinogen was determined as an index of adherent hepatocytes. To determine
culture content, adherent cells in the culture dishes were scraped off in soopl of
culture medium and this homogenate was similarly stored at -20°C for later
Fibrinogen ELISA.
In a further parallel experiment, cells were plated out at different densities on
type I collagen coated wells and later trypsinised and counted so as to determine
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the approximate numbers of cells able to persist in culture. These cells were
photographed at day o and day 7 in vitro, so as to provide morphological
information on the cells proliferating in the culture system.
3.2.6. Different cell types in liver cell culture
The fetal liver contains a large population of haematopoietic cells, in addition to
the resident hepatocytes, biliary tract cells and stromal cells. In order to gain
insight to the types of cells which might be interactingwith the developing
hepatocytes, it was elected to carry out flow cytometry using antibodies directed
against a number of well characterized surface antigens.
Flow cytometry was carried out exactly as described for anti-cytokeratin 18
antibody (Chapter 2), except that the permeabilisation step was not required.
The antibodies chosen and the dilutions used are shown in Table 3.1. These
antibodies had been extensively characterized in the laboratory previously. All
antibodies were obtained from DakoCytomation, excepting anti CD29, which
was from Serotec UK.
3.2.7. Spectrum of secreted liver proteins
Having determined the appropriate culture conditions to maintain fetal
hepatocytes in vitro for at least 7 days, culture supernatant was assessed by
various specific ELISAs to determine the spectrum of proteins which were
secreted by the cultured cells. In each case, ELISAs were carried out as
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described in chapter 2. Culture supernatant was stored frozen at -20°C prior to
assay. Samples were thawed and vortex-mixed, then centrifuged at I2,000g for l
minute so as to precipitate any cells or other particulate material which might
contaminate the assay. Samples were then diluted appropriately with assay
buffer as previously described prior to assay, so as to ensure that the sample
would fall in the dynamic range of the assay. Alpha-fetoprotein, fibrinogen,
alpha-i-antitrypsin, C-reactive protein and prealbumin were determined by
specific ELISA.
3.2.8. Urea synthesis
Urea synthesis by cultured cells is highly indicative of the presence of functional
hepatocytes. To demonstrate urea synthesis, cells were cultured in 24 well
plates as previously described. Culture medium was removed and stored for
later assay. Wells were washed twice with warmed 0.5ml PBS per well. 300pl
ureagenesis buffer (Table 2.1, chapter 2) were added per well and cells were then
returned to the incubator for 4 hours. The incorporation of free ammonia was
demonstrated by adding imM NH4CI to half the wells. All media and liquid
supplements were from Invitrogen, and all biochemicals were from Sigma. After
the incubation was complete, the supernatant was removed and stored at
-20°C for later urea assay (chapter 2). Wells were washed twice with 0.5ml
culture medium per well which was removed and discarded, then a further 0.5ml
culture medium were added and cells were returned to the incubator.
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Table 3.1 Antibodies for cell surface antigens.
Antibody Dilution Specificity
CD 3 1:50 T cells
CD 14 1:50 Mononuclear cells
CD29 1:50 Pi-Integrin
CD34 1:50 Haematopoietic stem cells
CD45 1:50 Leukocyte common antigen
CD90 1:100 Thy-i stem cell marker
CD235a 1:100 Erythrocyte lineage
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The urea assay was carried out with and without urease by dividing the sample
in two portions, so as to demonstrate the urea and the residual free ammonia
present in culture supernatant.
3.3. Results
3.3.1. Histology of the developing liver.
The photomicrographs in Figure 3.1 demonstrate the integrity of the tissues and
clearly show plates of cells which correspond to hepatocytes. At this gestational
age, the ductules are still maturing from the primitive ductal plate. The
histology shows no evidence of oedema or other cellular injury within
hepatocytes, or any distortion of the architecture. Histological assessment
reveals no adverse features or impediments to further cell preparation.
3.3.2. Optimising tissue digestion.
The method designed to prepare cell culture readily yielded single cell
suspensions with little remaining tissue pieces. To assess the effects of
preparation on the cells, viability was calculated as previously described.
Table 3.2 shows that viability in the first 15 preparations was lower than
expected, certainly below the 95% viability level which any satisfactory method
should deliver. The poor viability was of concern, as it was likely to be those
cells with the greatest metabolic requirements, the hepatocytes, which were
undergoing cell death. The technique of Popovici et al (2001) described the use
of DMEM for washing cells. Discussion with the authors of the paper revealed
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Figure 3.1. Photomicrographs ofhuman fetal liver x 200. Micrograph A
demonstrates a portal tract. At 'A', lies the portal vein. Within the surrounding mesenchyme, two hepatic arteries are
shown at 'B', and biliary ductules can be seen at 'C' within the remodeling ductal plate. Micrograph B shows the tissues
surrounding a central hepatic vein, the vascular outflow tract of the liver. Compared to the portal tract, there is no
mesenchyme, no arterial component, and no biliary structures.
Chapter 3 Characterisation of fetal liver 130
Table 3.2. The effect of glucose supplementation on cell viability.
Cultures (n) Glucose Viability
15 smmol/l 91-3 +/-1-3%
10 2ommol/l 95.4 +/-1.2%*
*p<0.05, Student's T test
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that they used high glucose DMEM (20mmol/l) for washes. To assess the effect
that additional glucose would have on cell viability, glucose supplementation
was added to all cell preparation media to bring the concentration from 5
mmol/1 to 20mmol/l. The effect of this modification on viability was significant
(Table 3.2). Accordingly, glucose supplementation during culture preparation
was routinely employed thereafter.
3.3.3 Flow cytometry for fetal hepatocytes.
Figure 3.2 demonstrates the proportions of hepatocytes determined by flow
cytometry before and after cell culture. Approximately 60% of cells are
hepatocytes by this single colour technique (Fibrinogen; n=8 preparations and
n=3 cultures; mean +/- SE). Two-colour flow cytometry directed against
fibrinogen and cytokeratin 18 was then used to confirm the presence of
hepatocytes after 7 days culture in vitro. Figure 3.3A shows the cytogram for the
control antibodies, and 3.3B the cytogram using both primary antibodies. The
proportion of cells falling in the top right square is equal to the % of dual positive
hepatocytes, which in this example is 50.3%. Those cells in the top left square
are cytokeratin 18+ve, fibrinogen-ve (9.9%), and those cells in the lower left
square are dual negative (39.5%). It is worthy of note that fewer than 1% of cells
lie in the lower right square, meaning that essentially all cells which are
fibrinogen +ve are cytokeratin 18+ve, whereas there is a not insignificant
population of cells which are cytokeratin 18+ve and fibrinogen-ve. These data
confirm using a two-colour technique that there are hepatocytes present after 7
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Figure 3.2. Proportions of hepatocytes in vitro.
Tissue pieces were incubated with collagenase twice, and the supernatants spun down to prepare a single cell
preparation. The cells ('Cell Preparation') were then fixed with 0.5% formaldehyde and permeabilised with
0.1% triton X. Cells were labelled with rabbit anti-Fibrinogen and mouse anti-cytokeratin 18, and these
antibodies were detected by goat anti-mouse-PE and swine anti-rabbit-FITC. Flow cytometry with excitation
at 488nm and detection at 525nm and 575nm was used to determine the proportion of cells immmunopositive
for both labels. Alternatively, the cell preparation was cultured for 7 days in vitro in culture flasks, then
trypsinised and processed for flow cytometry exactly as before. n=8 preparations and 3 cultures; data are
shown as means +/- SEM.

























Figure 3.3. Two-colour cytograms demonstrate hepatocytes in vitro.
Cells were fixed with 0.5% formaldehyde and permeabilised with 0.1% triton X. After washing, cells were incubated with
mouse anti-cytokeratin 18 antibody or mouse immunoglobulin at 1:100 dilution, in combination with rabbit anti-
Fibrinogen antibody or normal rabbit immunoglobulin at 1:200 dilution. After a wash step, cells were incubated with
Goat anti-mouse Phycoerythrin conjugate antibody at 1:20 dilution and Swine anti-rabbit FITC conjugate at 1:20
dilution. Immunopositive cells were detected by flow cytometrywith excitation at 488nm and detection at 525 and
575nm. Panel A; control antibodies: Panel B; anti-cytokeratin 18 and anti-Fibrinogen antibodies.
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days in vitro.
3.3.4 Phase contrast microscopy of cell cultures.
The appearance of the cultures after plating out, and at day 7 in vitro, is shown
in Figure 3.4. Whilst cells initially show the rounded appearance expected of
freshly prepared cells, the morphology is more complex by day 7 in vitro.
Hepatocytes are shown well in Figure 3.4D, however, other cells with very
different appearances are also present.
3.3.5. Optimisation of culture substrate and cell adhesion.
Figures 3.5A and 3.5B demonstrate the effects of different substrate coatings on
the secretion of fibrinogen by the cultured cells, and figures 3.6A and 3.6B
demonstrate the culture content of fibrinogen.
These results demonstrate first of all that there is a trend towards increasing
fibrinogen secretion with time in vitro, with twice as much fibrinogen secretion
in the 24 hours between day 6 and day 7, as compared with day o and day 1.
Secondly, there is no obvious difference between type I and type IV collagen in
terms of fibrinogen secretion. Finally, fibronectin seems to have little effect on
fibrinogen secretion.
Chapter 3 Characterisation of fetal liver 135
Figure 3.4. Photomicrographs ofhuman fetal liver cells in culture.
Phase contrast photomicrographs show cells just after plating (A) or at one week in vitro (B,C,D). Several distinct
morphologies are present: B; 'fried egg' cells, C; fusiform mesenchymal cells, D; hepatocytes with non-adherent cells in
the foreground, xioo, except B; X200.
Chapter 3 Characterisation of fetal liver 136


































Type IV Collagen B
Fibronectin level added at plating (pg/ml)
Figure 3.5. Time course of fibrinogen secretion. Cell cultures were prepared and
plated in 12 well plates coated with type I (A) or type IV collagen (B). Coating was carried out by adding i8opl of
collagen in 0.2% acetic acid at a concentration of o.img/ml, to give a coating of 5pg/cm2. At the time of plating,
fibronectin was added to each culture well, to give final concentrations of 1 - 20 micrograms/ml. Culture medium was
removed on days 1,36 and 7 in vitro, and the medium was stored at -200C until later Fibrinogen assay. Data shown are
expressed as ng/dish/24 hours. n=6 wells for each treatment. Data are shown as mean+/-SE.
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Figure 3.6. Time course of fibrinogen content. Cell cultures were prepared and
plated in 12 well plates coated with type I (A) or type IV collagen (B) atspg/cm2. At the time of plating, fibronectin was
added to each culture well, to give final concentrations of 1 - 20 micrograms/ml. Cell cultures were washed on days 1, 3
and 6 in vitro, and cultures were scraped from the substrate and the material stored at -200C until later Fibrinogen
assay. Data shown are expressed as ng/dish. n=2 wells for each treatment. Data are shown as mean+/-SE.
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Figure 3.6 reveals the very small amounts of fibrinogen which represent
intracellular stores. In each case, the culture content is about 5% of the secreted
amount, or less. Nonetheless, some general upward trend is visible in the
culture content of fibrinogen in those cells plated on type IV collagen by day 6 of
culture. In this experiment, there were insufficient wells to permit the
preparation of day 7 culture homogenate.
Figure 3.7 shows the number of cells present in the culture dishes (plated on
type I collagen) as a function of the number of cells added to the well in the first
instance. There is obviously a linear relationship, but what is more striking is
the very small number of cells which are adherent from a large number of cells
plated. From 20 million cells plated, approximately 0.5 million were present in
culture 1 week later. This may simply reflect the very large number of non-
anchorage dependent haematopoietic cells present in the original cell
preparation. Certainly, when changing the medium at day 3, it was clear there
were a great many floating cells. Despite the reduction in cell number, the data
describing protein secretion support the hypothesis that hepatocyte function was
not deteriorating over time.
Given the lack of any obvious difference between the substrates, or between
fibronectin levels, and the very much increased cost and complexity associated
with type IV collagen or fibronectin, it was decided to continue with type I
collagen as the preferred culture substrate without fibronectin. Certainly, the
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Figure 3.7 The relationship between cells plated and residual
cell number. Cell cultures were prepared and plated on type I collagen at 5pg/cm2. Cultures were
plated at 5 - 20 million cells per well in 12 well plates. Cultures were maintained for 7 days in vitro, and then
cultures were trypsinised and counted using a trypan blue technique. n=5 wells at each point. Data are shown
as mean, +/- SE.
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upward trend in fibrinogen secretion over l week in vitro seen in all culture
conditions was most reassuring, despite the small number of cells adherent to
the culture dishes.
3.3.6. Different cell types in liver cell culture.
To understand the cell types which are present in culture alongside fetal
hepatocytes, flow cytometry was carried out against a range of surface antigens
present in freshly prepared cell suspension. Figure 3.8 demonstrates the relative
abundance of cells bearing these antigens (note; y axis: log scale). Whilst some
cells are plainly absent, mononuclear cells (CD14), epithelial cells (CD29; pi-
integrin), leucocytes (CD45), red cells lineages (CD235a; Glycophorin A) and
haematopoietic stem cells (CD34, CD 90) are present. Clearly, many
haematopoietic lineages are present, presenting the possibility that this model
could also be used to investigate haematopoiesis.
3.3.8. Spectrum of secreted liver proteins
Alpha-fetoprotein, fibrinogen, alpha-i-antitrypsin, C-reactive protein and
prealbumin in culture supernatant were determined by specific ELISA. Figure
3.9 shows the quantities of these proteins detected (n=6 wells for each data
point). It is noteworthy that CRP and prealbumin were undetectable.
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Surface Antigen
Figure 3.8. Different cell types in fetal liver cell culture.
Cells were prepared as a unicellular suspension by collagenase digestion of fresh tissue. The cell preparation
was washed in flow cytometry buffer, and incubated with mouse monoclonal antibodies at 1:50 dilution in
blocking solution directed against a selection ofwell-characterised surface epitopes. After a wash step, cells
were incubated with Goat anti-mouse Phycoerythrin conjugate antibody at 1:20 dilution. Immunopositive
cells were detected by flow cytometry with excitation at 488nm and detection at 575nm. The
immmunopositive fraction is shown. N=i experiment.
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Figure 3.9. Secretion of different hepatocellular proteins by cultured
liver cells. Cell cultures were prepared from fresh tissue and plated on type I collagen at 5pg/cm2. Cultures were
plated at 5 million cells per well in 24 well plates. Cultures were maintained for 7 days in vitro, with a medium change on
day 3. Culture supernatant was removed on day 7 and stored for later protein assay at -20°C. Data are shown as mean,
+/- SE. n=6 wells for each data point.
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3.3.9. Ureagenesis in cultured liver cells.
Figure 3.9 shows the amounts of urea synthesised under basal conditions and in
response to NH4CI loading (n=6 wells for each data point, +/- SEM). The data
clearly show that urea is synthesised at a basal level which is increased in
response to addition of ammonia, confirming ureagenesis. This response was
significant, and was observed at two different times in vitro.
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Day in Vitro
Figure 3.10. Urea synthesis in vitro. Cell cultures were prepared from fresh tissue and plated
on type I collagen at 5pg/cm2. Cultures were plated at 5 million cells per well in 24 well plates. Cultures were
maintained for 7 days in vitro, with a medium change on day 3. On day 3 and day 6, medium was removed, the cells were
washed with HBSS, and fresh HBSS containing glucose, HEPES, BSA and pyruvate, +/-1 mM ammonium chloride, was
added. Cells were incubated for 4 hours. The HBSS was removed and stored at -20°C for later assay. Medium was
replaced and the cells returned to the culture incubator. Data are shown as mean, +/- SE. n=6 wells for each data point.
*p<0.05; **p<o.oi compared to control, t-test.
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3.4 Discussion.
The purpose of this section of the thesis was to develop and characterize the cell
cultures so as to establish a satisfactory model for the study of developing
human hepatocytes. The data in this chapter convincingly demonstrate that
human fetal hepatocytes can survive in the culture system, and indeed can
secrete appropriate hepatocellular proteins and incorporate ammonia as
expected of living hepatocytes. Furthermore, subsidiary experiments in this
chapter demonstrated the existence ofmany other cell types in this culture
system, including haematopoietic cells and some cells with surface markers of
stem cells. This model therefore represents an exciting prospect to investigate
hepatocytes, and to examine the dynamic interactions between different lineages
in the developing human liver.
Human fetal liver cultures have been prepared historically using collagenase
digestion of minced tissue (Guguen-Guillouzo et al., 1984), dispase enzymatic
dispersion (Tokiwa et al, 1987) or a combination of several different enzymes
(Salas-Prato et al., 1985). More recently, collagenase/dispase (Popovici et al.,
2001) or collagenase alone (Malhi et al., 2002) was reported in the preparation
of purified fetal human hepatocyte cultures, as was mechanical disruption alone
(Muench et al., 2002). Most authors report excellent viability with these various
techniques, implying that the specific method of tissue digestion has little
bearing on the subsequent outcome. For the purpose of the studies described in
this thesis, techniques of enzyme digestion of liver tissue (O'Riordain et al.,
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*995) and fetal tissues in general (Currie et al., 1994) were adapted to suit fetal
liver cultures. The data described in this chapter suggest that the enzyme
incubation is satisfactory, and indeed the cell yield for these 2nd trimester livers
compares most favourably with other published work (Malhi et al., 2002,
Muench et al., 2002,).
Despite good cell yield, viability was initially problematic in this work.
Discussion with Dr. R. Popovici determined that the use ofDMEM with
increased, rather than normal, glucose as a wash buffer was a potentially
significant difference between protocols (Popovici et al., 2001, personal
communication). Glucose supplementation of the collagenase solution to a level
of 20mmol/litre, as found in high glucose DMEM, restored viability to an
satisfactory level. It is likely that fetal hepatocytes, which exist in a
comparatively hypoxic environment compared to adult liver cells, are more
dependent on glycolysis than adult cells. The presence of increased glucose
levels during cell preparation would permit increased glycolysis during relative
anoxia, thereby preventing cell death.
Having optimized the preparation of single cell suspensions, the presence of
hepatocytes was confirmed by flow cytometry in the fresh cell preparation and in
cultured cells. However, optimal culture conditions, and hence appropriate
culture substrate, were central to the further success of the culture system.
Fibronectin, laminin, type IV collagen and |3i-integrins have been implicated in
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the binding of adult human hepatocytes to extracellular matrix (Newsome et al.,
2004; Popovici et al., 2001). Histochemical studies have shown that the
cytoplasm of neonatal human hepatocytes is immmunopositive for fibronectin,
and the matrix surrounding the hepatocytes shows a pericellular fibronectin
reaction product, consistent with the expected distribution of this adhesive
glycoprotein (Rescan et al., 1989). Fibronectin immunoperoxidase studies of 1st
trimester human fetal liver show scattered immmunopositive hepatocytes and
reaction product lining the sinusoids (Terrace J, 2005, personal
communication). It is therefore likely that fetal hepatocytes are able to
synthesise and secrete fibronectin. In the present study, no credible effect of
fibronectin supplementation was observed on functional status, in terms of
fibrinogen secretion, whether cells were plated on type I or type IV collagen.
This implies that fibronectin is unimportant to hepatocyte adhesion and
function. By contrast, it is also reasonable to suggest that sufficient fibronectin
was present as a result of endogenous hepatocellular synthesis in vitro, obviating
the effects of added fibronectin. Whilst no attempt was made to assess whether
liver cultures secreted fibronectin, the simultaneous production of large
quantities of other hepatocellular proteins would support this view.
Pi-integrin (CD 29) is expressed by proliferating liver progenitors (Tanimizu et
al., 2004), and is complexed with as- integrin to form a binding site for the RGD
motif of fibronectin, and with a6-integrin to form the laminin receptor; both
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these transmembrane heterodimers link the cytoskeleton and intracellular
kinase pathways with extracellular collagens, bridging via laminin or fibronectin
(Wierzbicka-Patynowski and Schwarzbauer, 2003). Published evidence suggests
that such ligand interaction with (h-integrin signals to prevent hepatocyte
apoptosis, (Newsome et al., 2004), actions which are likely mediated via a MAP
kinase-dependent mechanism (Zhang et al., 2002). Antibodies to pi-integrin
prevent hepatocyte adhesion to fibronectin, laminin, type I and type IV collagen,
however, the same antibodies reduce apoptotic cell death (Pinkse et al., 2004).
[li-integrin was detected on the cell surface of approximately 80% of cultured
cells in the present work. These initial experiments were not designed to show
which integrin heterodimers were expressed, nor whether hepatocytes in
particular bear CD29. However, it seems very likely that if 50% or more of
cultured cells are hepatocytes, as demonstrated by two-colour flow cytometry,
then most or perhaps all express (3i-integrin. This would be entirely consistent
with the known epithelial distribution of pi-integrin. It remains a strong
possibility that the haematopoietic cells in the cultures also express Pi-integrin,
thus accounting for the large proportion of cells which were positive for this
antigen. In fact, knockout studies have shown that is an absolute requirement
for haematopoietic cells to colonise the liver in fetal life, strongly supporting the
view that at least some of these cells were haematopoietic in nature (Potocnik et
al., 2000). This is further corroborated by the data from the present work
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showing that the stem cell antigens CD34 and CD90 were detected in the
developing liver.
Type IV collagen has been identified within the periportal mesenchyme and in
close relation to the ductal plate as it arises at week 9 of gestation in humans,
although prior to this stage, laminin appears to be the primary extracellular
matrix protein, fading significantly as type IV collagen appears (Quondamatteo
et al., 1999). Type I collagen is found in the perisinusoidal space, along with
fibronectin, laminin, and type IV collagen (Amenta and Harrison, 1997). Type
IV collagen, the physiological basement membrane collagen, was expected to
confer a benefit on cell function as compared to Type I in vitro. However, the
present study showed no obvious difference in Fibrinogen secretion between the
two. It is clear that early in development, there is no type IV collagen present in
the liver, and so the concept of a formalised basement membrane may be
inappropriate at this stage of liver development. If hepatocytes are not
dependent for survival on attachment to a basement membrane, but instead rely
on anchorage mediated by adhesive glycoproteins such as laminin and
fibronectin, it is perhaps unsurprising that there was no great difference
between the two collagens. Certainly over the 7 day period of study, no
detriment accrued to either group of cells. On this basis, it was elected to
continue with type I collagen.
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In order to provide robust evidence that the cultures contained viable
hepatocytes, effort was made to quantify urea synthesis and measure specific
hepatocellular protein secretion. In developing human liver, previous authors
have determined that the full complement of urea cycle enzymes is present as
early as week 9 of development (Karsai and Elodi, 1982), and that urea cycle
activity rises to near adult levels by week 36 (Mukarram Ali Baig et al., 1992).
No authors have examined urea synthesis in a culture model of human fetal
hepatocytes, and so no data are available to compare the level of function in
these cultures. It is notable that very large amounts of ammonia are taken up by
cultured cells, corresponding to the large amounts of urea which are synthesised.
It is also notable that urea is present in culture supernatant, even when no
ammonia has been added; suggesting that endogenous urea synthesis from
amino acids is taking place. Such data are most reassuring, as is the observation
that urea synthesis does not deteriorate between day 3 and day 6 in vitro,
confirming that culture viability remains satisfactory during the study period.
Protein synthesis by cultured human hepatocytes has been demonstrated
extensively in adult liver (O'Riordan et al., 1995), and, to a lesser degree, in fetal
liver (Gitlin and Biasucci, 1969; Gitlin et al., 1972; Gulbis et al., 1998). However,
whilst adult tissue culture systems have been developed to carry out
interventional experiments on cultured material, this is much less the case with
human fetal liver material. Presently, only Popovici et al. (2001) has studied
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liver protein secretion in culture in response to treatment with an external agent.
The literature is scant in this regard.
In the present work, secretion ofAFP, Fibrinogen and a-i-antichymotrypsin was
detected, however, we did not detect prealbumin release from cultured cells.
Only one previous report of prealbumin secretion from a short-term culture of
human fetal liver exists in the literature, using a technique very different to the
present work (Gitlin and Biasucci, 1969). Interestingly, a number of authors
have noted that prealbumin immunostaining in the liver is weak or absent, as is
prealbumin mRNA by in situ techniques, in second trimester human fetal liver
(Jacobsson, 1989; Gray et al., 1985). These data suggest that liver production of
prealbumin in fetal life is low. It may also be that the culture conditions did not
favour prealbumin release, or that the amount of protein was extremely modest.
C-Reactive Protein (CRP) is an acute phase protein, and is only detected in
quantity during an acute phase response. In fact, the total amount in the plasma
volume of a healthy adult is approximately 10 mg, giving a plasma concentration
of less than 2 pg/ml. In cord blood from second trimester fetuses without
inflammatory disease, the median CRP concentration is approximately 40ng/ml
(Yoon et al., 2003), which is 50 times less than the adult. Although the assay
used to detect CRP in this study extended as low as long/ml, it is possible that
fetal liver CRP secretion in vitro, in the absence of an acute phase stimulant, was
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too low to detect reliably. It may yet be possible to investigate CRP, and
prealbumin, secretion from these cultures, however, a different approach with
higher cell densities or acute phase stimulants might be required. Nonetheless,
these data confirm the synthesis of an acute phase protein (fibrinogen), a house¬
keeping protein (AFP), and a negative acute phase protein (a-i-ACT),
confirming the validity of this preparation as a valuable model in the study of
developing liver.
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Chapter 4.
Maturation signals in the fetal liver.
4.1 Introduction.
In animal studies, a range of hormones are implicated in the maturation of fetal
liver. Glucocorticoids in the fetal circulation increase markedly during late
gestation (Norman et al., 1985) in parallel with glucocorticoid receptor
expression (Speirs et ah, 2004), which may enhance ureagenesis in the liver
(Ulbright and Snodgrass, 1993). Maturation of the urea cycle is an absolute
requirement for perinatal survival (Schofield et al., 1999) and for perinatal
gluconeogenesis (Hanson and Reshef, 1997). Thyroid hormones increase
albumin mRNA and protein synthesis in a dose-dependent manner whilst AFP
mRNA and protein is co-ordinately decreased (Anteby et al.,1993). Whilst there
are few data linking maturational effects of sex steroids in fetal liver, there is a
strong gestational trend in both oestrogen and gestagen levels. These are
present in extremely high concentrations and are conducted directly to the fetal
liver by the umbilical veins and may act to mediate liver maturation.
In order to address maturational endocrine signals in human fetal liver, the
following experiments set out to examine several hormonal stimuli. The work
assessed the changing functions of liver cells in response to specific endocrine
influences, and to delineate proliferative and morphological responses.
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4.2 Materials andmethods.
Human fetal liver was collected under aseptic conditions, and a liver cell
suspension was prepared as described in chapter 3. Cells were made up to
specific densities as required for individual experiments, and plated on type I
collagen-coated dishes. Cells were exposed subsequently to various added
endocrine agents, and protein secretion and cellular proliferation was assessed
as described below.
Stock solutions
Dexamethasone (MWt. 392.5) was dissolved in absolute ethanol and made up to
a concentration of o.392mg/ml (1 mmol/1). Cortisol (MWt. 362) was similarly
dissolved and prepared at 3.62mg/ml (10 mmol/1). Progesterone (MWt. 314.5)
was made up to o.3i4mg/ml (1 mmol/1), and oestradiol was prepared at a
concentration of 2.72 mg/ml (MWT. 272; 10 mmol/1). Working solutions were
made by adding 1 part in 1000 to culture medium, then carrying out serial 10-
fold dilutions. Control solution contained ethanol at 1:1000 dilution. All steroid
stock solutions were kept at -20°C.
Glucagon (MWt. 3485) was made up in EBSS to 0.348 mg/ml (ioopmol/1).
Working solution was prepared by adding the appropriate volume to culture
medium and canying out serial dilutions as described. Stock was stored at 4°C
for up to 1 month.
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Tri-iodothyronine ('T3'; MWt. 651) was dissolved in 0.1M NaOH to a
concentration of 0.651 mg/ml (1 mmol/1). This was further diluted 10-fold with
water to provide the final stock solution at ioopmol/1. Working solutions were
made by carrying out a 1000-fold dilution, and then further 10-fold dilutions.
Experiments showed that this small amount of added base was buffered
successfully by culture medium, leading to no change in pH, and was not
therefore neutralised. Control medium was prepared using the same amount of
added base. Stock was stored at 4°C for up to 1 week.
4.2.1. Effects of endocrine agents on fibrinogen secretion.
Cells were diluted to a density of 1 x lo^/ml in warmed culture medium. 50 pi
containing 5 x ios liver cells were added to each well of a 96-well plate previously
coated with type I collagen at 5 pg/cm2 (16 pi of collagen solution per well,
loopg/ml). To each well were added a further 50 pi culture medium containing
either control medium, Cortisol, dexamethasone, oestradiol, progesterone,
insulin, glucagon or tri-iodothyronine at concentrations encompassing
physiological levels. In each case, four different concentrations of agent were
prepared by serial 10-fold dilution. Each treatment was applied in triplicate.
Culture medium was changed on day 3, and removed on day 7 for storage at -
20°C and subsequent fibrinogen ELISA. This experiment was repeated in 3
separate wells for each treatment (n = 3 wells, +/- SEM).
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4.2.2. Effects of endocrine agents on liver cell proliferation.
Cell cultures were set up as described in 4.2.1 above. Cells were maintained in
culture until day 7, at which point the thiazylol blue technique was employed to
determine the relative cell content of each culture well, as described in chapter 2,
(section 2.5). The mean absorbance of each triplicate treatment was calculated,
as was the standard error of this mean (n = 3 wells, +/- SEM).
4.2.3. Effects of Dexamethasone on fibrinogen secretion.
Having carried out an initial screening experiment in sections 4.2.1 and 4.2.2, a
more detailed assessment of the response to glucocorticoid was carried out.
Cells were plated as described above, and dexamethasone was added to triplicate
wells as before. A serial dilution of control medium was carried out to match
vehicle concentration precisely. Medium was collected between days 3-7 for
fibrinogen ELISA. This experiment was performed in triplicate wells from which
the mean was taken for each culture. This was repeated in each of 7 separate
liver preparations (n = 7 cultures, +/- SEM).
4.2.4. Effects of Dexamethasone on liver cell proliferation.
Cultures were prepared and treated with dexamethasone or control as described
in 4.2.3. On day 7, cultures were processed for thiazylol blue assay as previously
described. Treatments were in triplicate, from which the mean was calculated
for each culture. This experiment was repeated in 7 separate cultures (n=7).
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4.2.5. Effects of Dexamethasone on urea synthesis.
Cells were made up to txKC/nil in culture medium, and soopl were added to
each well of a 24 well plate. In half the wells, 5pi control medium was added. In
the remainder, 5 pi dexamethasone solution was added to give a final
concentration of 1x10-7mol/l. Urea synthesis was determined in each well using
the technique described in section 3.2.7. Each treatment was carried out in
duplicate, and this experiment was repeated in 5 separate cell cultures (n=5) on
day 7 in vitro. In addition to urea synthesis, the effects of dexamethasone on
ammonia uptake and incorporation of ammonia into non-urea metabolites was
determined.
4.2.6. Effects ofDexamethasone on cellular morphology.
The effect ofglucocorticoid on morphology was assessed by adding
dexamethasone at a final concentration of ioopmol/1 to cultures of liver cells
growing on type I collagen-coated slides. Cells were photographed at day 7 in
vitro under phase contrast conditions.
In order to appreciate the histological maturation of liver cells cultured on
chamber slides, cultures were processed for immunocytochemistry directed
against cytokeratin 18 and fibrinogen, such that hepatocytes could be identified
unequivocally. The technique for immunocytochemistry was identical to that
described for cytokeratin 18 and fibrinogen flow cytometry, except that slides
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were washed in a bath of PBS rather than subject to centrifugation between
steps. Slides were mounted in Faramount (DakoCytomation), coverslipped, and
examined with a fluorescence microscope (Leica, UK) using Openlab image
acquisition, with a filterset appropriate to 525nm and 575 nm fluorescence
maxima.
4.2.7. Statistics.
Analyses in which more than 2 groups were compared were first assessed by
Analysis of variance using the SPSS package. Pairwise comparisons were carried
out using a t-test where permitted by ANOVA. The significance level was set at
O.05.
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4.3. Results.
4.3.1. Effects of endocrine agents on fibrinogen secretion.
Figure 4.1 shows the responses of cell cultures in terms of fibrinogen secretion
after 7 days incubation, with each dose of the six compounds, compared to a
matched control. Dexamethasone and Cortisol demonstrate similar dose-
response curves, but neither progesterone, oestradiol, T3 nor glucagon
demonstrated a convincing dose-response in terms of fibrinogen secretion.
4.3.2. Effects of endocrine agents on liver cell proliferation.
The thiazylol blue technique was used to determine whether the various agents
had any growth promoting activity on the cultured cells, quite separately from
the effects on secretory function. The data suggested that none of the agents had
an effect on cell proliferation (Figure 4.2).
4.3.3 Effects of Dexamethasone on fibrinogen secretion.
Figure 4.3 shows the marked effect of glucocorticoid on fibrinogen secretion by
these cells in comparison to paired vehicle controls. ANOVA revealed
dexamethasone to have a significant overall effect (p = 0.001). Dexamethasone
had a significant stimulatory effect (p<0.05) on fibrinogen secretion compared
to paired controls at 10 - iooonmol/1. This was in stark contrast to the effects of
vehicle, which showed no effect at any of the dilutions applied in this experiment
(ethanol; 1:1000 to 1:10,000,000).
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Figure 4.1. The dose-response of fibrinogen secretion in fetal
liver cultures. Cultures were prepared from fresh tissue and plated in 96 well plates at 5x10s cells
per well on type I collagen. Hormone supplements were added, and the cultures were maintained in vitro for 7
days, with a medium change on day 3. Culture supernatant was removed for later assay on day 7 and stored at
-20°C. (n=3 wells. Mean +/- SEM).
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Figure 4.2. The dose-response of cell proliferation in fetal liver
cultures. Cultures were prepared from fresh tissue and plated in 96 well plates at 5x10s cells perwell
on type I collagen. Hormone supplements were added, and the cultures were maintained in vitro for 7
days, with a medium change on day 3. MTT solution was added to the cultures on day 7, incubated for 4 hours,
and then acid SDS solution was added to solubilise the formazan crystals. After an overnight incubation, the
absorption at 570nm was read. n=3 wells. Mean+/-SEM.
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Figure 4.3. The dose-response of fibrinogen secretion to
dexamethasone. Cell cultures were prepared from fresh tissue and plated on type I collagen at spg/cm2.
Cultures were plated at 0.5 million cells per well in 96 well plates. T o each well was added dexamethasone in vehicle or
vehicle alone in triplicate. Cultures were maintained for 7 days in vitro, with a medium change on day 3. On day 7,
culture supernatant was removed and stored at -20°C for later assay. n=7 cultures. Mean +/- SEM. * p<o.os or **
p<o.Oi compared to paired vehicle control.
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4.3.4 Effects of Dexamethasone on liver cell proliferation.
Figure 4.4 shows that compared to control, there was no effect of
dexamethasone or vehicle on cell proliferation.
4.3.5 Effects of Dexamethasone on urea synthesis.
Figure 4.5 shows the effects of dexamethasone and time in vitro on urea
synthesis, ammonia uptake, and incorporation of ammonia into non-urea
metabolites (organification). The data show that neither time in vitro nor
dexamethasone had any effect on urea synthesis. However, uptake of ammonia
increased with time in vitro, an effect which was significant only in the absence
of dexamethasone. The data also demonstrate that the incorporation of
ammonia into metabolites other than urea (that is, ammonia uptake which is in
excess of urea synthesis) is significantly increased with time in vitro in the
absence of dexamethasone. When dexamethasone was present, the increase in
ammonia organification was less marked, and did not reach statistical
significance in this series of experiments.
4.3.6 Effects of Dexamethasone on cellular morphology.
Figure 4.6 shows that at day 7, cells cultured in the absence of dexamethasone
adopt a spindle-shaped morphology, reminiscent of mesenchymally-derived
cells rather than mature epithelioid hepatocytes. Cells cultured in the presence
of dexamethasone show a flatter pavement of polygonal cells, more in keeping
with a mature, epithelial phenotype.
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Figure 4.4. The dose-response ofproliferation to dexamethasone.
Cultures were prepared from fresh tissue and plated in 96 well plates at 5x10s cells per well on type I collagen.
Dexamethasone in vehicle or vehicle alone was added to each well in triplicate. The cultures were maintained in vitro for
7 days, with a medium change on day 3. MTT solution was added to the cultures on day 7, incubated for 4 hours, and
then acid SDS solution was added to solubilise the formazan crystals. After an overnight incubation, the absorption at
570nm was read. n=7 independent cultures. Mean+/-SEM.
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Figure 4.5. Nitrogen metabolism in fetal liver cultures. Cell cultures were
prepared from fresh tissue and plated on type I collagen at spg/cm2. Cultures were plated at 5 million cells per well in 24
well plates. Cultures were maintained for 7 days in vitro, with a medium change on day 3. On day 3 and day 6, medium
was removed, the cells were washed with HBSS, and fresh HBSS containing glucose, HEPES, albumin, pyruvate and
imM ammonium chloride was added. Cells were incubated for 4 hours. The HBSS was removed and stored at -20°C for
later assay or urea and ammonia. Medium was replaced and the cells returned to the culture incubator. Data are shown
as mean, +/- SE. n=5 cultures. * p<0.05 compared to day 3 matched control.
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In order to assess the morphology of specifically identified hepatocytes in vitro
in the presence and absence of dexamethasone, two-colour
immunocytochemistry was carried out, staining for cytokeratin 18 and
fibrinogen. Figure 4.6 shows the spindle-shaped morphology of cells expressing
cytokeratin 18 (orange) and faintly staining for fibrinogen (green). This
contrasts with the flatter, epithelioid cells seen which stain more strongly for
fibrinogen in the presence of dexamethasone. These data, although subjective,
emphasise the morphological, and hence structural, maturation observed in the
presence of glucocorticoids.
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Control Dexamethasone 10~7 mol/l
Figure 4.6. Culture morphology in response to glucocorticoid, ceil
cultures were prepared from fresh tissue and plated on type I collagen at 5pg/cm2. Cultures were plated at SxicH cells per
well in chambered slides. Cultures were maintained for 7 days in vitro, with a medium change on day 3, in the presence
and absence of glucocorticoid. Cells were then rinsed and fixed in 0.5% formaldehyde. After a blocking step, cells were
incubated with mouse anti-cytokeratin 18 antibody at 1:100 and rabbit anti-Fibrinogen antibody at 1:200 dilution. After
a wash step, cells were incubated with Goat anti-mouse Phycoerythrin conjugate antibody at 1:20 dilution and Swine
anti-rabbit Fi'l'C conjugate at 1:20 dilution. Cultures were rinsed, mounted in Faramount and coverslipped. Cultures
were photographed under phase contrast and immunofluorescence conditions at 525 and 57511m. Phase contrast
micrographs were obtained at xioo, immunofluorescence at X400.
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Section 4.4. Discussion.
This chapter investigated which endocrine substances might affect maturation
and proliferation in fetal liver during development. The data showed that
glucocorticoids alone influenced fibrinogen secretion from the cultured cells.
This effect was not mediated by cell proliferation; rather, it appeared to be the
result of increased secretion per cell. Immunofluorescence studies showed that
glucocorticoids enhanced the phenotypic maturation of hepatocytes to favour a
mature, epithelioid, morphology with increased cytoplasmic fibrinogen
expression.
The most striking finding in this study was of the dramatic effect of
glucocorticoids to stimulate fibrinogen secretion from cultured human fetal
hepatocytes. Although there are no published data from fetal tissues, it is
relevant that patients with Cushing's syndrome, in which glucocorticoid excess is
the central pathological feature, demonstrate markedly elevated plasma
fibrinogen concentrations, a finding which was highly significant compared to
controls (Tauchmanova et al., 2002). Such linkage may be indirect. However, in
the hepatoma cell line HepG2, dexamethasone is reported to have a modest
enhancing effect on fibrinogen secretion when cells are previously stimulated by
11-6 (Kasza et al., 1994). Dexamethasone also stimulates fibrinogen secretion by
isolated rat hepatocytes (Crane and Miller, 1977). Moreover, glucocorticoid
response elements, which positively regulate gene transcription, are present in
the upstream regulatory sequences of human (3- and y- fibrinogen precursors
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(Huber et al., 1990; Asselta et al., 1998). Whilst this does not conclusively
demonstrate that intact, hetero-hexameric ((aPy)2) fibrinogen synthesis can be
increased by glucocorticoids, increased expression of any of the fibrinogen
precursors, a-, (3-, or y-, leads to increased synthesis of all precursors and
increased synthesis and release ofmature fibrinogen (Redman and Xia, 2001).
Together with the present results, these data confirm for the first time that
fibrinogen secretion from human liver can be strongly enhanced by
glucocorticoids.
The effects of dexamethasone noted here might occur only with non-
physiological concentrations of glucocorticoid, as plasma levels of Cortisol in the
fetus may be much lower than the range in adult humans, which is 100-700
nmol/1. Published evidence suggests, however, that fetal Cortisol levels in the
last few weeks of gestation are relatively high, with levels recorded at parturition
of around iooonmol/1 (Goldkrand et al., 1976). This level is well above the
apparent maximally effective concentration ofCortisol in this work which was
approximately ioonmol/1. Similarly, the levels of dexamethasone which had
effects on fibrinogen secretion in this study are the same as those in cord blood
samples from dexamethasone-treated premature human neonates (Kream et al.,
1983). The glucocorticoid effects that have been observed in the present study,
therefore, tie in well with previous work, suggesting that this is not an effect
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secondary to supra-physiological doses of steroid but is in fact a physiological
response of developing hepatocytes to glucocorticoid.
Gestational glucocorticoid is clearly required to bring about organ maturation in
preparation for birth (Cole et al., 1995; Hanson and Reshef, 1997). Exposure to
glucocorticoids may, however, have deleterious effects. Exogenous
glucocorticoid during fetal life leads to reduced body weight and liver weight at
birth (Quinlivan et al., 1998) and adverse biochemical and physiological changes
in adult life, namely, impaired glucose tolerance, hyperinsulinaemia, persistently
elevated glucocorticoid receptor expression (Nyirendra et al., 1998) and
increased blood pressure (Levitt et al., 1996). This constellation, which has
been termed the 'metabolic syndrome', has been likened to the complications of
Cushing's syndrome (Seckl and Walker, 2001). The physiological relevance of
these findings has been emphasised by experiments in which 11 (3-
hydroxysteroid dehydrogenase type II (ii(3-HSD II), the placental and fetal liver
enzyme which metabolises glucocorticoids, has been itself inactivated with a
potent inhibitor, carbenoxolone, administered to the mother. Such
experimental treatment leads to hypertension, hyperglycaemia and
hyperinsulinaemia in offspring which persists into adulthood (Lindsay et al.,
1996a; Lindsay et al., 1996b). In human studies, hyperfibrinogenaemia is a
super-added risk factor as part of the metabolic syndrome, the role of which as a
major risk for myocardial infarction has been confirmed in a prospective study
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of 10,500 men (Scarabin et al., 1998). The developmental aetiology of adult
hyperfibrinogenaemia is unclear, however, gene knockout techniques have
shown glucocorticoid action in the fetal liver has a significant role (Morton et al.,
2001). The data presented in this study strongly support the hypothesis that
fetal glucocorticoid could have a major role in the aetiology of
hyperfibrinogenaemia, and might therefore contribute to cardiovascular risk in
adult life.
No attempt was made to determine whether fibrinogen secretion might continue
at a high level after glucocorticoid was removed in the present work. However,
data exist to suggest that DNA demethylation, mediated by the glucocorticoid
receptor in fetal liver-specific sequences, could underpin lasting effects of
glucocorticoids, long after steroid has been withdrawn (Thomassin et al., 2001).
This mechanism is an attractive explanation for observed persisting changes into
adult life secondary to fetal glucocorticoid exposure.
The difference between the effects of Cortisol and dexamethasone in terms of
fibrinogen release were somewhat surprising. Whilst dexamethasone at the
highest concentration (1 micromol/1) had a fivefold stimulatory effect on
fibrinogen, the highest dose ofCortisol (10 micromol/1) had a threefold
enhancing effect. Notwithstanding that the efficacy of dexamethasone to bind
the glucocorticoid receptor is approximately 7 times that ofCortisol (Baxter and
Rousseau, 1979), both agonists fully occupy the glucocorticoid receptor at these
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biologically equivalent concentrations. It is therefore not clear why
dexamethasone should be a more efficacious ligand to increase fibrinogen
release.
On the other hand, dexamethasone is not a substrate for 11P-HSD II, the
endogenous liver enzyme which inactivates Cortisol. Work by Hirasawa et al.
(1999) has shown weak immunostaining for 11P-HSD II in hepatocytes at week 8
and week 20 of gestation in human fetal liver. Stewart et al. (1994) detected 11P-
HSD II mRNA and low levels of enzyme activity in fetal human liver from mid
gestation. Notably, they found no 11P-HSD I mRNA or enzyme activity in any
fetal tissues. Whilst 11P-HSD II was not localised as part of this thesis, it
remains an attractive possibility that the inactivation of Cortisol by lip-HSD II
explains the relative ineffectiveness of Cortisol compared to dexamethasone in
stimulating fibrinogen release shown here. In this regard, the data show that the
maximal efficacy of Cortisol was observed at ioonmol/1, and it may be that any
levels in excess of this concentration were metabolised by 11P-HSD II.
In this work, considerable emphasis was placed on the effect of hormones to
cause liver cell proliferation, as the implications of altered protein secretion were
different if cell proliferation was also taking place. As glucocorticoids alone had
an effect on protein secretion, and the initial study showed no effect of any agent
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on cell proliferation, only glucocorticoids were selected for further investigation
in this regard.
The literature concerning the role of corticosteroids in hepatocyte proliferation
is a little contradictory. In whole animal models, published data suggest that
there is no effect on liver cell replication. For example, methylprednisolone
administration pre-operatively to rats undergoing partial hepatectomy caused
no difference in hepatocyte Ki-67 labelling, cyclin Di expression, or mitotic
index in liver tissues examined during the post-operative phase. In fact, post¬
operative liver function tests suggested reduced liver injury in the steroid-
treated group (Glanemann et al., 2004). However, dexamethasone pre-
treatment of rats which subsequently underwent partial hepatectomy caused
delay in hepatocellular DNA replication by 6 hours (Nagy et al., 2000), and
glucocorticoid treatment in a rat cold ischaemia/liver transplant model caused
impaired hepatocyte proliferation after transplantation as detected by reduced
BrdU uptake, and lead to increased hepatocellular necrosis (Debonera et al.,
2003). None of these studies was able to identify specific mechanisms of
glucocorticoid action, however, data from HepG2 cells show that dexamethasone
causes induction of cyclin-dependent kinase inhibitor p2iWAFi/CIPi, thus
abolishing Cdk2 phosphorylation and preventing cell cycle progression (Park et
al., 2001). Glucocorticoid receptor activation was linked to P53
phosphorylation, and downregulation of p53 by antisense techniques prevented
dexamethasone-induced p2i expression (Urban et al., 2003).
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Data from the present work clearly shows no decrement in cell numbers after
corticosteroid treatment, even after dexamethasone at l micromol/1 for 7 days,
when compared to control. Together, these data support the hypothesis that
glucocorticoids act neither to inhibit nor stimulate proliferation in human fetal
liver cells. The explanation for the stimulation of fibrinogen secretion by
dexamethasone must lie with increased fibrinogen synthesis and release in each
cell.
In this chapter, it was expected that glucocorticoids would stimulate the
production of urea from ammonia. Published studies show that glucocorticoids
promote synthesis ofmRNA and subsequent enzyme activity for carbamoyl
phosphate synthestase I (Lamers et al., 1984), arginiosuccinate synthetase
(Bourgeois et al, 1997), argininosuccinate lyase (Husson et ah, 1990) and
arginase (Nebes and Morris, 1988), four out of five enzymes of the urea cycle.
Ornithine transcarbamylase mRNA was not increased by steroid, however,
enzyme activity increased, potentially by a protein stabilization mechanism
(Ulbright and Snodgrass, 1993). Thus, the synthesis and/or activity of the five
enzymes of the urea cycle is increased by glucocorticoid treatment (Husson et
ah, 1985).
Despite these observations, no effect was noted of dexamethasone on urea
synthesis in these mid-trimester liver cultures. This was somewhat surprising,
given the body of literature which describes the effects of glucocorticoids on the
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urea cycle. It may be that the quantity of urea synthesized, or ammonia taken
up, is not a reliable marker of urea cycle enzyme activity in these cultures. In
general, enzyme activity is best measured by dynamic studies of maximal
enzyme velocity (Vmax). This would have required detailed studies investigating
the rate of urea synthesis in the presence of different quantities of ammonia.
The present work utilised the quantity of urea as an end point after a 4 hour
incubation. This is very likely to represent a dynamic equilibrium. In fact, the
quantity of urea present at equilibrium simply provides an index of the relative
thermodynamic favourability of the forward and back reactions, which is little
affected by the quantities of enzymes present. Detailed studies of urea cycle
enzyme activities may be prudent before asserting that glucocorticoids exert no
effect on urea synthesis in fetal liver cells in vitro.
The potential exists for other mechanisms to inhibit urea synthesis in vitro. For
example, insulin has previously been reported to inhibit markedly the stimulant
effect of glucocorticoids in cultured hepatocytes. In fact, insulin causes marked
downregulation of all urea cycle enzymes, excepting ornithine transcarbamylase,
in fetal rat liver cultures (Husson et al., 1985). The culture system developed for
these studies required insulin as a growth-supporting supplement. Full
characterization of the cell cultures with and without insulin was not possible. It
is well recognized that primary culture of fetal cells in particular, but also of
many primary cell types in general, often requires insulin as a pleiotropic factor
to support growth. Therefore, these cells were grown in insulin-supplemented
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medium to ensure cell survival. It may be that the absence of a dexamethasone
effect in these studies was secondary to the presence of high levels of insulin.
Whether or not dexamethasone had any effect, it was noted that only two thirds
of added ammonia were taken up within a 4 hour period. This was thought to be
a rather small fraction of the total, implying urea cycle immaturity. Previous
authors have noted that the rate limiting enzyme, CPSI, is present in fetal liver
cells at only i/50th the level of adult cells, with i/ioth the synthetic capacity
during development (Lamers et al., 1984). Despite this, urea synthesis is
demonstrable in vitro in preparations of human fetal liver by week 9, although
urea synthesis in vivo seems to occur only in the second half of gestation (Karsai
and Elodi, 1982). It is possible that there were insufficient quantities of L-
aspartate present in the cultures. This amino acid is a necessary requirement for
ureagenesis which is consumed in the pathway. However, adult human
hepatocytes grown in the same medium and subject to the same protocol
metabolise all added ammonia to urea (J. Black, personal communication),
refuting this explanation. Taken together, it is likely that the urea cycle activity
reflects physiological immaturity, and that any enhancing effect of
glucocorticoids was abrogated by the significant quantities of insulin present.
Further work could allow these hypotheses to be explored.
Despite the unremarkable effects of dexamethasone on urea synthesis, it was
noted that over time in vitro, less ammonia was left in the supernatant. That is
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to say that ammonia incorporation increased with time, although urea synthesis
appeared static. This effect was significant when dexamethasone was omitted
from the culture medium. Ammonia may be incorporated in the liver via the
glutamate dehydrogenase reaction as well as the urea cycle. Glutamate
dehydrogenase, a mitochondrial enzyme found only in hepatocytes, catalyses the
reaction in which ammonia and a-ketoglutarate combine to form glutamate.
This is a key step towards the synthesis of non-essential amino acids, and is
complemented by further ammonia uptake in the reaction to form glutamine
from glutamate and ammonia. These data support the hypothesis that the
metabolic pathways in developing liver are maturing in vitro, so as to favour the
synthesis of various amino acids as would normally be observed in adult liver.
In this series of experiments, the classical flattened morphology ofmature
hepatocytes was evident only in the presence of glucocorticoids. Previously, the
role of hepatic transcription factors in the maintenance of hepatocyte
morphology has been examined at the molecular level, and it is clear that the
mature phenotypc is critically dependent on the expression of the transcription
factor HNF4a and the subsequent cell surface expression of E-cadherin (Parviz
et al., 2003). For example, dedifferentiated, fusiform, hepatoma cells can be
driven to express mature hepatocyte morphology after transfection with an
HNF40C vector, which leads to surface expression of E-cadherin (Spath and
Weiss, 1998). Molecular ablation of the HNF40C transcription factor with Cre-
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recombinase techniques in whole animals results in an abnormal developing
liver, populated with small rounded hepatocytes, without intercellular junctions,
and which express extremely low levels of hepatocyte-specific enzyme systems
(Parviz et al., 2003).
Whilst the role of HNF40C is in little doubt, it is not clear from the present work
how glucocorticoids might bring about the mature morphology noted. There are
no data in human liver as to the relationship between HNF40C and
glucocorticoids. Surprisingly, there is only one publication demonstrating
glucocorticoid binding activity in the fetal human liver (Ballard and Ballard,
1974), but no studies demonstrating immunolocalisation of glucocorticoid
receptor in liver (Condon et al., 1998). However, DNA footprinting techniques
have shown that the upstream regulatory region of the HNF4a promoter
sequence contains an enhancer element which is activated by glucocorticoids
and liver enriched transcription factors (Bailly et al., 2001). As previously
stated, the glucocorticoid receptor has not been mapped in developing human
liver, but the marked effects of corticosteroids on fibrinogen secretion as noted
here strongly support the presence of GR in developing hepatocytes. Therefore,
it is likely that glucocorticoids in this work are binding to glucocorticoid receptor
and enhancing HNF40C expression, with resultant phenotypic maturation.
Confirmation of this hypothesis awaits further study.
Chapter 4 Maturation Signals 179
In this study, only corticosteroids showed a credible dose-response relationship
between hormone concentration and fibrinogen release. In cell culture studies
of HepG2 cells, oestradiol was previously noted to have no effect on fibrinogen
release (Niessen et al., 1995). By contrast, human fetal liver cultures respond to
estradiol levels between o.mmo/1 and 0.1 micromol/1, as used in the present
study, by synthesising increased quantities of cholesterol in a dose-responsive
manner (Carr and Simpson, 1984). The lack of a clear dose relationship between
oestradiol concentration and fibrinogen secretion, in the presence of oestradiol
levels clearly shown to be effective in other studies, suggests that oestradiol has
no specific effect on fibrinogen secretion from human fetal liver. This is
supported by the absence of oestradiol receptors detected in fetal liver of rat and
monkey (Hochner-Celnikier et al, 1986). However, the results of Carr and
Simpson (1984) suggest that the human fetal liver may well possess oestradiol
receptors. Without further detailed experiments, any role for oestradiol remains
obscure.
Progesterone levels in the current experiments span the levels seen in
physiological menstrual cycles (10-60 nmol/1) and in term pregnancy (1-5
micromol/1). Fibrinogen secretion has not previously been investigated in
response to progesterone, however, cholesterol synthesis in fetal human
hepatocytes may be increased by progesterone when present at levels greater
than 1 micromol/1 (Carr and Simpson (1984). It is reasonable to suppose that
the fetal liver is insensitive to circulating progesterone. Therefore, the present
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observation, that progesterone may have caused a small increase in fibrinogen
release, only at a level of 10 nmol/1, the lowest physiological level in women,
remain speculative.
Several other hormones, in addition to the steroid hormones above, were
investigated to determine whether there were stimulatory effects on hepatocyte
function. Glucagon has a physiological role to stimulate gluconeogenesis in
liver. It is also a stress hormone, is elevated as part of the metabolic response to
adverse physiological conditions, and may have a role in the acute phase
response of the liver. In normal humans, glucagon infusion results in acutely
increased fibrinogen synthesis and plasma levels (Tessari et al., 1997), an
observation which might explain pathophysiological hyperfibrinogenaemia in
type II diabetic patients (Barazzoni et al,. 2000). However, in cultured rat
hepatocytes, glucagon had no effect on fibrinogen secretion (Zupke et al., 1998).
Detailed studies of fetal liver confirm that glucagon receptor levels are much
lower than adult levels (Berthoud et al., 1992). In fetal sheep, data have been
presented to suggest that there is marked glucagon resistance during fetal life
(Devasker et al., 1984), which is supported by observations ofmarkedly
impaired adenylate cyclase activation in response to glucagon (Vinicor et al.,
1976).
Chapter 4 Maturation Signals 181
It is likely that the absence of any observed effect of glucagon on cultured
hepatocytes in the present study is due to the marked insensitivity of fetal liver
cells to glucagon. In support of this, the concentrations of glucagon employed
here were more than sufficient to elicit a physiological response (Vinicor et ah,
1976). Although there are no studies of human fetal liver and responses to
glucagon in the literature, low receptor expression likely plays a significant role.
Tri-iodothyronine (T3) was investigated in the present work as fetal cells may
require T3 as a permissive or trophic agent to support normal function. The
data here suggested that T3 neither caused cell proliferation, nor had any effect
on protein secretion. The absence of an effect on proliferation was noteworthy;
in adult rats, T3 supplementation in vivo causes hepatocyte proliferation, a
response which has been used in whole animals to produce massive proliferation
in transplanted hepatocytes (Selden et al., 2003) and to enable viral
transduction of replicating hepatocytes in situ, paving the way for liver gene
therapy (Forbes et al., 2000).
With regard to hepatocyte function, many studies have demonstrated the
significant role of thyroid hormones to support normal liver function. For
example, T3 is central to bile acid synthesis (Ellis et al., 1998) and glycogen
synthesis (Betley et al., 1993) in rat and human hepatocytes. In humans,
hypothyroidism may present with coma and hyperammonaemia, mimicking
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hepatic failure, and suggesting a supportive role for thyroid hormones in
ureagenesis (Thobe et ah, 2000).
In cell culture studies, T3 causes a dose-responsive decrease in AFP and a-i-
antitrypsin secretion, in contrast to a stimulation of a-i-acid glycoprotein
(Kobayashi and Horiuchi, 1995). T3 also mediates the maturational change
from fetal liver AFP secretion to neonatal albumin synthesis and release in fetal
mouse hepatocytes in vitro (Anteby et al., 1993). In support of the absence of
any effect as seen in the present study, other workers have shown that T3 has a
significant effect on hepatocyte protein synthesis in vitro, but had no effect on
protein secretion from cultured primary rat hepatocytes (Gallo et al., 1987). The
present study was designed to assess any simple effects of T3 on fetal human
hepatocyte function, and no effect was observed on proliferation or fibrinogen
release. It remains possible that detailed study might reveal significant effects of
T3, for example on AFP release, metabolic rate, or urea production. However,
within the confines of the present work, no effects were observed.
This study set out to assess which of several hormones present during fetal life
might have significant maturational effects on human fetal liver cells.
Fibrinogen secretion and cell morphology were chosen as indices ofmaturation.
Glucocorticoids had a potent maturational effect in terms of protein synthesis,
observations which were confirmed with two separate glucocorticoid agents.
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These data were corroborated by the effect of glucocorticoid to bring about a
more mature epithelial phenotype in cultured cells. This chapter has provided
good evidence that glucocorticoids are implicated in the functional and
phenotypic maturation of fetal human liver cells.
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Chapter 5.
Cytokines, growth factors, and proliferation in fetal liver.
5.1 Introduction.
Prior to ductal plate formation, developing hepatoblasts and haematopoietic
cells form the liver parenchyma, with only portal and central venous channels
interrupting these two compartments. The liver cell complement must therefore
be derived by proliferation of hepatoblasts, or from a stem cell compartment
which gives rise to hepatoblasts, or both. Although the role of growth factors and
cytokines in liver cell proliferation has been investigated extensively in adult
liver, the data in the developing liver are scant, and the data from fetal human
liver even more so. Understanding the proliferation signals in developing liver is
important, as such insight also allows understanding of liver repair and liver
cancer.
During fetal life, bile ducts contain strong staining for both TGF-a and EGF
receptor (Terada et al., 1994), and published data show a generalised
proliferative response to EGF in cultured human liver cells (Malhi et al., 2002).
Hepatocyte growth factor, and its receptor c-met, have been localised in fetal
liver, c-met is expressed in the ductal plate and in the developing bile ducts, as
well as in hepatocytes, but only at low levels (Terada et al., 1998). HGF may be
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important in the proliferation ofbiliary ductules during development (Pagan et
al., 1999), whereas KGF may cause significant proliferation in hepatocytes
(Housley et al., 1994).
Ultimately, the growth factors and cytokines implicated in fetal liver
development are not adequately defined, and the true mechanisms which
subserve hepatoblast and cholangiocyte proliferation in developing liver are not
known. In order to clarify which growth factor pathways may be implicated in
the developing human liver, this chapter sought to examine the effects of
different growth factors and cytokines on cellular proliferation in developing
liver cells.
5.2 Materials and Methods.
Cell cultures were prepared as previously described. Cells were diluted as
required and on plated type I collagen-coated dishes as appropriate to individual
experiments. Cells were then exposed to various growth factors and cytokines,
and cellular proliferation was assessed as described below.
Growth Factors and Cytokines.
All growth factors and cytokines were obtained from Peprotech, UK.
Epidermal Growth Factor (EGF) was prepared in sterile water to a concentration
of 1 mg/ml, divided into 20 aliquots of 50 pi and stored at -70°C. Keratinocyte
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Growth Factor (KGF), Hepatocyte Growth Factor (HGF), Interleukin-6 (IL-6)
and Tumour Necrosis Factor a (TNF) were similarly prepared and stored.
For experimental purposes, peptides were diluted in culture medium to give a
final working concentration when added to cells as follows; EGF; 25ng/ml: KGF;
20ng/ml: HGF; long/ml: IL-6; 20ng/ml: TNF; ing/ml. Peptides, once thawed,
were discarded after single use.
5.2.1 [3H] Thymidine incorporation in cultured fetal liver cells.
Cells were diluted in culture medium to a density of 2x107 cells per ml, and 25pi
were added to each of triplicate wells in a 96-well plate (5x10s cells per well). To
each well were added a further 25 pi culture medium containing growth factor or
cytokine. The total volume was made up to loopl, and cells were cultured in a
humidified C02 incubator as previously. After 24 or 48 hours, tritiated
thymidine (Amersham, Berks) was added at an activity of 25pCi per ml in a
volume of 20pi to all wells using an Eppendorfmultichannel micropipette
(Sigma).
72 hours after plating, plates were gently agitated to resuspend particulate
matter and dead cells, and the medium was removed by gentle suction. 200pl of
warm PBS without calcium/magnesium was added per well, then the plate was
gently agitated and the medium removed as before. This wash step was
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repeated, and toopl ofwarm trypsin solution per well were added. Cultures
were returned to the incubator for 10 minutes or more, and cell detachment was
confirmed visually at this stage. An automated cell harvester (Skatron type 7020
semiautomated cell harvester, Lier, Norway) was used to transfer the contents of
each well onto individual filter mats (Skatron). Filter mats were then thoroughly
dried. Filter discs, each one corresponding to a single well, were punched out
into individual counting vials (Pony vial, Packard), to which were added 5 ml
Aquasafe 300 Plus scintillation fluid (Zinssen Analytical, Berkshire). Vials were
counted automatically on a Hewlett Packard Tricarb 1900 LA liquid scintillation
counter (Canberra Packard UK). Specific activities were calculated
automatically by the scintillation counter and these data were used for
calculating proliferation indices.
In each culture, means of triplicate wells were calculated. These experiments
were repeated and means calculated (n= 3 cultures for the 24 hour
incorporation, n=2 cultures for the 48 hour incorporation). Data were plotted as
means +/- SE for the different growth factors and cytokines.
5.2.2. Cell proliferation as determined by manual counting.
Initial data suggested a potentially toxic effect of tritiated thymidine on cultured
cells. To verify and complement the proliferation indices calculated from the
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experiments described above, further studies were designed which would allow
manual cell counts to be performed.
Cell cultures were prepared in 24-well plates to provide sufficient cells to allow
cell counting. 250pl of freshly prepared primary cell suspension in culture
medium at a density of 2 x to? cells/ml were added (5 x tos cells per well) to each
well previously coated with type I collagen. A further 250pi culture medium was
added containing no additive (control) or peptide to provide the appropriate
working dilution. Cells were cultured in a humidified C02 incubator. On day 3,
culture medium was removed and replaced with 250pl fresh culture medium,
after which a further 2sopl culture medium containing no additives (control) or
peptide was added as before. Each experimental group was carried out in
duplicate wells and each experiment was repeated in 4 separate cultures (n=4
cultures).
On day 7, culture medium was removed from the wells, and soopl ofwarmed
PBS without calcium or magnesium was added to each well. This was removed
after gentle agitation and placed in a polystyrene tube on ice (LP3), with one
tube per well. This wash step was repeated, and the supernatant retained once
more, loopl of trypsin solution was added to each well, and cells were returned
to the incubator for 10 minutes. After trypsinisation, 200 pi chilled buffer (Flow
cytometry buffer, as described in chapter 3, section 3.2.4) were added to each
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well, and the cell suspension was removed into the relevant polystyrene tube.
Tubes were then centrifuged at 340g for 5 minutes at 4°C. The supernatant was
discarded, and cells were resuspended in 200ml chilled PBS/BSA. A portion
was removed and made up with an equal volume of trypan blue, and viable cell
counts were carried out (mean of two separate counts for each well), as
described in chapter 2, section 2.2. Means were taken between the two
replicates in each culture, and means +/- SE were calculated for the 4 separate
cultures (n=4 cultures). The effects of growth factors and cytokines were
expressed as a percentage of the matched control wells.
5.2.3 Immunophenotyping of proliferating cells.
Cell cultures were prepared as described in the preceding section, and treated
with growth factors or cytokines in the same manner. On day 7 in vitro, cells
were trypsinised, spun down as before, and then washed in 2 ml PBS. Cells were
spun down again and fixed by incubating with 1 ml 0.5% paraformaldehyde in
lOmM PBS on ice for 15 minutes in the refrigerator (4°C). These fixed cells were
then processed for two-colour flow cytometry as described in chapter 3. The
proportions of cells expressing cytokeratin 18 but not fibrinogen, cytokeratin 18
and fibrinogen, the total of cytokeratin 18-expressing cells, or cells negative for
both markers, were calculated for each treatment. The means of two wells for
each treatment were taken, and the experiment was repeated in 4 separate
cultures.
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Results were calculated by multiplying each phenotype proportion by the total
number of cells in the well. The quantities of cells in each of the four groups
were then expressed as a percentage of the appropriate cell phenotype in control
cultures (n=4 cultures). Data were analysed by ANOVA, followed by post-hoc
testing where permitted.
5.2.4 Immunocytochemistry of developing liver.
To gain insight to the cell types detected by flow cytometry, liver tissues were
fixed in formaldehyde, embedded, sectioned and dewaxed as previously
described in section 3.2.1. Antigen retrieval was carried out by boiling in citrate
buffer, 0.1M, pH 6.0, for 3x5 minutes in a microwave. After cooling to room
temperature, slides were placed in 0.05M Tris buffered saline (TBS), then
incubated with 5% normal serum as appropriate (Blood Transfusion Service,
Edinburgh) in TBS for 30 minutes. This blocking buffer was carefully dabbed
off, and primary antibody or control IgGiwas applied to tissue sections diluted in
blocking buffer for 1 hour at room temperature in a humidified chamber. Slides
were then rinsed with TBS, and incubated in a rocker bath ofTBS for 10
minutes. The second antibody (HRP conjugate) was then added, diluted in
blocking buffer for an hour under the same conditions as previously. Slides were
rinsed and washed as before. To develop the slides, Di-amino Benzidine (DAB;
DakoCytomation) solution was added as per the manufacturer's instructions for
up to five minutes, or until the colour reaction had taken place. The reaction
was stopped, and the slides were counterstained with haematoxylin, dehydrated
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and mounted in Pertex (CellPath, Powys, UK) as previously described. Mouse
monoclonal anti-cytokeratin 18 and cytokeratin 19 antibodies were used to
assess the epithelial lineages in the liver. Rabbit anti-Ki67 was used to examine
proliferation in various compartments, whereas mouse monoclonal anti-EGF
receptor was used to document the distribution of this important pathway in the
epithelial compartment. Rabbit anti-mouse HRP conjugate or Goat anti-rabbit
HRP conjugate was used as the second antibody in each case. All antibodies
were obtained from DakoCytomation.
Slides were then photographed on an Olympus CK2 photomicroscope with
Kodacolour ASA 200 film using a tungsten correction filter as described in
chapter 3.
5.2.5. Statistics.
Analyses in which more than 2 groups were compared were first assessed by
Analysis of variance using the SPSS package. Pairwise comparisons were carried
out using a t-test where permitted by AMOVA. The significance level was set at
O.05.
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5.3 Results
5.3.1 [3H] Thymidine incorporation in cultured fetal liver cells.
Figure 5.1.A shows the incorporation of tritiated thymidine over a 24 hour
period in fetal liver cultures incubated in the presence of control medium, or
with a range of growth factors or cytokines. Figure 5.1.B shows a parallel study
in which thymidine incorporation was carried out for 48 hours. It is clear from
simple inspection that there is no stimulatory effect of any of the growth factors
tested, over either 24 or 48 hours. However, the data from the second
experiment show markedly less thymidine incorporation than the 24 hour
experiment. This suggested a toxic effect of [3H] Thymidine on cultured liver
cells.
5.3.2 Cell proliferation as determined by manual counting.
In control cultures, there were 5.54 +/- 2.0 x 104 cells per well after 7 days in
vitro (n=4 separate cultures). There was considerable variation in control cell
number between different cell preparations; however, the responses within
preparations were consistent. To derive maximum information from the data,
cell counts in response to the growth factors or cytokines were therefore
expressed as a percentage of the culture control. Figure 5.2 shows these data
represented graphically. EGF alone significantly stimulated cell proliferation to
180.0+7-34.4% compared to matched control (100%).
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Figure 5.1. The effects ofgrowth factors on liver cell proliferation
determined by tritiated thymidine. Cell cultures were prepared from fresh tissue and plated on
type I collagen at 5pg/cm2. Cultures were plated at 0.5million cells per well in 96 well plates. T o each well was added
growth factor or cytokine in triplicate, and o.spCi tritiated thymidine was added either 24 or 48 hours after plating. Cells
were washed and tiypsinised at 72 hours, and an automated cell harvester was used to transfer cells onto individual filter
mats. Mats were placed in scintillation vials, to which was added 5ml scintillation fluid. Cultures underwent scintillation
counting (Packard Tricarb). Panel A; 24 hour label (n=3 cultures, +/- SEM) and Panel B; 48 hour label (n=2 cultures,
+/- SEM).
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Figure 5.2. Proliferative responses to growth factors and
cytokines by cell counting. Cell cultures were prepared from fresh tissue and
plated on type I collagen at 5pg/cm2. Cultures were plated at 5 million cells per well in 24 well
plates. Cultures were maintained for 7 days in vitro, with a medium change on day 3. Cultures were
trypsinised on day 7 and cell counting was carried out using a haemocytometer in cells stained with
trypan blue. EGF was significantly different from paired control, p<o.os. n=4 cultures, data shown
+/- SEM.
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5.3.3 Immunophenotyping proliferating cells.
In order to determine which cell population was responding to EGF,
immunophenotyping was carried out by dual-label flow cytometry directed
against cytokeratin 18, a liver epithelial marker, and Fibrinogen, a
hepatocyte marker.
In control cultures, 26.25+7-7.8 % of all cells were cytokeratin 18 +ve alone,
whereas 27.13+7-9.5% were dual positive hepatocytes (cytokeratin 18+ve;
Fibrinogen +ve). A total of 56.75+7-8.5% of cells were therefore cytokeratin
18+ve epithelial cells, and 46.0+7-9.5% were dual negative cells (n=4 cultures,
means +/-SEM). 2.3+/-o.4% of cells were fibrinogen +ve alone, which
represents the background detection of light signals not related to epithelial
cells.
In order to demonstrate the magnitude of the proliferative response, the number
of cells within each phenotype was calculated by multiplying the number of cells
in each well by the % for each phenotype. This number was expressed as a % of
the relevant control figure for each culture. Figure 5.3A shows the responses of
the cell population which was positive for cytokeratin 18 and negative for
fibrinogen (epithelial cells). Figure 5.3B shows the population positive for
cytokeratin 18 and fibrinogen (hepatocytes), whereas figure 5.3.C shows the
entire cytokeratin 18+ ve population (A+B). Figure 5.3D shows the responses of
non-parenchymal cells, positive for neither cytokeratin 18 nor fibrinogen, to the
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Figure 5.3. The effects ofgrowth factors on proliferation of liver cell
subsets. Cell cultures were prepared from fresh tissue and plated on type I collagen at 5|ig/cm2. Cultures were
plated at 5 million cells per well in 24 well plates, to which were added the various growth factors. Cultures were
maintained for 7 days in vitro, with a medium change on day 3. Cultures were trypsinised on day 7, placed in polystyrene
tubes, fixed with 0.5% formaldehyde and permeabilised with 0.1% triton X. After washing, cells were incubated with
mouse anti-cytokeratin 18 antibody at 1:100 dilution, in combination with rabbit anti-Fibrinogen antibody at 1:200
dilution. After a wash step, cells were incubated with Goat anti-mouse Phycoerythrin conjugate antibody at 1:20 dilution
and Swine anti-rabbit FITC conjugate at 1:20 dilution. Immunopositive cells were detected by flow cytometry with
excitation at 488nm and detection at 525 and 575nm. Data show that EGF selectively stimulated the proliferation of
cytokeratin i8+/Fibrinogen -ve cells (ANOVA =0.001; p<o.05). The effects of growth factors on other cell types were
not significant.
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various growth factors and cytokines. These data show that only EGF caused a
significant expansion of cells (ANOVA; p = 0.001; Pairwise comparisons;
p<0.05), and that these cells were strictly within the epithelial compartment
(cytokeratin 18+ve), but were not hepatocytes (Fibrinogen -ve). In fact there
was no significant effect on dual labelled hepatocytes (cytokeratin
18+ve/Fibrinogen+ve; Figure 5.3.B) or on non-parenchymal cells (dual negative;
Figure 5-3-C).
5.3.4 Immunocytochemistry of developing liver.
Figure 5.4 shows the results from the immunocytochemistry studies.
Cytokeratin 18 reaction product was present in the epithelial compartment
alone. The cells which were labelled corresponded to hepatocytes and to biliary
tract cells. By contrast, cytokeratin 19 labelled only the ductal plate and
developing biliary ductules. Interestingly, these data confirmed that biliary tract
and ductal plate were positive for cytokeratins 18 and 19. Ki-67 labelling showed
that cell proliferation occurred in all compartments within the developing liver,
although the ductal plate seemed to show no staining. EGF receptor was present
on the ductal plate, biliary ductules and the hepatocytes.
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Figure 5.4. Immunocytochemistry in the second trimester fetal liver.
A and B; Haematoxylin and eosin stained sections (X400) are provided for
reference. Multiple biliary ductules can be seen in A along the ductal plate. In
B, intraportal haematopoiesis is evident from the nucleated red cells present.
Hepatocytes are faintly eosinophilic cell outside the portal tract.
Haematopoiesis is also evident within the liver sinusoids.
C and D; Mouse immunoglobulin (IgGi) control and anti-cytokeratin 18
(1:100) x 200. The cytokeratin 18 antibody stains all epithelial structures
(biliary tract and hepatocytes) whereas the control slide is not stained.
E and F; Mouse immunoglobulin (IgGi) control and anti-cytokeratin 19 (1:25)
x 200. The cytokeratin 19 antibody stains only biliary structures (biliary
ductules and ductal plate). The control is negative.
G and H; Rabbit immunoglobulin control and Rabbit anti-Ki-67 (1:50) x 400.
The nuclear labelling indicates cells within the replicative phase. The arrow
clearly shows a labelled hepatocyte nucleus. Many other proliferating cell types
are present. No labelling is observed in control sections.
I and J; Mouse immunoglobulin (IgGi) control and anti-EGF receptor (1:100)
x 200. EGFR immunostain is observed on hepatocytes, bile ducts and ductal
plate. Whilst the haematopoietic fraction in the sinusoids appears negative,
there may be some staining in the periportal mesenchyme.
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5.4 Discussion.
These experiments set out to investigate which growth factors might have a role
in supporting proliferation in the developing liver. The data showed that EGF
alone was effective in stimulating proliferation. This proliferative effect was
restricted to the epithelial compartment, in particular, cells which were positive
for cytokeratin 18, but negative for fibrinogen. Immunocytochemistry suggested
that the cells responding to EGF are within the epithelial compartment, namely
the ductal plate, the developing biliary ductules or the hepatocytes. These data
support the hypothesis that EGF is a potent mitogen for primitive liver cells
during human liver development.
To investigate the pathway that mediates proliferation of fetal liver cells during
development, cultures were incubated with a number of different growth factors
in the presence of tritiated thymidine. The results showed that cells did not
respond to growth factors with a proliferative response. This was a surprising
finding, and the concern that insufficient time had been allowed for labelling to
take place was addressed by doubling the incubation time from 24 hours to 48
hours. This revealed a paradoxical reduction in the labelling of cultured cells,
and no effect of growth factors. This response, which was consistent with the
first set of observations, introduced the possibility that tritiated thymidine might
have a deleterious effect on cultured cells.
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Tritiated thymidine has been extensively utilised to assess proliferative
responses in cell cultures, including the proliferative response to EGF in fetal
(Fabregat et ah, 1992) and neonatal rat hepatocytes (Ragan et ah, 1997).
Tritiated thymidine has been used to label human fetal hepatocytes proliferating
in vitro in response to EGF (Malhi et al, 2002). This paper showed a stimulatory
effect of EGF, however, the effect was only observed in fetal human liver cells
passaged 10 times, and not seen in primary cultures. The present study showed
the same result as Mahli; no proliferation was detected in response to EGF in
primary cultures as detected by tritiated thymidine. The data presented here are
entirely consistent with a toxic effect of tritiated thymidine, and the data of
Mahli et al. can be interpreted in the same way.
It is not clear why a stimulatory EGF effect might appear after 10 passages of
cultured cells, however, long term culture may allow changes in differentiation
status which may reduce the toxicity of tritiated thymidine, or increase
resistance to apoptosis. Ultimately, Mahli et al. did not determine the cell type
responding to EGF in the serially passaged cells.
Given the potential for a toxic effect of tritiated thymidine as noted above, the
hypothesis that growth factors could cause proliferation in cultured liver cells
had not been appropriately addressed by the initial experiments of this chapter.
The experiment was redesigned such that cultures were subject to cell counting
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after exposure to growth factors and cytokines. These data revealed that EGF
alone caused a significant increase in cell counts in vitro.
EGF has previously been reported to cause proliferation in human fetal
hepatocytes. EGF treatment resulted in an increase cell numbers at 7 days, as
determined by cell counting, of approximately 180% compared to control, and
an increased gamma-glutamyl transferase activity (Rehman et al., 2004).
However, these authors used unpurified hepatocytes to prepare their cultures,
and did not clarify which cell types were in fact undergoing proliferation in
response to EGF. Furthermore, they did not distinguish whether changes in
enzyme activity were related to maturation of a subset of cells, or whether an
increase in the number of cells expressing the enzymes were responsible.
Gamma-glutamyl transferase activity is usually associated with the biliary tract.
Therefore, increased gamma-glutamyl transferase activity may in fact relate to
proliferation of cholangiocytes rather than hepatocytes. Previous work in mouse
hepatoblasts by Rogler (1997) described gamma-glutamyl transferase activity in
association with a ductular phenotype, in cells lacking albumin expression.
Therefore, despite the assertions of the authors, the data, as presented by
Rehman et al (2004), do not definitively support the hypothesis that hepatocytes
per se proliferate in response to EGF. Ultimately, it is not possible to say what
the cell of origin might be which gives rise to the very primitive cytokeratin
i8+/fibrinogen- progeny in this study, however, it seems likely to be an
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epithelial progenitor bearing the EGF receptor. Immunocytochemistry in this
study showed that all of the epithelial cells are candidates, however, evidence of
proliferation in vivo was noted only in the hepatocellular fraction. There are
strong data to support both a biliary and a hepatocellular origin for the primitive
epithelial cells observed in this study.
The data from these experiments support the hypothesis that EGF-induced
proliferation of a primitive fraction of liver epithelial cells, positive for
cytokeratin 18 and negative for fibrinogen. Is not clear whether this might
represent primitive hepatocytes or cholangiocytes undergoing proliferation, or a
fraction more primitive still. In rat liver injured by administration of 2-
acetylaminofluorene, biliary ductules proliferate, invading the hepatic
parenchyma, and give rise to both hepatocytes and cholangiocytes. These
proliferating ductules are positive for cytokeratins 7,8,18 and 19, but are
negative for markers of hepatocellular differentiation, such as P450 enzymes
(Alison et al., 1995). These authors do not provide evidence as to whether cells
were positive or negative for fibrinogen, however, it seems likely that these
proliferating progenitors were negative. Data from isolated biliary epithelial
cells in adult human liver show that the phenotype is cytokeratin 7,8,18 and 19
positive (Liu et al., 2004). No extensive immunophenotyping of the
proliferating cytokeratin 18+ fibrinogen- cells was possible in the present study,
as there were limitations imposed by the flow cytometer as to how many labels
could be utilised in one pass. Interestingly, proliferating ductular cells in injured
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livers have been described as "oval cells", given their striking morphology
(Alison et al, 1996; Petersen et al, 1998;). These cells express the haematopoietic
marker Thy-1, and are thought to represent a progenitor compartment, giving
rise to hepatocytes and cholangiocytes. In this study, no Thy-i labelling was
carried out, however, it remains a fascinating possibility that cytokeratin
i8+/Fibrinogen- cells are in fact oval cells.
In support of a physiological role for EGF in development,
immunocytochemistry has shown the presence of TGFa, a potent, physiological
EGF receptor agonist, in the fetal human liver, specifically within hepatocytes
(Yasui et al., 1992). By contrast, the most intense immunostaining for EGF
receptor was in the bile ducts (Terada et al., 1994). It is notable that both
agonist and receptor were also present in the same cell types, that is to say that
cholangiocytes were positive for EGFR and TGFa, as were hepatocytes (Terada
et al, 1994), raising the possibility of an autocrine signalling loop. The data in
the present study agree with these findings.
In conclusion, studies were carried out to determine the responses of fetal liver
cells to growth factors and cytokines. Whilst initial studies suggested that none
of the experimental agents had stimulatory effects on liver cells, a second
experiment confirmed that EGF alone caused proliferation of fetal liver cells.
Two-colour flow cytometry was developed in this thesis, and then used to
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determine which fraction responded to EGF. The data showed that cells that
were cytokeratin 18+ and fibrinogen - proliferated in response to EGF. Neither
maturing hepatocytes, which were cytokeratin 18+ and fibrinogen +, nor non-
epithelial cells, which were dual negative, showed a significant response.
Immunocytochemistry showed only one population of cytokeratin 18+ cells
which corresponded to liver epithelium. These data show that EGF acts on the
liver epithelium to stimulate proliferation in developing human liver.
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Chapter 6.
Cytokines, growth factors, glucocorticoid,
and fetal hepatocyte function.
6.1 Introduction.
In developing liver, specific regulation of cellular proliferation, differentiation
and functional capacity is critical to the acquisition of sufficient liver mass with
adequate biochemical competence at term. The parallel demands of
proliferation and biochemical maturation may result in separate compartments
within the developing liver, each dedicated to proliferation or maturation.
Despite the clinical and scientific importance of functional status and liver cell
proliferation in humans, no data describe this relationship in the literature.
It is not clear whether proliferating hepatocytes are, in general, functionally
competent. In the fetal rat, hepatocytes isolated late in gestation correspond to
two fractions; one proliferating and one quiescent (Gruppuso et al., 1997).
Extensive studies by this group resulted in the surprising finding that the
differentiation status, as determined by immunostaining for carbamoyl
phosphate synthase I and alpha-fetoprotein, was independent of proliferative
status, as detected by proliferating cell nuclear antigen (PCNA) staining
(Gruppuso et al., 1999). However, to support this assertion, these authors
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directly equated immunostaining for a particular antigen with maturity or
immaturity, and made no assessment of functional capacity. This is a very
important distinction, as the presence or absence of particular enzymes or
proteins has no bearing on the functional status of liver cells (Van Beers et al.,
1998; Mukarram Ali Baig et al., 1992).
In order to understand how the functional capacity of liver cells might change
during development, and the interaction between proliferation and maturation
signals, liver cell cultures were exposed to cytokines, growth factors and
glucocorticoids which have previously been shown to exert significant
proliferative or maturational effects on liver cells. Hepatocyte function was then
assessed by measuring protein secretion and urea synthesis over one week in
vitro.
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6.2 Materials and Methods.
Cell cultures were prepared and plated on type I collagen-coated 24-well plates
as previously described. Cells were then exposed to various growth factors and
cytokines, +/- dexamethasone lcrAnol/l, then protein secretion and urea
synthesis was assessed as described below. Growth factors and cytokines were
used at the same concentrations as described in the previous chapter. Each
experiment included paired groups of 12 wells, one set including dexamethasone
iO"7mol/l, the other set including vehicle (ethanol; 1:10,000 dilution).
6.2.1.
The effects of growth factors, cytokines, and glucocorticoid, on urea synthesis.
Medium was changed on day 3 in vitro. Culture medium containing the relevant
peptide +/- steroid, was then replaced. On day 7, cultures were washed with 2
changes of 500 microlitres ofwarm HBSS. Cells were then incubated with imM
ammonium chloride for 4 hours as described in chapter 3. The medium was
removed and stored at -20°C for later assay.
All treatments were carried out in duplicate, and the experiment was repeated in
5 separate cultures. Samples were divided into 2 portions, which were assayed
in the presence and absence of urease as previously described in chapter 3. In
order to assess the effects of the various treatments, urea released by the cells
into the medium, and residual ammonia, was determined. The ratio between
urea released and ammonia removed was calculated and expressed as a
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percentage. A figure of 100% implied that all ammonia taken up was released as
urea. Conversely, a figure less than 100% implied that some ammonia had been
incorporated into anabolic pathways, whereas, a figure greater than 100%
suggested that catabolic processes were funnelling nitrogen into urea synthesis.
Finally, these data were expressed as a percentage of paired control wells.
6.2.2.
The effects of growth factors, cytokines, and glucocorticoid, on protein secretion.
Medium was changed on day 3 in vitro and was replaced with fresh medium
containing the relevant peptide, with and without steroid. Cultures were
maintained until day 7, when supernatant was removed and stored at -20°C for
later assay. All treatments were carried out in duplicate, and the experiment was
repeated in up to eight separate tissue preparations. Protein assays for AFP, 0C-
l-ACT, Fibrinogen, CRP and TBPA were carried out as previously described.
Protein secretion was expressed as a percentage of the matched culture control.
6.2.3 Statistics.
Data were plotted as means (+/- S.E.). Statistical analysis utilised univariate
analysis of variance plus post-hoc pairwise t-test, as permitted by univariate
ANOVA.
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6.3 Results
6.3.1.
The effects ofgrowth factors, cytokines, and glucocorticoid, on urea synthesis.
Figure 6.1. shows the effects of the various growth factors and cytokines, with
and without dexamethasone, on urea synthesis in vitro. Importantly, steroid
alone had no significant effect on urea synthesis, or ammonia uptake or ratio
between the two (ANOVA; p = 0.439, 0.797 and 0.809 respectively). However,
ANOVA showed that growth factors (ANOVA p=o.oos) and the interaction
between steroid and growth factors on urea synthesis (ANOVA p = 0.036) were
significant. Pairwise comparisons showed that, in the absence of
dexamethasone, a small but significant enhancement of urea synthesis was
observed in those cultures treated with EGF or HGF. By contrast, urea synthesis
was significantly reduced in response to KGF, but only when dexamethasone
was present.
Figure 6.2 shows that there were no significant effects of any treatment on
ammonia uptake by cultured cells (ANOVA; growth factor effect: p=o.i69.
steroid and growth factor interaction; p = 0.224).
In Figure 6.3, EGF and HGF caused a significant increase in the ratio of urea
synthesis to ammonia uptake in the absence of dexamethasone, implying a
catabolic funnelling of nitrogen from cellular stores towards urea (ANOVA;
growth factor effect: p=o.ooi. Steroid and growth factor interaction; p = 0.019).
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Figure 6.1. Urea synthesis in response to growth factors +/- steroid.
Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days in vitro with a medium change
on day 3. Growth factors +/- dexamethasone icr7M were added to cultures in duplicate. On day 7, the cells were washed
with HBSS, and fresh HBSS containing imM ammonium chloride was added for 4 hours. HBSS was removed and stored
at -20°C for later assay. Data are shown as mean, +/- SE. n=5 cultures for each data point. ANOVA with post hoc t-test
showed * p<0.05 compared to matched control.


































Figure 6.2. Residual ammonia in response to growth factors +/-
steroid. Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days in vitro with a
medium change on day 3. Growth factors +/- dexamethasone io*7M were added to cultures in duplicate. On day 7, the
cells were washed with HBSS, and fresh HBSS containing imM ammonium chloride was added for 4 hours. HBSS was
removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=5 cultures for each data point. ANOVA
showed that no treatment was significantly different from control.
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Figure 6.3. Ratio ofurea synthesis to ammonia uptake in response to
growth factors + /- steroid. Cultures were plated at 5 million cells per well in 24 well plates and
maintained for 7 days in vitro with a medium change on day 3. Growth factors +/- dexamethasone tO"7M were added to
cultures in duplicate. On day 7, the cells were washed with HBSS, and fresh HBSS containing imM ammonium chloride
was added for 4 hours. HBSS was removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=5
cultures for each data point. ANOVA with post hoc t-test showed * p<o.os compared to matched control.
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In the presence of dexamethasone, this effect was abolished. However, KGF
caused a significant reduction in the ratio of urea synthesis to ammonia uptake.
This suggests that KGF favoured the channelling of ammonia into anabolic
pathways such as glutamate synthesis rather than urea.
6.3.2.
The effects of growth factors, cytokines, and glucocorticoid, on protein secretion.
CRP and TBPA levels were below the limit of detection in all cases.
Figure 6.4 demonstrates the effects of glucocorticoid on the secretion ofAFP,
fibrinogen and 0C-1-ACT. In each case, dexamethasone significantly enhanced
protein secretion.
Figure 6.5 demonstrates that there were no significant effects of growth factors
or cytokines on AFP secretion by fetal liver cultures (ANOVA; growth factor
effect: p=o.i35. Steroid and growth factor interaction; p = 0.267).
Figure 6.6 shows that there were no significant effects of the various treatments
on fibrinogen secretion in the absence of dexamethasone. However, EGF and
TNF both significantly inhibited fibrinogen secretion when glucocorticoid was
present (ANOVA; p = 0.004 and 0.017 respectively).












































Figure 6.4. Protein secretion in vitro in the presence and absence of
dexamethasone. Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days
in vitro with a medium change on day 3. Dexamethasone 10"7M or vehicle was added to wells in duplicate. On day 7, the
medium was removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=4 cultures for each data
point. ANOVA with post hoc t-test showed * p<0.05 compared to matched control.


























EGF KGF HGF IL-6 TNF
Control Dexamethasone 10"7mol/l
Figure 6.5. AFP secretion in response to growth factors +/-steroid.
Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days in vitro with a medium change
on day 3. Growth factors and Dexamethasone 10'7M or vehicle were added to wells in duplicate. On day 7, the medium
was removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=4 cultures for each data point.
ANOVA showed no significant effects.






































EGF KGF HGF IL-6 TNF
Control Dexamethasone 107mol/l
Figure 6.6. Fibrinogen secretion in response to growth factors +/-
steroid. Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days in vitro with a
medium change on day 3. Growth factors and Dexamethasone 10 7M or vehicle were added to wells in duplicate. On day
7, the medium was removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=4 cultures for each
data point. ANOVA with post hoc t-test showed* p<o.os and ** p <0.01 compared to matched control.
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Figure 6.7 demonstrates that in the absence of dexamethasone, there were no
significant effects on 0C-1-ACT. By contrast, EGF significantly inhibited Ot-i-ACT
secretion in the presence of this steroid (ANOVA; p = 0.019).




































EGF KGF HGF IL-6 TNF
Control Dexamethasone 10"7mol/l
Figure 6.7. OC-i-ACT secretion in response to growth factors +/-
steroid. Cultures were plated at 5 million cells per well in 24 well plates and maintained for 7 days in vitro with a
medium change on day 3. Growth factors and Dexamethasone io-?M or vehicle were added to wells in duplicate. On day
7, the medium was removed and stored at -20°C for later assay. Data are shown as mean, +/- SE. n=4 cultures for each
data point. ANOVAwith post hoc t-test showed* p<o.os compared to matched control.
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6.4 Discussion.
In this chapter, the interactions of dexamethasone and growth factors on urea
synthesis and protein secretion were investigated. Overall, the data show that
dexamethasone exerted a general enhancing effect on protein secretion.
However, growth factors had highly selective effects which were different in each
case. In contrast to dexamethasone, growth factors had effects on both protein
secretion and nitrogen metabolism, and the presence of these effects was
dependent on glucocorticoid.
Glucocorticoid had no effect on ammonia metabolism in the experiments carried
out in chapter 4 of this thesis, and this result was confirmed in the present
chapter. However, ammonia metabolism in fetal liver cells was modulated by
growth factors, and these responses were, in turn, moderated by glucocorticoid.
In the absence of dexamethasone, EGF and HGF significantly stimulated urea
synthesis by approximately 10%, had no significant effect on ammonia uptake,
but significantly increased the ratio of urea synthesis to ammonia uptake. These
data indicate that the source of increased urea nitrogen in response to EGF and
HGF is not ammonia, and implies that amino acids are being increasingly
metabolised in response to these growth factors. However, the data do not show
precisely which mechanism underlies this relatively subtle effect.
The time allowed during the incubations with added ammonia (4 hours) permits
enzyme-catalysed steps to proceed towards equilibrium, independently of
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quantitative limitations in enzyme activity, but dependent on the various
equilibrium constants of the cycle. In fact, the relatively small increases in urea
synthesis may represent a large increase in the amount or activity of urea cycle
enzymes present. Alternatively, this may indicate that post-translational
processing of specific enzymes is enhanced by certain growth factors, leading to
a greater proportion of cellular nitrogen being metabolised to urea. Maturation
in vivo is likely to involve at least three mechanisms, with increased quantities of
enzyme possessing increased specific activity, and a change in the equilibrium
constant in favour of urea synthesis. Finally, these same observations could be
simply explained by increased amino acid breakdown, in the absence of any
increase in enzyme activities.
Ultimately, mature adult human hepatocytes in vitro metabolise all added
ammonia to urea in this model (J. Black; personal communication), and so the
not insignificant amount of residual ammonia is a likely corollary of immaturity
in the human fetal urea cycle. Clearly, elucidation of the true mechanisms
subserving the modest effects of EGF and HGF on urea synthesis would require
substantial further studies.
When glucocorticoid was present, the effects of EGF and HGF were abolished.
By contrast, KGF, which had had no effect in the absence of dexamethasone,
caused a significant reduction in urea synthesis with no change in ammonia
uptake. These data indicate that ammonia nitrogen was being channelled
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towards anabolic pathways, most likely the synthesis of glutamate from
ammonium and a-ketoglutarate, as a precursor of non-essential amino acids.
The observation that glucocorticoids may modify the responses of developing
hepatocytes to growth factors was unexpected. Surprisingly, there are no data in
the literature which demonstrate immunostaining for glucocorticoid receptor in
the human fetal liver, although glucocorticoid receptors have been detected
there by radioisotope binding studies (Ballard and Ballard, 1974). The effects of
glucocorticoids in human tissues are dependent on the activity of an intracellular
glucocorticoid-inactivating enzyme, 11 (3-hydroxysteroid dehydrogenase type II
(lip-HSD II), which has a physiological role to reduce the effects of
glucocorticoid exposure in developing liver in animals (Lindsay et al., 1996a,b).
In humans, n|3-HSD II mRNA (Stewart et ah, 1994) and n(3-HSD II
immunoreaction product (Hirasawa et ah, 1999) have been detected in
developing liver in early to mid gestation. As dexamethasone, in contrast to
Cortisol, is not substrate for n|3-HSD II, it is likely that the responses of the
developing liver to growth factors are modulated by glucocorticoid, and the
activity of glucocorticoid in turn is determined by the level of ii(3-HSD II. As the
current studies used dexamethasone, no insight is provided as to the potential
role of 11P-HSD II in moderating glucocorticoid effects. However, it is now clear
that the role of this enzyme is much more complex than previously suspected, as
these data show that glucocorticoid activity modulates growth factor responses.
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Whilst the published data relating to the effects of growth factors and cytokines
on ammonia metabolism is exceedingly scant, the literature which describes
their effects on hepatocellular protein secretion is considerable. In the current
chapter, EGF selectively inhibited fibrinogen and a-i-antichymotrypsinogen
secretion from human fetal liver cells, but had no effect on AFP. Notably, effects
were only observed in the presence of glucocorticoid. EGF treatment of murine
hepatocytes has previously been shown to inhibit the secretion of acute phase
response proteins in vitro (Rokita and Szuba, 1991). More recent studies show a
complex interrelationship between EGF-mediated inhibitory and IL-6-mediated
stimulatory pathways in HepG2 cells. EGF brought about activation of Src
kinases and STAT pathways, with activation of Erki and Erk2. These factors
interacted with downstream signaling by STAT3, resulting in stimulation or
inhibition of IL-6-mediated acute phase protein release (Wang et al., 1999).
These studies feature tumour cell data, and may not reflect accurately the
physiology of developing primary human hepatocytes. In cell culture of fetal
human hepatocytes, EGFR protein was detected in physical combination with
STAT3 protein, suggesting a signaling link after receptor activation (Runge et al.,
1999). Available data, although complex, support an inhibitory effect of EGF on
acute phase proteins, as shown here.
Although the current results show an effect of EGF, they do not determine
whether there is a biological role for EGF in the human liver during
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development. In the human fetus, TGFa and the EGFR show a strong
immunoreactive signal in developing bile ducts, contrasting with a less marked
immunostain for TGFa, and weak stain for the receptor, in hepatocytes (Terada
et al., 1994). With maturation, TGFa and EGFR signals diminished further in
hepatocytes, however, the signals in bile ducts remained similar to those seen in
development. In contrast to the results shown here, no functional data were
presented by these authors. However, the expression of both agonist and
receptor on bile ducts implies an autocrine loop to support biliary proliferation.
As noted in chapter 5, the identification of an EGF-mediated
CKi8+ve/Fibrinogen-ve fraction in these experiments is consistent with an EGF
effect occurring in the biliary compartment. What cannot be ignored, however,
is the observation that hepatocellular protein secretion is inhibited by EGF,
whereas urea synthesis is stimulated. Regardless of any proliferative effects on
different cell compartments, EGF has potent and specific effects on developing
human hepatocytes, effects which are dependent on glucocorticoids.
TNF (and IL-6) are key mediators of the acute phase response in mammals.
Secretion ofTNF by macrophages, for example, leads to the re-prioritisation of
liver protein synthesis and secretion, one of the defining features of the acute
phase response. Data suggests that TNF may act as a trigger, rather than a
primary initiator, in this regard. In humans, TNF infusion results in an early IL-
6 rise, followed by a later rise in acute phase reactants (Stam et al., 2000a; Stam
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et al., 2000b). These acute phase reactants include fibrinogen, C-reactive
protein, serum amyloid A and complement C3, the levels of which are massively
increased during the acute phase response. By contrast, albumin and transferrin
levels fall, as is expected for negative acute phase reactants. Whilst TNF may act
as a trigger, IL-6 is critical to the induction of the acute phase response, and data
from rat and human hepatocyte culture experiments show that IL-6 causes an
acute phase response in hepatocytes in vitro (Wigmore et al., 1997) Castell et al.,
1990; Bader et al., 1992). Critically, IL-6, rather than TNF, is both necessary and
sufficient to elicit the acute phase response (Saad et al., 1995).
In the present work, an inhibitory effect of TNF was noted on fibrinogen
secretion. This appears at odds with the documented role of TNF as stimulatory
to the acute phase response. However, this observation is not without
precedent. Adult human hepatocytes, proven to respond to IL-6 with an acute
phase response in vitro, showed no response to TNF treatment over a 20 hour
period (Castell et al., 1990). Whilst fibrinogen secretion was stimulated by IL-6
in primary cultures of human hepatocytes and in a hepatoma cell line
PLC/PRF/5, TNF was inhibitory to fibrinogen secretion in both cell types (Gabay
et al., 1995). Paradoxically, this paper showed that TNF was synergistic in
stimulating Fibrinogen when added with IL-6 (Gabay et al., 1995). . Other
studies, utilizing rat and human cell cultures in parallel, have confirmed that
TNF alone does not cause an acute phase response in liver cells in vitro (Bader et
al., 1992).
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The present experiments confirmed previous studies showing that TNF was
inhibitory to fibrinogen secretion, although previous data relate to adult human
liver cells and cell lines rather than fetal human liver cells (Gabay et al., 1995).
The mechanism by which TNF might cause inhibition of fibrinogen secretion is
not known. The presence of a tissue response to TNF, as shown by the inhibitory
effects on fibrinogen, strongly suggests the presence ofTNF receptor in the fetal
human liver. TNF receptors 1 and 2 are expressed ubiquitously in developing
tissues, and TNF mRNA and protein are detected in the fetal mouse liver by RT-
PCR and immunocytochemistry respectively (Doi et al., 1999; Kamiya and
Gonzalez 2004; Kutteh et al., 1991). Disruption of the TNF signaling pathway in
fetal development, for example by knockout of the Rel A subunit ofNFkB which
transduces the nuclear TNF signal, causes death in utero at day 14-15 of
development in mice. This fetal death is characterized by massive hepatocyte
apoptosis (Beg et al., 1995), which is prevented in Rel A -/- TNF -/- double
knockout animals (Doi et al., 1999). The TNF signaling mechanism mediated by
NFkB is therefore critically important in protecting fetuses from the pro-
apoptotic effects ofTNF during development. The absence of cell death caused
by TNF, as seen in the previous chapter, in conjunction with the inhibitory TNF
response seen here, suggests that the TNF cellular signaling mechanism is
functionally intact in the mid-trimester fetal human liver. These data reveal how
TNF could have an effect, but do not clarify the intracellular mechanism
subserving an inhibitory response.
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STAT3, which binds to the IL-6RE, and NFkB, has been shown to compete for
upstream binding sites in acute phase protein promoter regions (Zhang and
Fuller, 1997; 2000). Specifically, NFkB shows greater affinity for an overlapping
NFkB/IL-6RE sequence than does STAT3, can displace STAT3, and inhibits
fibrinogen gene transcription. Furthermore, these rat studies are complemented
by human sequence data showing that such NFkB/IL-6RE overlapping regions
are present in both the a- and y-fibrinogen promoter regions. These data show
that TNF, acting through NFkB, could inhibit fibrinogen gene transcription and
so inhibit fibrinogen secretion. Such a model supposes that some level of
STAT3-stimulated fibrinogen gene transcription is ongoing in these cell cultures.
No attempt was made to measure such activity, however, STAT3 activity may be
stimulated by many signaling pathways, including glucocorticoid receptor
(Zhang et al., 1997). Inhibitory effects ofTNF were only seen in the presence of
glucocorticoids in this study. This suggests that inhibitory TNF effects require a
background of enhanced protein transcription, in this case, mediated by
glucocorticoid.
Surprisingly, IL-6 had no effect on protein secretion in this study. In particular,
the acute phase proteins fibrinogen, and C-reactive protein were expected to
demonstrate a positive response to IL-6. In humans in vivo, data suggest that
IL-6 is the final common mediator of the acute phase response (Stam et al.,
2000a; 2000b) and a previous study in human fetal liver cells suggests that IL-6
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stimulates CRP release (Bauer et al., 1991). To bring about its effect, IL-6 binds
to a specific 8okD receptor subunit, which confers specificity to the particular
IL-6/LIF family member, and a gpi30 subunit, which mediates the signalling
pathway. In human fetal liver, immunocytochemistry has demonstrated the
specific IL-6R receptor subunit on hepatocytes, and the corresponding mRNA is
detected in liver by RT-PCR (Dame and Juul, 2000). In addition, human fetal
liver has been documented to produce IL-6 in vitro (Sennikov et al., 2001) and to
express the gpi30 protein. In fetal rat liver cultures, IL-6 showed no effect on
liver cells, until soluble IL-6 receptor was added (Kamiya et al 1999), at which
point, cellular responses were restored to normal. There are no data which
describe the status of soluble IL-6 receptor during human or rat development,
and the absence of this moiety from the present studies maywell explain the lack
of effect of IL-6 on fetal liver cells.
This lack of effect seen begs the question as to what might be the physiological
role for IL-6 during normal development. IL-6 knockout animals show
decreased liver weight compared to wild-type animals (Wallenius et al., 2001)
and gpi30 knockout mice demonstrated abnormal liver maturation (Kamiya et
al., 1999), observations which support the hypothesis that IL-6 treatment should
affect fetal human hepatocytes. On the other hand, the fetal acute phase
response is relatively quiescent, as attested to by the largely undetectable levels
of CRP in human fetal blood, even after parturition (Thompson et al., 1993).
This may reflect a developmental down-regulation of the acute phase response.
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The nature of such a down-regulation in not clear. However, it is now
recognized that SOCS (suppressors of cytokine signaling), in particular SOCS3,
down regulate IL-6 signaling, and that this is relevant in physiological regulation
(Lang et al., 2003). Although the activity of this pathway in fetal development is
unknown, SOCS3 activation may explain the lack of a fetal acute phase response
in vivo (Thompson et ah, 1993), and in vitro, as seen here.
Keratinocyte growth factor has been recognised as a potent inducer of
hepatocyte proliferation (Housley et ah, 1994) and differentiation (Krakowski et
ah, 1999). Over-expression of KGF in mouse liver, using an apolipoprotein E
promoter during development, exerts a widespread and complex range of effects.
In particular, the developing liver is enlarged, with prominent biliary
hyperplasia. There are also grossly dilated collecting ducts within the renal
cortex and medulla (Nguyen et ah, 1996). The KGF receptor is a tyrosine kinase,
which is largely expressed by epithelial cells, in contrast to KGF which is
secreted in the main by mesenchyme (Rubin et ah, 1995). Administration of
KGF to rats in vivo results in proliferation of hepatocytes and increased systemic
albumin levels (Housley et ah, 1994). In human hepatoma cells, KGF receptor
mRNA is detected, however, addition of KGF had no effect. In parallel, human
primary hepatocytes did not express the KGF receptor mRNA, neither did they
respond to KGF (Asada et ah, 2003). The data shown in the present chapter are
in support of previous experiments, showing that, despite positive findings in
the rat, KGF has no effects on protein secretion from human hepatocytes (Strain
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et al., 1994). However, KGF appeared to have a modest effect on urea synthesis,
channeling ammonia nitrogen into synthesis of non-essential acids. Clearly, this
effect requires detailed further study as KGF may be important in the acquisition
ofmature liver function.
In contrast to the effects of EGF and TNF, HGF showed no effect on protein
secretion in this study. By definition, cells capable of protein secretion are
undergoing maturation, appropriate to function in post-natal life. During
development, c-met, the HGF receptor, is expressed by immature hepatocytes,
and undergoes a dramatic downregulation in maturing cells (Spijkers et al.,
2001), perhaps abrogating any effect on protein secretion. On the other hand,
HGF was identified as capable of increasing albumin, transferrin and alpha-2-
macroglobulin after burn injury in adult rats, confirming the ability of HGF to
support the negative acute phase reactants in mature liver (Jeschke et al., 2000).
As previously noted, it may not be possible to extend observations in fetal rat to
fetal human liver cells, and the present work supports the hypothesis that HGF
has no effect on protein secretion from fetal human liver cells.
In summary, these studies have demonstrated complex actions of glucocorticoid,
growth factors and cytokines on fetal hepatocyte urea synthesis and protein
secretion. Urea synthesis was easily demonstrable, and treatment with
glucocorticoids had no effect on any index of ammonia metabolism. However,
specific growth factors were mildly stimulatory or inhibitory to urea synthesis,
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and interacted with dexamethasone in this regard. By contrast, a robust
stimulatory response to glucocorticoid was observed in terms of protein
secretion, although the acute phase response appeared inactive in mid trimester
liver. Nonetheless, selective inhibitory effects of experimental peptides strongly
support specific, receptor-mediated mechanisms. Again, the data supported an
interaction between growth factors and glucocorticoid to bring about these
effects.
These data show that the fetal liver behaves in a manner quite different to the
mature organ, which may reflect the differing developmental requirements
placed on the liver in mid-trimester compared to the demands in mature
animals. Furthermore, the data reveal a complex interaction between growth
factors and glucocorticoids, and potentially with n(3-HSD II, which has not
previously been described in the literature.




The shortfall in liver grafts for human liver transplant has lead to new initiatives
in liver transplantation research, in particular directed towards cell-based
strategies for liver replacement and support. Whilst early work demonstrated
that adult human liver cells had little capacity for replication or maintenance of
differentiated function over time in vitro, animal studies suggested that fetal
cells in general possess a superior capacity to survive, divide and differentiate in
the laboratory. These studies were directed to explore the pathways which might
be active in stimulating human fetal liver cells to undergo proliferation and
maturation in vitro. This may provide a starting point to develop novel cell-
based therapies in human liver disease, with a hope to reduce the significant
mortality of patients awaiting liver transplantation.
7.2 Maturation in human fetal liver.
Maturation of liver function prior to parturition is central to survival of the
parturient phase. In particular, adequate hepatic glycogen stores and
coagulation pathway proteins are necessary to prevent fetal and neonatal loss.
Previous studies indicate that glucocorticoids are central to fetal maturation in
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preparation for birth. Glucocorticoids enhance secretion of surfactant from type
II pneumocytes (Grier and Halliday, 2004), promote maturation of the adrenal
medulla and adrenaline synthesis (Kennedy and Ziegler, 2000) and markedly
enhance glycogen synthesis (Plas and Nunez, 1976; Schwartz et ah, 1975), all of
which are absolute requirements for the survival of parturition.
In the present study, glucocorticoids massively enhanced secretion of certain
liver proteins (AFP, Fibrinogen, oc-i-ACT), but had no effect on others (CRP,
prealbumin). Fibrinogen is a key player in neonatal haemostasis, such that
null/null mice genetically modified so as not to express fibrinogen die from
overwhelming haemorrhage during the first two weeks of life (Camerer et al.,
2004). Similarly, humans affected by the genetic condition afibrinogenaemia
have a very high incidence of fatal haemorrhage which may occur anytime
during fetal or postnatal life. (Neerman-Arbez et al., 2003). Clearly, adequate
haemostasis in humans is significantly dependent on plasma fibrinogen levels.
This thesis shows for the first time in human fetal liver that glucocorticoids can
bring about a maturational response in fibrinogen secretion. This observation is
important both in the pursuit of novel therapies in liver disease and in paediatric
practice. The medical management of preterm babies, in which spontaneous
intracranial haemorrhage is a devastating complication, may be positively
influenced by the observations in this thesis. It is noteworthy that intracranial
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haemorrhage is a significant cause of death in those children suffering from
afibrinogenaemia noted above. It is possible that low plasma fibrinogen levels
may somehow predispose to spontaneous intracranial haemorrhage. A natural
extrapolation from the data presented here suggests that glucocorticoid therapy
for preterm neonates may reduce the incidence of intracranial haemorrhage by
favourably altering the coagulation pathway. Whilst the mechanism of such an
effect has not yet been demonstrated in humans, such an association has already
been observed (Crowley, 1995).
The favourable effect of glucocorticoids on haemostasis proteins is clearly very
important for the treatment of patients with liver disease. An artificial liver
device would ideally provide coagulation factors as well as the necessary
detoxification mechanisms for seriously ill patients with liver failure.
Haemostatic failure with massive haemorrhage is a major cause of death of such
patients with liver failure. This thesis suggests that the haemostatic function of a
cell-based, artificial liver support device could be markedly improved by
glucocorticoid treatment of the liver cells.
Glucocorticoid also produced a morphological maturation in cultured liver cells,
with cultures adopting a mature epithelial phenotype and increased fibrinogen
immunofluorescence after glucocorticoid exposure. Such morphological
maturation may be associated with the functional polarisation of hepatocytes
observed in mature liver, with a sinusoidal aspect and an oppositely disposed
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face applied to a basement membrane. Such morphological changes and
polarisation have been observed in dedifferentiated hepatoma cells transfected
with a constitutively expressed HNF40C construct, the phenotypic effects of
which have been shown to results from E-cadherin expression (Parviz et al.,
2003; Spath and Weiss, 1998). It is likely that the morphological effects of
glucocorticoid as seen here are mediated via transcriptional control of this factor
(Bailly et ah, 2001).
At odds with a maturational role for glucocorticoids was the observation that
AFP secretion was markedly enhanced in the presence of dexamethasone. In
human development, AFP levels decline during fetal life, such that term levels
are 10% of those present at 32 weeks (Bader et al, 2004). A maturation signal
should theoretically result in a fall in AFP secretion, not an increase as observed
here. However, the observations of Bader et ah relate to liver late in gestation,
not mid trimester liver as utilised here. It may be that the responses of liver cells
to certain signals are different at different points in development, perhaps due to
the interplay of different factors. These studied have shown that the responses
of cells to growth factors and cytokines are different in the presence and absence
of glucocorticoid, and a subtle interplay of trimester-dependent factors may
differentially regulate AFP secretion. Tri-iodothyronine has been shown to
differentially regulate AFP secretion in a manner consistent with physiological
maturation in rats (Anteby et ah,1993). No effect of T3 was seen on fibrinogen
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secretion in chapter 4, and so further studies were not undertaken. It may be
that had the focus been on AFP, not fibrinogen, then a specific effect would have
been observed. The role of hormones in regulating AFP during development
awaits further study.
Taking further the point that glucocorticoids did not bring about 'true'
maturation ofAFP secretion, steroid had no demonstrable effect on urea
synthesis. In part this was due to the approach taken in these studies, which was
largely a qualitative assessment of urea cycle function. No dynamic studies were
carried out, which, as indicated in the relevant chapter, would be essential to
demonstrate any functional effects. Nonetheless, it was notable that the
concentration of residual ammonia was significant, at approximately 300 pmol/1
after a 4-hour incubation, under the conditions documented. By contrast, adult
hepatocytes maintained in the same conditions metabolise essentially all added
ammonia. There is clearly scope for further studies on the maturation of the
urea cycle, and it may be that the answer lies with growth factors or cytokines.
The experiments reported here show that KGF appeared to direct ammonia
towards anabolic pathways, with a consequent reduction in urea output for the
same ammonia uptake. This result establishes the potential for growth factor
modulation of urea synthesis. In addition, there may be a factor, as yet
unreported, which can better support ammonia detoxification in the fetal human
liver than those investigated here.
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The studies in this thesis demonstrate that glucocorticoids can exert dramatic
effects on developing hepatocytes in vitro. However, a further level of
complexity is introduced by the presence of the hydroxysteroid dehydrogenase
enzymes which can inactivate (11 PHSD II) or reactivate (11 pHSD I) endogenous
glucocorticoids. In fetal humans, low levels of 11 PHSD II mRNA, protein and
enzyme activity are detected in the second trimester with no evidence of 11
PHSD I activity (Hirasawa et al., 1999; Stewart et al., 1994). These observations
indicate that endogenous Cortisol could have direct effects similar to those
shown in this thesis. It was noted in chapter 4 that the maximal concentration
of Cortisol (io,ooonmol/l) had effects similar to toonmol, in support of the
hypothesis that active 11 PHSD II is destroying Cortisol above this concentration.
By contrast, the effects of dexamethasone, which is a poor substrate for 11 PHSD
II, increased with each rise in concentration. These data suggest the possibility
that the overall glucocorticoid activity in fetal liver is regulated by 11 pHSD II
activity, rather than glucocorticoid concentration.
By contrast to the many effects of glucocorticoid observed in these studies,
growth factors either had no maturational effects, or had only very subtle effects
to promote an immature state. Chapter 5 showed that EGF, KGF and IL-6
appeared to have a positive effect on the proportion of hepatocytes in culture
compared to control, implying a maturational effect. However, the effect was
not significant owing to considerable variation in responses between different
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cultures. It may be that repetition of these studies, looking specifically at
individual factors, may yield significant results in this regard. With the present
data, it must be concluded that there were no effects of cytokines or growth
factors on phenotypic maturation of hepatocytes. In subsequent functional
studies of growth factors, it was clear that there were no obvious maturational
effects of any growth factors on liver cells.
It is likely that glucocorticoids exert a significant maturational effect on
developing fetal liver, in particular with regard to protein synthesis and
secretion. More importantly, these studies show that there are likely to be many
subtle interactions between different agents acting on the liver, and it is
probable that a complex interplay is responsible for liver maturation in vivo,
rather than any overriding single maturation signal.
7.3 Cellular proliferation in developing human liver
In contrast to the striking effects of glucocorticoid on protein secretion, there
was no effect of this agent on cell proliferation or survival. Data from chapter 3
show that there was no discernable effect on the number of cells in vitro after
one week of exposure to different levels of glucocorticoid. These data
underscore the observations above, namely that steroid increases the secretion
of fibrinogen per cell. They also provide powerful evidence that glucocorticoid is
not a proliferation signal in developing liver.
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Although glucocorticoids had no effect on cell number, EGF provided a powerful
proliferative signal to developing liver cells. Two-colour flow cytometry showed
that EGF stimulated the proliferation of cytokeratin 18+ve/fibrinogen-ve cells,
which corresponded to an epithelial phenotype. The response in this
compartment was striking, with cell counts showing an increase of 250%
compared to controls. This proliferation was associated with a small reduction
in Fibrinogen and a-i-ACT secretion, with a very modest increase in urea
synthesis, providing dexamethasone was absent. These data lend credence to
the hypothesis that EGF stimulates the proliferation of presumptive biliary tract
cells, or of primitive epithelial cells which are not differentiated hepatocytes.
Whilst the role of the EGF/TGFa pathway has been investigated extensively with
regard to liver tumour progression, fewer data exist to describe the role of this
pathway in liver development. Overexpression of TGFa in transgenic mice
expressing TGFa under the control of a metallothionein promoter resulted in a
doubling of liver size, as a result of increased cell number, without obvious
morphological abnormality (Sandgren et al., 1990). These authors did not
report at which point in development the TGFa effect took place, but available
data in humans reveals the presence of EGFR in hepatocytes and cholangiocytes
throughout development (Terada et al., 1994). The proliferative effect of EGF as
reported in this thesis, acting predominantly in the epithelial compartment in
second trimester liver, may reflect the stage of development, in which
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hepatocytes and cholangiocytes are present in culture and able to respond
independently to EGF. In fact, the data in this thesis strongly support this view.
Presumably, the increased liver size with normal morphology in animals
transgenic for TGFa reflects the activity of this pathway from the earliest stages
in development, before the lineage separation of hepatocytes and cholangiocytes.
This suggests that TGFa is a mitogen for hepatoblasts, which could be explored
in developing human liver in first trimester cells. No such data exist in the
literature.
The observation that EGF may stimulate the specific expansion of the
cholangiocyte lineage is novel, but as stated in chapter 5, all available data in
human fetal studies support this interpretation, despite the assertions of authors
that hepatocyte expansion is the mode of action. Previous data from Terada et
al. (1994) indicates that in fetal human liver, EGFR immunostaining is present
at the greatest level in biliary epithelium. The data from chapter 5 certainly
show a high level of EGFR signal in this compartment, but also support the
presence of EGFR in the parenchymal hepatocytes. Further data from TGFa/c-
myc transgenic mice show that cholangiolar proliferation may be conspicuous in
tumours arising in the livers of these animals (Sandgren et al., 1993). It is not
unreasonable to say that the EGF/TGFa pathway acts predominantly on
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cholangiocytes in second trimester human liver, however, more detailed studies
would be required to confirm this hypothesis.
Of course, the possibility exists that the phenotype of the progeny may be
different compared to the cells of origin; in particular these proliferating cells
may be less differentiated and so fail to express markers such as fibrinogen.
Whilst data in the literature are scant, Alison's group have already shown in rat
liver that cellular proliferation in response to injury occurs in the biliary
compartment, and that these cells then differentiate into mature hepatocytes
(Golding et al., 1995). It may be the case that removal of the proliferation signal
allows the epithelial cells to differentiate, perhaps into hepatocytes or
cholangiocytes. This experiment was not attempted here, but would clearly be
an important avenue to pursue.
Knockout studies of the EGF/TGFa pathway have rarely touched on the
developing liver. In part, the redundancy in ligands (EGF and TGFa) may
minimise the effect of a single knockout. EGFR knockout results in fatality
within the first few days of life, with stunted growth, gut and pulmonary
immaturity contributing to death (Miettinen et al., 1995). Interestingly, no
mention was made of liver in this paper, however, the mice shown in colour
photographs did not appear jaundiced, nor was any mention made of
subsequent jaundice prior to death. This implies sufficient development of the
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biliary tree, at odds with the assertions made above. Of course, there may be
species differences between rodents and humans which renders the EGFR less
important in rodent development. In the fetal rat and mouse liver, EGFR is
absent until late in gestation (Hortsch et al., 1983), which contrasts sharply with
the human (Terada et ah, 1994).
An interesting observation was made by Miettinen et al. (1995) in their studies of
EGFR null mice. These authors noted that EGFR null mice died from epithelial
immaturity, and went on to state that lung immaturity, resembling neonatal
respiratory distress, was the main cause of death. This was accompanied by a
necrotising enterocolitis-like disorder. Both of these pathologies are associated
with pre-term delivery in humans, and both are reduced by corticosteroids in
human studies. This implies a role for both EGF and glucocorticoids in fetal
maturation, quite aside from any role in cellular proliferation.
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7.4 Suggestions for further research
The observations in this thesis have revealed potential avenues for further
research. These are summarised as follows.
1) A role for thyroid hormones in re-prioritisation of liver protein synthesis
during development.
2) A role for oncostatin M in liver cell maturation.
3) Urea cycle regulation in fetal liver development.
4) Sequential proliferation and maturation signals in fetal human liver.
5) EGF-induced proliferation in developing human liver; cell compartment
of origin and differentiation after proliferation.
6) Studies of first trimester liver and the effects of growth factors on
proliferation.
Clearly, many studies might be pursued in this new area of research. The above
project outlines tie in well with this thesis, and will be very important in the
search for new treatments for liver dysfunction.
7.5 Summary and conclusions.
This thesis set out to examine maturation and proliferation signals in the
developing human liver. A wide range of putative signalling molecules were
investigated, and interactions between these agents were also assessed. The data
show conclusively that glucocorticoid positively enhances hepatocyte
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maturation, but that other factors are likely involved in true, physiological
maturation with reprioritisation of protein synthesis as would be observed in
vitro. With regard to proliferation, EGF was the sole agent capable of inducing
proliferation in the cultured cells. Whilst the data indicate that this proliferation
occurred in the biliary compartment, published data leave room to speculate
that removal of the proliferation signal, or the action of other signals, may
induce the differentiation of hepatocytes from the proliferating compartment.
From a functional standpoint, urea synthesis and protein secretion were
influenced very subtly by growth factors, and differentially by glucocorticoid.
Taken together, these studies have identified, for the first time in fetal human
liver, dynamic responses to maturation and proliferation signals, and have
shown which factors might be useful in the development of novel, cell-based
liver therapies to treat human liver disease.
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